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Recent genome-wide studies found that patients with hypotonia, developmental delay, 
intellectual disability, congenital anomalies, characteristic facial dysmorphic features, and low 
cholesterol levels suffer from Kaufman oculocerebrofacial syndrome (also reported as 
blepharophimosis-ptosis-intellectual disability syndrome). The primary cause of Kaufman 
oculocerebrofacial syndrome (KOS) is autosomal recessive mutations in the gene UBE3B. 
However, to date, there are no studies that determine the cellular or enzymatic function of 
UBE3B. Here we report that UBE3B is a mitochondria-associated protein with HECT E3 
ubiquitin ligase activity.  Mutating the catalytic cysteine (C1036A) or deleting the entire HECT 
domain (aa758-1068) results in loss of UBE3B’s ubiquitylation activity. Knockdown of UBE3B 
in human cells results in changes in mitochondrial morphology, a decrease in mitochondria 
volume and an increase in mitochondrial oxidative stress. We also discovered that UBE3B 
strongly interacts with calmodulin (CaM) via the N-terminal IQ domain of UBE3B. Deletion of 
the IQ domain (aa29-58) results in loss of calmodulin binding. We also found that in vitro 
changes in the concentration of calcium resulted in decreased the interaction between UBE3B 
and CaM. In both these cases we saw an increase in the ubiquitylation activity of UBE3B. These 
studies are the first to demonstrate that UBE3B is an E3 ubiquitin ligase. Further, the changes in 
the interaction between UBE3B and calmodulin implicate a role for calcium signaling in 
mitochondrial protein ubiquitylation and turnover in the cell. 
UBE3B is a mitochondria-associated E3 ubiquitin ligase whose activity is modulated by 
its interaction with Calmodulin to respond to oxidative stress 
Andrea Catherine Braganza, Ph.D. 
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2.0  INTRODUCTION 
2.1 UBIQUITYLATION 
In 2004, Aaron Ciechanover, Avram Hershko and Irwin Rose were awarded the Nobel Prize in 
Chemistry for “the discovery of ubiquitin-mediated protein degradation". This was the first time 
that the mechanism of protein degradation at the molecular level, as well as its involvement in 
numerous biological processes, such as activation and deactivation of proteins, subcellular 
localization, cell cycle control, DNA damage repair, gene transcription and immunity, were 
revealed (1).  
Protein degradation, also referred to as proteolysis, is a major process in the maintenance 
and perseverance of the cellular structure and function of a cell. It helps to tightly regulate the 
concentrations of essential proteins within the cell, in addition to enabling the cell to remove 
damaged and misfolded proteins (2). The main mechanism of proteolysis is through 
ubiquitylation, wherein, one or more ubiquitin molecules are added to the target protein (3). 
These targeted proteins are then taken to the 26S proteasome for degradation. This system is 
known as the ubiquitin/proteasome system (UPS) (4-6).  
In the first step of ubiquitylation, the 76-residue, 8.5 kDa ubiquitin protein is adenylated 
on its C-terminus by the ubiquitin-activating enzyme (E1) using ATP as the energy source (7). 
This activated ubiquitin is covalently fused via a thioester linkage to a cysteine residue in the E1 
2 
(8). This step is crucial for cellular homeostasis because failure to activate ubiquitin, as seen by 
the chemical inhibition of E1 activity in the cell, results in the almost immediate shutdown of the 
entire UPS (9). At this point the E1 cannot take the activated ubiquitin straight to the substrate 
(except for the case of non-ribosomal polypeptide synthesis) (10). Therefore, ubiquitin is 
transferred from the E1 onto a cysteine residue of an ubiquitin-conjugating enzyme (E2), and 
then to a lysine residue on protein targets in concert with an ubiquitin ligase (E3) (11). 
Ubiquitylation can either be the attachment of a single ubiquitin protein (mono-ubiquitylation) or 
the attachment of a chain of ubiquitins (poly-ubiquitylation). While there is little diversity in E1 
and E2 enzymes, the human genome contains >1,000 annotated ubiquitin E3 ligases (12,13). In 
some cases, members of the E4 ligases can add a poly-ubiquitin chain to a mono-ubiquitylated 
site. For example, p300 carries out this function on a site monoubiquitylated by Mdm2 on p53 
(14). It is, however, the E3 ligases that specify the timing and substrate selection of 
ubiquitylation reactions (12,13,15-17). E3 ligases only share a few conserved motifs and are, 
therefore, very specific (18). E3 ligases contain a RING (Really interesting new gene), a HECT 
(Homologous to the E6-AP Carboxyl Terminus), or an Ubiquitin-Fusion Degradation 2 (UFD2) 
homology (U-box) domain, which catalyzes covalent addition of ubiquitin to the substrate (19). 
The process of ubiquitylation has been summarized in Figure 1. Therefore, ubiquitin ligases are 
key regulatory determinants in the ubiquitylation reaction.   
Whether a substrate is mono-ubiquitylated or poly-ubiquitylated, the ubiquitylation bonds 
are always formed with one of the seven lysine residues from the ubiquitin molecule. These 
'linking' lysines are represented by a "K" (which is the one-letter amino acid notation of lysine) 
and a number, referring to its position in the ubiquitin molecule. First, an ubiquitin molecule is 
bonded by its C-terminus to a specific lysine residue (e.g. K48, K29, K63, etc.) on the target 
3 
protein. Poly-ubiquitylation occurs when the C-terminus of another ubiquitin, will be linked 
again to a lysine residue (for example again K48 or K29) on the previously added U ubiquitin 
molecule, forming a chain. This process repeats several times, leading to the addition of several 
ubiquitins (20). 
         
Figure 1. Model of Ubiquitylation.  
Ubiquitylation is a post translation modification (PTM) that is mainly associated with protein degradation by the 
proteasome. It occurs in three steps and involves the protein ubiquitin, ATP, the ubiquitin activating enzyme (E1), 
an ubiquitin conjugating enzyme (E2), an ubiquitin ligase (E3) and a substrate. In the first step ubiquitin is activated 
by the E1 using ATP and attached to the active site cysteine on E1. In the next step, ubiquitin is transferred from the 
E1 to the active site cysteine on an E2 via a trans(thio)esterification reaction. In the final step the E3 binds to the 
4 
substrate and the E2-ubiquitin to facilitate the transfer of the ubiquitin to a lysine on the substrate, either directly (as 
in the case of RING E3 ligases) or through an intermediate self-ubiquitylation step (as in the case of HECT and 
RBR E3 ligases). The substrate can either be mono-ubiquitylated or poly-ubiquitylated depending on the signal. 
Sometimes there is a fourth step where an E4 can add an already assembled poly-ubiquitin chain to a mono-
ubiquitylated substrate.   
 
As mentioned before, not all ubiquitin-labeled proteins are degraded by the proteasome. 
Mono-ubiquitylation (or specific cases of poly-ubiquitylation) and different chain linkage types 
can alter the fate of a protein in a less terminal fashion, by potentially affecting its function, 
trafficking in multiple pathways or its degradation through lysosomes (21-24). For example, 
even though sometimes a single K29 or K48-linked poly-ubiquitin (tetra-ubiquitin) chain is 
sufficient to target a substrate to 26S proteasomes for destruction and recycling (referred to as 
the “molecular kiss of death”), K63, K11 and K6-linked poly-ubiquitin chains on target proteins 
are involved in DNA damage tolerance, kinase activation, trafficking, non-proteolytic translation 
and inflammation (20,24-27). Of all the known lysine linkages, K48-linked chains are the most 
studied.  
The ubiquitylation process is also reversible by deubiquitylating enzymes (DUBs) that 
catalyze the removal of ubiquitin moieties from proteins as well as disassemble ubiquitin chains 
to replenish the pool of intracellular ubiquitin (28,29). Deubiquitylation is an important process 
because it can cancel ubiquitylation signals, serve as a quality control for regulating 
ubiquitylation, and remove ubiquitin chains from substrate proteins prior to degradation by the 
proteasome (28). Five subclasses of DUBs have been described with the largest and most diverse 
being the USP (ubiquitin-specific protease) or UBP (ubiquitin-specific processing protease) 
subclass (from now on referred to as USP). USPs contain two highly conserved short motifs, 
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termed the Cys and His boxes, which encompass key catalytic residues. USPs are believed to 
target specific protein substrates. Ubiquitin C-terminal hydrolases (UCH) constitute the second 
class of DUBs and are believed generally to function nonspecifically in the cleavage of free 
ubiquitin chains. Finally, recent studies have identified the ovarian tumor (OTU), Josephin, and 
JAB1/MPN/MOV34 metalloenzyme catalytic domain (JAMM/MPN+) as three additional 
families of deubiquitinating enzymes (28-30). 
Ubiquitylation plays a critical role in a number of diseases such as Cystic Fibrosis. 
Ubiquitylation is responsible for the degradation of the mis-folded Cystic fibrosis 
transmembrane conductance regulator (CFTR) chloride ion channel. In Liddle’s syndrome, a 
mutation in the catalytic HECT domain of the E3 ligase neural precursor cell expressed 
developmentally down-regulated protein 4-2 (NEDD4-2) prevents the efficient ubiquitin-
mediated degradation of the epithelial sodium channel (ENaC), leading to hypertension through 
excessive sodium and water re-absorption (31-33). In certain cancers, oncogenic targets such as 
the oncogene c-Myc are mutated so that they are no longer subject to ubiquitylation, and 
therefore escape degradation and promote cell growth (34). The human papilloma virus (HPV), 
responsible for certain forms of cervical cancer, relies on its own viral E6 protein to promote 
ubiquitin-mediated degradation of the tumor suppressor cellular tumor antigen p53 (p53) (35). 
Other cancers may promote the over-expression of E3 ligases such as Murine Double Minute 
Clone 2 (MDM-2) leading to inactivation and enhanced degradation of p53 (36,37).  
There are still many unresolved questions in the field of ubiquitylation. For example, a 
majority of the E3 ligases have yet to be characterized, with an even larger number of substrates 
that have not been defined. Therefore, identifying theses E3s and their substrates as targets for 
human therapy and cancer treatments make for promising drug discoveries.  
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2.2 REACTIVE OXYGEN SPECIES (ROS) IN THE MITOCHONDRIA 
The human genome is constantly damaged by genotoxins that include endogenous cellular 
metabolites (such as reactive oxygen species (ROS) and alkylating agents) and exogenous UV 
light and ionizing radiation. These genetic insults activate oncogenes, inactivate tumor 
suppressors and change the level or function of ‘modifier’ proteins, which when left unrepaired 
can potentially increase an organism’s susceptibility to cancer, organ dysfunction, neuro-
degeneration and a myriad of other diseases (38,39).  
Besides converting energy substrates into ATP, the mitochondria have been found to be 
very dynamic organelles. Recent advance in imaging technologies have revealed that the 
mitochondria move rapidly within and between subcellular compartments, undergo rapid fission 
and fusion, and accumulate damage to their DNA (mtDNA) as they age (40-42). They also 
respond to changes in electrical activity and growth factor receptors, function as signaling 
outposts that contain kinases, deacetylases and other signal transduction enzymes, signal 
apoptosis, and participate in ROS metabolism (43-46).  
ROS are natural byproducts of normal metabolism and include superoxide (O2•−), 
hydrogen peroxide (H2O2), hydroxyl radical (•OH), peroxyl radical (ROO•), alkoxyl radical 
(RO•), ozone (O3), and singlet oxygen (1O2) (47). The majority of ROS are generated from 
complex I (NADH dehydrogenase) and complex III (ubiquinone-cytochrome c reductase) of the 
electron transport chain (ETC) in the mitochondria (47-49). The majority of electrons that enter 
the ETC are accepted by oxygen to form water in a process that does not yield free radicals (47). 
However, under basal conditions, 1-3% of electrons escape from respiratory complexes distal to 
cytochrome c oxidase (complex IV) as a side-product of oxidative respiration, and in turn reduce 
mitochondrial oxygen to produce O2•− (47,50). For a long time, it was thought that ROS were 
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exclusively toxic molecules that caused harm and damage to the cells. However, it is now known 
that low levels of some ROS species have signaling roles and are in fact essential for cell 
survival (51). Under normal physiological conditions a number of protective mechanisms, which 
include the amino acid cysteine or the enzymes thioredoxin, glutathione (GSH), catalase and 
superoxide dismutases (SODs) scavenge ROS and keep the oxidative damage to a minimum 
(52,53). However ROS can increase dramatically during times of high environmental and 
metabolic stress, overcome protective mechanisms, and cause a plethora of detrimental effects in 
the cell. This includes significant damage to cellular organelles, particularly the macromolecules 
such as lipids, DNA and proteins, as well the progression of pathologies such as 
ischemia/reperfusion injury and sepsis (54-56). The ‘mitochondrial free radical theory of aging’ 
suggests that these oxidatively damaged proteins may become inactivated, lose their proper 
tertiary structure and potentially form toxic aggregates within the organelle, leading to 
mitochondrial dysfunction which has been linked with age-related neurological degenerative 
diseases such as Alzheimer’s and Parkinson’s disease, among other aliments (57-61). This theory 
is supported by the inverse correlation between mitochondrial ROS production and lifespan in 
mammals, and the protective effects of mitochondrially-targeted catalase against cancer, cardiac 
diseases and insulin resistance in mice (62,63). Unfortunately ROS are not the only aspects of 
dysfunctional mitochondria. Mutations in mitochondrial DNA (mtDNA), ATP shortage, 
activation of mitochondrial permeability transition, loss of MMP, altered fusion/fission 
dynamics, calcium (Ca2+) deregulation, inflammation, and mitochondrial autophagy are all 
disrupted in many diseases (50,64). Hence understanding the functions of quality control 
processes to eliminate the damaged mitochondria are critical. 
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2.3 MITOCHONDRIAL DISEASES 
The mitochondria are dynamic organelles that can move along the cytoskeleton, change 
morphology through fission and fusion events and supply the cell with energy by oxidative 
phosphorylation, amongst its other important functions. As seen in Figure 2, mitochondrial 
quality control is tightly regulated and involves a large number of players that help with repair or 
clearance of damaged proteins. Current research suggests that mitochondrial dysfunction plays a 
key role in a large number of neurodegenerative and age-related diseases such as Alzheimer’s 
disease (AD), Parkinson’s disease (PD), intestinal barrier dysfunction, depression, chronic 
obstructive pulmonary disease (COPD), diabetes, and cancer (65-71). Here I review a few 
diseases that result from defects in the mitochondria. 
In humans, the mitochondria has a circular genome (mtDNA), contains approximately 
16,600 base pairs and codes for 37 genes (72). In most species the mtDNA is solely inherited 
from the mother (73). A vast majority of the proteins present in the mitochondria are coded for 
by nuclear genes. Those imported into the inner compartments of the mitochondria, that is, inside 
the outer mitochondrial membrane (OMM), contain a mitochondrial targeting sequence (MTS) 
(74,75). mtDNA is known to be preferentially damaged (before nuclear DNA) by cellular 
oxidative stress, especially mitochondrial ROS (76). One key repair gene that is activated by 
DNA double-strand breaks (DSBs) and oxidative stress is Ataxia telangiectasia mutated (ATM) 
(77). ATM has been linked to the regulation of mtDNA copy number and mitophagy (78-80).  
Deficiencies in ATM results in the downregulation of the only DNA ligase in the mitochondria 
ligase III (ligIII), and lowered mitochondrial base excision repair (mtBER) capacity (81,82).  
Patients with defects in ATM suffer from an autosomal recessive disease known as ataxia-
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telangiectasia (A-T), and are predisposed to cancer, insulin resistance and neurodegeneration 
(83). 
    
Figure 2. Schematic of mitochondrial quality control pathways.  
The mitochondria are divided into two compartments, the intermembrane space (IMS) and the matrix. The outer 
mitochondrial membrane (OMM) separates the IMS from the cytosol, while the inner mitochondrial membrane 
(IMM) divides the IMS from the matrix. There are numerous quality control mechanisms in place in, and around the 
mitochondria to repair and degrade damaged proteins. In the matrix, the mitochondrial matrix repair enzymes, 
proteases and peptidases control the repair, refolding and degradation of damaged proteins (symbolized by the 
lightning bolt in the protein chain). Proteins are also damaged by reactive oxygen species (ROS) that are generated 
from the electron transport chain (ETC) that resides in the IMM. Proteases in the IMM and the IMS process and 
degrade the proteins in the IMM. The nuclear transcribed kinase PINK1 is imported from the cytosol through the 
OMM to the IMM under normal conditions. However, when there is a drop in mitochondrial membrane potential, 
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PINK1 gets stuck on the OMM where it recruits the cytosolic E3 ligase Parkin and participates (with other OMM E3 
ligases) in mitochondrial associated degradation (MAD) of proteins by the proteasome. These proteins might retro-
translocate to the OMM from different mitochondrial sub-compartments. This figure is modified from (84). 
 
Low-density lipoprotein (LDL) is one of the five major groups of lipoproteins that deliver 
cholesterol to cells throughout the body via the bloodstream. However when the LDLs leave the 
vasculature and invade the endothelium, they can be exposed to endothelial cell mitochondrial 
ROS and become oxidized to form ox-LDL (85,86). In diets high in fat and cholesterol, ox-LDL 
can accumulate in the arterial wall to induce endothelial dysfunction by impairing the bioactivity 
of endothelial nitric oxide, promoting leukocyte adhesion, inflammation, thrombosis and smooth 
muscle cell proliferation to lead to a disease known as atherosclerosis (50,87). The mtDNA in 
aortic samples from patients suffering from atherosclerosis had greater damage than age-matched 
non-atherosclerotic aortic samples (88). In murine models there was a correlation between 
mtDNA damage and the extent of atherosclerotic lesions in apolipoprotein E (apoE) knockout 
mice, as well as manganese superoxide dismutase (SOD2) deficiency that resulted in 
mitochondrial dysfunction in apoE knockout mice (87). These results support the notion that an 
increase in mitochondrial ROS and mtDNA damage is a precursor to the development of 
atherosclerosis. 
A highly studied mitochondrial maintenance pathway is that of the mitochondrial kinase 
PTEN-induced putative kinase 1 (PINK1) and the cytosolic E3 ubiquitin ligase Parkin, where 
mutations in both have been found to be associated with early-onset PD (89-93). Under normal 
cellular conditions, PINK1 is imported into the mitochondria, cleaved by mitochondrial 
proteases and degraded, while Parkin is in the cytosol in an auto-inhibited state (94-96). When 
the MMP is depolarized the import of PINK1 is blocked on the outer mitochondrial membrane 
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(OMM), which leaves its kinase domain facing the cytosol, and triggers the recruitment of Parkin 
to the mitochondria (97-99). How PINK1 recruits Parkin to the mitochondria is a very complex 
process with several different proposed mechanisms. In one mechanism, PINK1 can 
autophosphorylate itself, and directly and indirectly trigger Parkin phosphorylation, which can 
activate its E3 ligase activity (100-102). Another mechanism suggests that PINK1 transiently 
recruits Parkin to the mitochondria, which then catalyzes K63-linked ubiquitin chain formation 
on mitochondrial proteins; which in turn serve as secondary docking sites for activated Parkin 
proteins and synthesis of additional K63 chains, thus amplifying the signal (103,104). Recently a 
novel mechanism of Parkin activation involving phosphorylated ubiquitin was identified (105-
107). Here, PINK1 phosphorylates ubiquitin at Ser65 and the phosphorylated ubiquitin then 
interacts with phosphorylated Parkin, thus releasing the E3 ligase’s auto-inhibition, allowing 
Parkin to perform its ubiquitylation function. Since Parkin plays a major role in PD, it is vital 
that its molecular mechanism in mitochondrial dysfunction is completely understood.  
AD is characterized by extracellular amyloid-β (Aβ) aggregates as well as intracellular 
neurofibrillary tangles (NFTs) consisting of hyperphosphorylated tau protein (50). The amyloid 
precursor protein (APP) has both an endoplasmic reticulum (ER) signal as well as a MTS (50). 
In disease conditions, APP is overexpressed and directed to the mitochondria where it can get 
stuck in the mitochondrial double membrane (108). Here it is cleaved by mitochondrial γ-
secretases at the OMM and the mitochondrial protease Omi in the intermembrane space (IMS) 
and cleared from the mitochondria (109,110). However when Aβ is imported into the 
mitochondria it complexes heme groups to affect ETC function and inhibits Aβ-binding alcohol 
dehydrogenase (ABAD), resulting in increased ROS, mitochondria swelling and apoptosis (111-
114). In patients with AD the mitochondria are very fragmented (possibly due to increased 
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fission), the function of various mitochondrial enzymes are impaired, there is an accumulation of 
oxidation products, and there is a change in the antioxidant levels in brain and fluid samples 
(113,115-117).   
In Huntington’s disease (HD) there is an expansion of a trinucleotide repeat in the 
Huntingtin gene leading to the accumulation of mutant huntingtin (mhtt) and formation of 
inclusions in the striatum (66). Defects in complexes I and II, lowered membrane potential, 
reduced aconitase activity, abnormal depolarization, and altered structure and number indicate a 
role of the mitochondria in HD (66,117). Mhtt activates the mitochondrial fission protein 
dynamin related protein-1 (Drp1), leading to mitochondrial fragmentation (118). This 
fragmentation results in reduced Ca+2-buffering capacity, changes in Ca+2 transport and a 
decreased Ca+2 threshold for the mitochondrial permeability transition pore (mPTP) opening 
(119,120). In neuronal cells, mhtt aggregates physically block the transit of mitochondria along 
neuronal processes (121). All these changes result in a decrease in the number of functional 
mitochondria that may contribute to the neurodegeneration in HD patients.  
Mitochondrial Ubiquitin Ligase Activator of NF-κB (Mulan) is a mitochondrial E3 ligase 
that was previously identified as an activator of NF-κB and is anchored to the OMM through two 
transmembrane domains such that the RING Finger (RNF) domain is in the cytosol where it can 
access the UPS components (122,123). The mitochondrial localization signal, as well as the RNF 
domain, is required for Mulan to function (124). Mulan is important in the regulation of 
mitochondria trafficking, with changes in Mulan levels leading to altered mitochondrial 
distribution (123). In addition to its interaction with NF-κB, Mulan also regulates cell growth, 
apoptosis and mitophagy through c-Jun N-terminal kinases (JNK), p53, protein kinase B 
(PKB/Akt) and Mitofusin 2 (Mfn2) (123-127). As a substrate, Mulan has been shown to be 
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regulated by the mitochondrial protease Omi/HtrA2, where inactivation of Omi/HtrA2 results in 
the accumulation of Mulan and an increase in mitophagy, which in turn could be responsible for 
the motor neuron disease and premature aging phenotype observed in mice (128). 
As seen above, mutations in mitochondrial proteins and any damage that is not repaired 
can have serious consequences for the organelle and the organism as a whole. Therefore 
understanding the molecular mechanisms that result in mitochondrial dysfunction is critical in 
finding a cure to these debilitating diseases.  
2.4 CALMODULIN AND CALCIUM SIGNALING 
Survival of an organism depends on the communication between and among its cells. This 
occurs either through direct contact or through signals delivered in the form of electrical 
impulses or chemical messengers. At the end of a chemical signal is a receiver, usually a protein 
that senses the arrival of the messenger, interprets the message and regulates the particular 
downstream activity (129). One such messenger protein is Calmodulin (CaM), a calcium-
modulated protein.  
In 1883, a British physiologist, Sydney Ringer, first noticed the importance of calcium 
(Ca+2) ions as a cell regulator in cardiac muscle contraction, and in the 1950’s, L.V. Heilbrunn 
showed that muscle fibers contracted after injection with Ca+2 (129).  Ca+2 ions are now known 
to affect almost all aspects of cellular physiology, ranging from endocytosis and exocytosis, 
neurotransmission, cell motility, cell division and chromosome movement, with many of these 
Ca+2-regulated processes mediated through CaM (130,131). 
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CaM is the fourth member of the Ca+2-binding protein family, with the other three being 
parvalbumin, intestinal Ca+2-binding protein and troponin-C (132-135). CaM consists of a single 
polypeptide with 148 amino acids, has a molecular weight of 16.7 kiloDaltons (kDa), and is 
highly conserved amongst all vertebrates (136). It is believed that this high degree of amino acid 
conservation is essential to maintain the interaction of CaM with the diverse family of CaM 
binding proteins (137). CaM can bind to a target in one of two ways, either in a calcium-bound 
(holoCaM) or calcium-free (apoCaM) form, and therefore making its interaction with partners 
either Ca+2-dependent or Ca+2-independent (138). The CaM binding regions of CaM target 
proteins do not have strong sequence homology. However, there is some conservation between 
these regions in that they are often found within or near a pseudosubstrate domain, 
serine/threonine phosphorylation sites, and regions responsible for interaction with other proteins 
(138). This sequence diversity could contribute to the multiple functions of the CaM receiver 
proteins. There are three classes of CaM binding motifs that are used to identify CaM binding 
regions. The first class was initially described in neuromodulin and unconventional myosins and 
is known as the IQ motif (139). It is ~20-25 amino acids in length, with the core fitting the 
consensus IQXXXRGXXXR (where X is any amino acid), and is usually arranged as an 
amphiphilic α-helical conformation (137,139-141). Frequently these motifs appear in tandem and 
can bind multiple CaM molecules with the highest affinity in the absence of Ca+2 (142). In the 
case of IQGAP1, CaM can bind to its IQ region both in the presence and absence of Ca+2 
(143,144). Interestingly, the length of the linker in repeated IQ motif containing proteins is 
similar between each IQ motif, which suggests the possibility that the linkers might have 
functions other than just serving as a connection between the different IQ motifs (145). The 
second and third classes of CaM binding motifs are closely related and are responsible for Ca+2-
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dependent binding. They are known as 1-8-14 and 1-5-10 based on the conserved hydrophobic 
residues within these motifs (138).  
CaM is a very stable and abundant molecule that is able to retain its biological activity 
after exposure to rough laboratory treatment. Because of this it can easily be prepared in its pure 
form and studied extensively (146). CaM has four calcium-binding domains and in the absence 
of Ca+2 ions it is in its inactive form. The affinity for Ca+2 is in the physiological range of 
micromolar concentration, therefore when the intracellular Ca+2 concentration is increased in 
response to an appropriate stimulus, CaM binds Ca+2 ions and assumes a more helical, active 
conformation (131).  From structure-function relationship studies, it has been found that the 
biological activity of CaM depends greatly on the integrity of the entire molecule. Therefore, a 
single mutation that results in a gross change of the primary structure of CaM may be lethal to 
the cell (130). The low 4.3 isoelectric point of CaM is due to the large number (~30%) of its 
amino acids consisting of acidic aspartate and glutamate residues. CaM contains seven helices, 
consisting of residues 7-19, 29-39, 46-55, 65-92, 102-112, 119-128 and 138-148 (146). The four 
Ca+2-binding domains contain 12 amino acids each; with the 1st domain consisting of amino 
acids 20-31, the 2nd amino acids 56-67, the 3rd amino acids 93-104 and finally the 4th amino acids 
129-140 (131). They all have a typical helix-loop-helix conformation, with one major difference 
in domains 2 and 3; these two domains share the long helix four. Helix four provides the 
carboxy-terminal helix for domain 2 and the amino-terminal helix for domain 3 and is two to 
three times longer than any of the other helices in the molecule (146). 
The mitochondria are thought to act as a Ca+2 buffering organelle to reduce to Ca+2 
concentrations (147,148). For example, when neuroblastoma cells are induced to differentiate 
into neuron-like cells, there is an increase in mitochondrial fusion and intra-mitochondrial Ca+2 
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levels suggesting a link between mitochondria Ca+2 handling and neurogenesis (149). Therefore, 
understanding the molecular mechanisms underlying CaM-dependent systems may lead to the 
identification of new strategies for therapeutic intervention.  
2.5 UBE3B 
E3 ubiquitin ligases catalyze the final step in the ubiquitylation reaction where they act as both 
the molecular matchmaker and the catalyst to specify both timing and substrate selection in the 
pathway (150). There are more than 1000 known E3 ligases, with 95% of these belonging to the 
RING family (123). Besides the three E3 ligase families of proteins mentioned before, there is 
another more recently discovered family known as the RING-between-RING (RBR) family. The 
RING ligases catalyze the direct transfer of ubiquitin from the E2 to the substrate (150,151). 
Conversely, the HECT and RBR E3 ligases covalently transfer the ubiquitin from the E2 to 
itself. The catalytic cysteine on the E3 ligase serves as the site of attachment for a thioester-
linked poly-ubiquitin chain, which then is transferred to the substrate (12,152-154). The HECT 
domain is approximately 350 amino acids in length and is always found at the carboxyl-terminal 
end of HECT E3 proteins (155). Several studies have shown a critical role of a number of E3 
ligases such as, Ubiquitin-protein ligase E3A (UBE3A), Ubiquitin-protein ligase E3B (UBE3B), 
HECT, UBA, and WWE domain containing 1 E3 Ubiquitin protein ligase (HUWE1), Midline 1 
(MID1), Cullin 4B (CUL4B), and Ubiquitin protein ligase E3 component N-Recognin 1(UBR1) 
in spatial and temporal control of protein turnover in the nervous system. Defects in these 
proteins results in development, maintenance and regulation anomalies of specialized neuronal 
structures and neuronal transmission (156-167).  
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HPV-E6-associated protein (E6AP) (also known as UBE3A) is encoded by the UBE3A 
gene locus and is the prototype for the HECT E3 ligase family. It is a cytosolic E3 ligase that is 
best known for the degradation of p53 in papillomavirus infected human cells (168). When 
UBE3A is mutated in humans it leads to defects in the overall proteasome function of the cell 
and manifests as a neurodevelopmental disorder known as Angelman syndrome (AS), 
characterized by motor dysfunction, severe intellectual disability, speech impairment, seizures, 
hyperactivity and autism spectrum disorder (ASD) (164,169-172). Because of the overlap of AS 
symptoms with other neurodevelopmental disorders, the progress made towards understanding 
and treating AS will be broadly applicable.  
Another HECT E3 ligase, the ubiquitin-protein ligase 3C (UBE3C, also known as 
KIAA10 or RAUL) has been implicated in the ubiquitin-proteasome pathway where it regulates 
physiological and cancer-related processes (173-175). UBE3C is overexpressed in glioma tissues 
(particularly glioblastoma multiforme; GBM) where it ubiquitylates and degrades the tumor 
suppressor gene annexin A7 (ANXA7) resulting in the progression of glioma, poor overall 
survival and early tumor recurrence (176). Inhibition of UBE3C results in a significant decrease 
in cell migration and invasion in vitro (176), therefore it might be a promising therapeutic target 
for glioma treatment.    
E3 enzymes, namely membrane-associated RING Finger 5 (MARCH5/MITOL) 
(177,178), Mulan/MAPL (179), RNF144B/IBRDC2 (180), RNF185 (181) and Parkin (182) were 
found to localize to the OMM. Furthermore, ubiquitin-dependent protein degradation was shown 
to modulate mitochondrial morphology and impact mitophagy (177,183-186). In addition, 
quality control of mitochondria-localized poly-Q, amyotrophic lateral sclerosis associated 
mSOD1 and S-nitrosylated proteins are performed by the ubiquitin-proteasome system 
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(187,188). Analogous to the ER, which is quality controlled by ER associated degradation 
(ERAD), mitochondria might be considered to be under control of OMM-associated degradation 
(OMMAD) (189,190). 
Kaufman oculocerebrofacial syndrome (KOS), also referred to as Blepharophimosis-
Ptosis-Intellectual-Disability Syndrome (BP-ID), is an autosomal recessively inherited disorder 
that is caused by bi-allelic mutations in the UBE3B gene. It is characterized by intellectual 
disabilities (ID) and developmental delay, hypotonia, microcephaly, structural eye anomalies and 
other organ malformations, as well as distinctive facial dysmorphic features (191). Following the 
identification of the genetic variants that cause KOS, 14 patients from eleven unrelated families 
have been reported (157,159,191,192). A homozygous mutation in UBE3B in monozygotic 
twins that results in an arginine to cysteine (R922C) substitution was identified in an Autism 
genome-wide association study (GWAS) (193). In cattle, a mutation that results in an altered 
UBE3B protein that lacks 40 amino acids (of which 20 are located in the conserved HECT-
domain) leads to a bovine phenotype that resembles human KOS and is known as Ptosis, 
Intellectual disability, Retarded growth and Mortality (PIRM) syndrome (194). However none of 
these studies have defined a functional role for UBE3B in cellular protein homeostasis nor have 
these or any studies demonstrated E3 ubiquitin ligase activity for the UBE3B protein.  
Damaged mitochondrial proteins need to be removed and replaced with functional 
counterparts to maintain mitochondrial function and cellular homeostasis. The UPS is suggested 
to be a major route of mitochondrial protein turnover. Select proteins from the OMM, the IMS, 
the inner mitochondrial membrane (IMM) and the mitochondrial matrix (MM) have been shown 
to be ubiquitylated and degraded by the proteasome. In this dissertation, I propose that UBE3B 
functions to ubiquitylate damaged mitochondrial proteins for proteasomal degradation in 
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response to oxidative stress induced an increase in cellular Ca+2 levels. Given the suggested role 
of defective UBE3B in KOS, autism and PIRM, defining the mechanism of action of this E3 
ligase and its role in the UPS regarding mitochondrial maintenance will have significant impact 
in this basic biological mechanism of protein turnover and give insight into multiple 
neurodegenerative conditions. 
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3.0  AIMS FOR DISSERTATION 
AIM 1: To define the role of UBE3B in response to mitochondrial stress 
1) To show that UBE3B is an E3 ligase I will determine the catalytic activity of full 
length UBE3B, UBE3B missing the catalytic domain (UBE3B∆HECT), or the autism 
mutant (UBE3B (R922C)) using an in vitro ubiquitylation assay. 
2) To measure the production of ROS species and visualize changes in the intracellular 
localization of UBE3B (full length and mutants) at different time points +/- ROS 
producing agents using live cell imaging. I will also perform subcellular fractionation 
and immunoblots to confirm the fluorescent microscopy data. 
In this dissertation, I was able to complete AIM 1.1 but not AIM 1.2. This is because I had 
unexpected difficulties showing the ubiquitylation activity of wild type UBE3B. I was able to 
follow a different hypothesis and showed that the problems I faced might have been due to the 
role CaM plays in regulating UBE3B’s function. Herein I find that when CaM is bound to the IQ 
domain of UBE3B, UBE3B’s activity is suppressed.   
AIM 2: To determine the effects of mitochondrial stress on the localization and 
function of ANKZF1 
1) To show the recruitment of ANKZF1-GFP to the mitochondria in response to treatment 
with mitochondrial stress agents using confocal microscopy. I will also perform 
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subcellular fractionation and immunoblots to confirm the microscopy data. I will also 
determine the effects of mitochondrial stressors on cell survival in ANKZF1 knockdown 
cells.   
2) I will make deletions in the three main domains of ANKZF1, i.e. the N-terminus, the 
mitochondrial targeting domain (MTD) and the VCP interacting motif (VIM), and show 
how these deletions affect (a) the recruitment of ANKZF1 to the mitochondria; and (b) 
the cell’s ability to cope with mitochondrial ROS. 
This AIM is detailed in Appendix 1. I was able to show that wild type ANKZF1 is recruited to 
the mitochondria after inhibition of proteasomal degradation but not stress caused by Oligomycin 
or H2O2. I was not able to work on AIM 2.1 because of the problems I had with AIM 1.  
AIM 3: To identify the binding partners of UBE3B and determine if UBE3B and 
ANKZF1 interact to remove these damaged mitochondrial proteins after ROS 
production 
1) I will identify the mitochondrial proteins that are ubiquitylated by UBE3B using our 
HA-UBE3B cell line by co-immunoprecipitation followed by mass spectrometry. 
Immunoblots will be performed to confirm the mass spectrometry results.   
2) To show if the interaction between UBE3B and ANKZF1 changes +/- stress, I will 
measure the levels of both proteins before and after treatment with mitochondrial 
stressor by co-immunoprecipitation and immunoblot. I will also show that the 
UBE3B/ANKZF1 interaction is necessary for mitochondrial protein turnover by over-
expressing ANKZF1-GFP and knocking down UBE3B (or the reverse) and by 
measuring the changes in the levels of the mitochondrial proteins identified in sub-
aim Aim 3.1. 
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I was able to identify that CaM binds to the IQ motif of UBE3B and deletion of this motif 
abolished this interaction. The mass spectrometry results using cells overexpressing HA-UBE3B 
and HA-UBE3B(C1036A) protein are detailed in Appendix 2. I also utilized a novel approach 
known as the proximity biotin ligation assay which utilizes Biotin ligase / UBE3B fusions and 
biotin to “tag” proteins that come within 10µm of the fusion proteins (195). This method was 
used to confirm the HA-tag mass spectrometry data we obtained. This project is still ongoing. 
However I was able to confirm the interaction between wild type UBE3B and CaM.  
I was not able to start AIM 3.2 because I was not able to complete AIMS 1.2 and 2.2.  
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4.0  MATERIALS AND METHODS 
4.1 CHEMICALS AND REAGENTS 
TransIT®-2020 Transfection reagent (Cat# MIR5400) was from Mirus and the siPORT™ 
NeoFX™ Transfection reagent (Cat# AM4511) was from Life Technologies. The siRNA 
UBE3B-s40200 (Cat# 4390824) was from Ambion. The Silencer® Negative Control siRNA #2 
(Cat# AM4613), TaqMan Primer Probe Set for UBE3B (Cat# 4331182) and β-Actin were from 
Applied Biosystems. OptiMEM, alpha EMEM and phosphate buffered saline (PBS) were from 
Invitrogen. FuGENE® Transfection Reagent (Cat# E2311) was from Promega. Puromycin was 
from Clontech Laboratories, and gentamycin was from Irvine Scientific. All the plastic tissue 
culture supplies were from Corning and Thermo Fisher Scientific. All PCR primers were from 
Eurofins MWG Operon. DreamTaq DNA Polymerase (Cat# FEREP0703) was from Thermo 
Fisher Scientific and dNTPs (Cat# 4303442) were from Life Technologies. The Pfu Turbo DNA 
Polymerase (Cat# 600250) and QuickChange II XL site-Directed Mutagenesis kit (Cat# 200521) 
were from Agilent Technologies. The TOPO® TA Cloning® Kit for Sequencing, with One 
Shot® TOP10 Chemically Competent E.coli (Cat# K4575-40), Gateway® LR Clonase® II 
Enzyme Mix (Cat# 11791-100) and T4 DNA Ligase (Cat# EL0011) were from Life 
Technologies. The plasmid p4054 HA-E6AP isoform II (Cat# 8658) was purchased from 
Addgene. Restriction enzymes XbaI, Bsu36I and BamHI were from New England Biolabs. The 
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QIAquick PCR Purification Kit (Cat# 28106) and QIAquick Gel Extraction Kit (Cat# 29706) 
were from QIAGEN. The TALON® Metal Affinity Resin (Cat# 635501) and HisTALON™ 
Buffer Set (Cat# 635651) were from Clontech. The Amicon Ultra-15 Centrifugal Filter Units 
(Cat# UFC900324) were from EMD Millipore and the DC Protein Assay Kit II (Cat# 500-
0112EDU) was from Bio-Rad. The Anti-6x-His Epitope Tag Ab, Clone HIS.H8 (Cat# 
MA121315) was from Thermo Fisher Scientific. FLOAT-A-LYZER G2 (Cat# G235051) was 
from Spectrum Laboratories. The Anti-HA Affinity Matrix (Cat# 11815016001) was from 
Roche. The Mitochondria Isolation Kit for Cultured Cells (Cat# 89874) was from Life 
Technologies. Primary antibodies: UBE3B antibody (Cat# SAB4503523) from Sigma Aldrich, 
ubiquitin (Ub) antibody (Cat# AUB01) was from Cytoskeleton, α-Tubulin antibody (Cat# CP06) 
from EMD Millipore, proliferating cell nuclear antigen (PCNA) antibody (Cat# sc-56) from 
Santa Cruz, cytochrome c oxidase IV (COX IV) antibody (Cat# A21348) from Life 
Technologies, Turbo-green fluorescent protein (TurboGFP) antibody (Cat# AB513) from 
Evrogen, adenosine triphosphate synthase beta (ATP synthase β) antibody (Cat# MA1-930) from 
Thermo Fisher Scientific, and calmodulin (CALM) antibody (Cat# ab45689) from Abcam. The 
hybridoma cell clone #12CA5, expressing the anti-HA monoclonal antibody, was a generous gift 
from Kara Bernstein (University of Pittsburgh). The 12CA5 hybridoma cells were used to 
generate ascites and the resulting Ab was purified using protein-A-agarose and isotyped 
(IgG2b/Kappa). Secondary antibodies: goat anti-mouse horseradish peroxidase (GAM-HRP) 
conjugates and goat anti-rabbit horseradish peroxidase (GAR-HRP) conjugates were from Bio-
Rad, goat anti-mouse Cy5 (Cat# ab150115) from Abcam and goat anti-rabbit Cy3 (Cat# A-
11011) was from Life Technologies. The Novex® NuPAGE® SDS-PAGE gel systems were 
from Life Technologies. Signal generation substrates were from Bio-Rad and Thermo Fisher 
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Scientific. All electrophoresis reagents were from Bio-Rad. The ubiquitin activating enzyme 
(UBE1) (Cat# E-305) and Ubiquitin Aldehyde (Cat# U-201) were from Boston Biochem. The 
ubiquitin conjugating enzyme (E2) Selection Panels (Cat# UB200) were from Life Sensors. The 
Magnesium/ATP Cocktail (Cat# 20-113) was from EMD Millipore. The Protease Inhibitor Mini-
Tablets (Cat# 88665) and IP Lysis Buffer (Cat# 87788) were from Thermo Fisher Scientific, and 
the MG-132 (Cat# 474790) was from Calbiochem. Biotin (Cat# BP232-1) was from Thermo 
Fisher Scientific and Dynabeads MyOne Streptavidin C (Cat# 65001) was from Life 
Technologies. 
4.2 STABLE CELL LINE GENERATION AND CULTURE CONDITIONS 
LN428 glioblastoma cells and culture conditions were as previously described (196). Cells were 
maintained at 37°C in 5% CO2 and grown in alpha EMEM media containing 10% heat-
inactivated fetal bovine serum (FBS), antibiotic/antimycotic, ʟ-glutamine and gentamycin. 
Human UBE3B complementary DNA was PCR amplified (using primers purchased from 
Eurofins MWG Operon) and cloned into the pENTR/D-TOPO plasmid to create the pENTR-
UBE3B vector as per standard Topo-cloning methodology (197). With this plasmid as the 
template, UBE3B tagged proteins or mutants were made, either via standard PCR or with the 
QuickChange XL Site-Directed Mutagenesis kit. The sequence of each primer is listed in Table 
1. Briefly, we made HA-UBE3B, UBE3B-HA, HA-UBE3BΔHECT, HA-UBE3B(619-end), HA-
UBE3B(757-end), and UBE3B(ΔIQ)-HA using primer pairs HA-UBE3B-F/UBE3B-R, UBE3B-
F/UBE3B-HA-R, HA-UBE3B-F/UBE3BΔHECT-R, HA-UBE3B(619-end)-F/UBE3B-R, HA-
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UBE3B(757-end)-F/UBE3B-R and UBE3B(ΔIQ)-F/UBE3B-HA-R, respectively (Figures 3A, 
4A, 5A, 6A and 7A, respectively).  
Table 1. Deoxyoligonucleotides used. 









































*The bold bases indicate the mutated bases.  
 
Using the pENTR-HA-UBE3B plasmid as template, we made the HA-UBE3B(C1036A) 
and HA-UBE3B(R922C) mutations using primer pairs UBE3B(C1036A)-F/UBE3B(C1036A)-R 




Figure 3. Generation of HA-UBE3B constructs.  
(A) Optimization of the primers HA-UBE3B-F and UBE3B-R using Platinum® Pfx DNA Polymerase and pENTR-
UBE3B in gradient PCR for amplification of HA-UBE3B for pENTR/D-TOPO cloning into pENTR vector. (B) 
PCR amplification screen using Taq DNA Polymerase of mini-prep pENTR-HA-UBE3B plasmids from 
transformed One Shot Top 10 E.coli cells. 
 
Figure 4. Generation of UBE3B-HA constructs. 
(A) Optimization of the primers UBE3B-F and UBE3B-HA-R using Platinum® Pfx DNA Polymerase and pENTR-
UBE3B in gradient PCR for amplification of UBE3B-HA for pENTR/D-TOPO cloning into pENTR vector. (B) 
PCR amplification screen using Taq DNA Polymerase of mini-prep pENTR-UBE3B-HA plasmids from 
transformed One Shot Top 10 E.coli cells. Lanes 13 and 26 were positive control lanes that used PCR purified DNA 
instead of mini-prep plasmids. 
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Figure 5. Generation of HA-UBE3BΔHECT constructs. 
(A) Optimization of the primers HA-UBE3B-F and UBE3BΔHECT-R using Platinum® Pfx DNA Polymerase and 
pENTR-UBE3B in gradient PCR for amplification of HA-UBE3BΔHECT for pENTR/D-TOPO cloning into 
pENTR vector. (B) PCR amplification screen using Taq DNA Polymerase of mini-prep pENTR-HA-
UBE3BΔHECT plasmids from transformed One Shot Top 10 E.coli cells. 
 
 
Figure 6. Generation of HA-UBE3B(619-end) and HA-UBE3B(757-end) constructs. 
 (A) Optimization of the primers (a) HA-UBE3B(619-end)-F and UBE3B-R, and (b) HA-UBE3B(757-end)-F and 
UBE3B-R, using Platinum® Pfx DNA Polymerase and pENTR-UBE3B plasmid in gradient PCR for amplification 
of (a) HA-UBE3B(619-end), and (b) HA-UBE3B(757-end) respectively, for pENTR/D-TOPO cloning into pENTR 
vector. (B) PCR amplification screen using Taq DNA Polymerase of mini-prep (a) pENTR-HA-UBE3B(619-end), 
and (b) pENTR-HA-UBE3B(757-end) plasmids from transformed One Shot Top 10 E.coli cells. 
 
Using the pENTR-HA-UBE3B(C1036A) plasmid as template, we made HA-
UBE3B(619-end)(C1036A) and HA-UBE3B(757-end)(C1036A) using primer pairs HA-
UBE3B(619-end)-F/UBE3B-R and HA-UBE3B(757-end)-F/UBE3B-R, respectively (Figure 
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10A). Using p4054 HA-E6AP isoform II plasmid (Addgene) as template we made HA-UBE3A 
and HA-UBE3A(418-end) using primer pairs HA-UBE3A-F/HA-UBE3A-R and HA-
UBE3A(418-end)-F/HA-UBE3A-R, respectively (Figure 11A).  
 
 
Figure 7. Generation of UBE3BΔIQ-HA constructs. 
 (A) Optimization of the primers UBE3B(ΔIQ)-F and UBE3B-HA-R using Platinum® Pfx DNA Polymerase and 
pENTR-UBE3B in gradient PCR for amplification of UBE3BΔIQ-HA for pENTR/D-TOPO cloning into pENTR 
vector. (B) PCR amplification screen using Taq DNA Polymerase of mini-prep pENTR-UBE3BΔIQ-HA plasmids 
from transformed One Shot Top 10 E.coli cells. 
 
 
Figure 8. Generation of HA-UBE3B(C1036A) and UBE3B(C1036A)-copGFP constructs. 
 (A) Site-directed mutagenesis on plasmid pENTR-HA-UBE3B with primers UBE3B(C1036A)-F and 
UBE3B(C1036A)-R to create pENTR-HA-UBE3B(C1036A) plasmid. (B) Optimization of the primers UBE3B-
GFP-F and UBE3B-GFP-R using Platinum® Pfx DNA Polymerase and plasmid pENTR-HA-UBE3B(C1036A) in 
gradient PCR for amplification of UBE3B(C1036A) with XbaI restriction digest sites for ligation into pCT-CMV-
MCS-copGFP-Puro vector. Gradient temperatures: 1: 52°C, 2: 52.5°C, 3: 53.6°C, 4: 54.9°C, 5: 57°C, 6: 59.6°C, 7: 
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62.6°C, 8: 65.2°C, 9: 67.2°C, 10: 68.6°C, 11: 69.6°C, and 12: 70°C. Best temperature chosen was 70°C. (C) XbaI 
restriction digested and gel-purified PCR amplified UBE3B(C1036A) insert and pCT-CMV-MCS-copGFP-Puro 
vector for ligation using T4 DNA Ligase. (D) PCR amplification screen using Taq DNA Polymerase of mini-prep 
pCT-CMV-UBE3B(C1036A)-copGFP-Puro plasmids from transformed One Shot Top 10 E.coli cells. 
 
Positive clones were selected and plasmids were extracted with the QIAprep Spin 
Miniprep Kit (Qiagen) (Figures 3B, 4B, 5B, 6B, 7B, 9B, 10B and 11B). Once sequence 
verified, the open reading frames from each of the plasmids pENTR-HA-UBE3B, pENTR-
UBE3B-HA, pENTR-HA-UBE3BΔHECT, pENTR-HA-UBE3B(C1036A), pENTR-HA-
UBE3B(R922C), pENTR-HA-UBE3B(619-end), pENTR-HA-UBE3B(619-end)(C1036A), 
pENTR-HA-UBE3B(757-end), pENTR-HA-UBE3B(757-end)(C1036A), pENTR-
UBE3B(ΔIQ)-HA, pENTR-HA-UBE3A and pENTR-HA-UBE3A(418-end) were transferred 
into a Gateway-modified pLVX-IRES-Puro vector, (Clontech) by the LR reaction using the 
Gateway LR Clonase II Enzyme Mix (Life Technologies) as per the manufacturer’s instruction. 
Positive clones were selected and plasmids were extracted with the QIAprep Spin Miniprep Kit 
(Qiagen). For the UBE3B-copGFP, UBE3BΔHECT-copGFP, copGFP-UBE3B and copGFP-
UBE3BΔHECT fusion plasmids we used pENTR-UBE3B and either pCT-CMV-MCS-copGFP-
EF1-Puro or pCT-CMV-copGFP-MCS-EF1-Puro (System Biosciences) respectively. For the 
UBE3B(C1036A)-copGFP, UBE3B(R922C)-copGFP, copGFP-UBE3B((R215C/I1059F) and 
copGFP-UBE3B(R346Q) fusion plasmids we used pENTR-UBE3B(C1036A), pENTR-
UBE3B(R922C), pENTR-UBE3B(R215C/I1059F) or pENTR-UBE3B(R346Q), respectively, 
and either pCT-CMV-MCS-copGFP-EF1-Puro or pCT-CMV-copGFP-MCS-EF1-Puro (System 
Biosciences) respectively. 
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We made copGFP-UBE3B, cop-UBE3B(R215C/I1059F) and copGFP-UBE3B(R346Q) 
using primer pair GFP-UBE3B-F/GFP-UBE3B-R, we made UBE3B-copGFP, 
UBE3B(C1036A)-copGFP, UBE3B(R922C)-copGFP, UBE3B(R215C/I1059F)-copGFP and 
UBE3B(R346Q)-copGFP using primer pair UBE3B-GFP-F/UBE3B-GFP-R, while we made 
UBE3BΔHECT-copGFP using primer pair UBE3B-GFP-F/UBE3BΔHECT-GFP-R (Figures 8B, 
12A, 13A and 14B). The UBE3B, UBE3B(C1036A), UBE3B(R922C), UBE3B(R215C/I1059F) 
and UBE3B(R346Q) open-reading frames were PCR amplified to engineer the restriction 
enzyme site XbaI on both ends, while the UBE3BΔHECT-copGFP open-reading frame was PCR 
amplified to engineer the restriction enzyme sites XbaI and BamHI for cloning in-frame with 
copGFP using standard protocols. After PCR, products were digested with the respective 
enzymes; purified fragments were ligated into the pCT-CMV-copGFP-MCS-EF1-puro lentiviral 
vector hydrolysed by XbaI, or XbaI and BamHI (Figures 8C, 12B, 13B and 14C). Positive 
colonies were selected and sequenced (Figures 8D, 13C, 14D and 15A). To determine if 
UBE3B was correctly inserted into pCT-CMV-copGFP-MCS-EF1-Puro and pCT-CMV-MCS-
copGFP-EF1-Puro, and if UBE3B(R922C), UBE3B(R215C/I1059F) and UBE3B(R346Q) 
clones were correctly inserted into pCT-CMV-MCS-copGFP-EF1-Puro the plasmids were 
digested with either XbaI or BamHI. If the constructs were present, there will be a 300bp band in 
the digested products. While, if the constructs are present in the correct orientation, there should 




Figure 9. Generation of HA-UBE3B(R922C) constructs. 
 (A) Site-directed mutagenesis and DpnI digestion of plasmid pENTR-HA-UBE3B with primers UBE3B(R922C)-F 
and UBE3B(R922C)-R to create pENTR-HA-UBE3B(R922C) plasmid. (B) PCR amplification screen using Taq 




Figure 10. Generation of HA-UBE3B(C1036A)(619-end) and HA-UBE3B(C1036A)(757-end) domain 
constructs. 
(A) Optimization of the primers (a) HA-UBE3B(618-end)-F and UBE3B-R, and (b) HA-UBE3B(757-end)-F and 
UBE3B-R using Platinum® Pfx DNA Polymerase and pENTR-UBE3B(C1036A) plasmid in gradient PCR for 
amplification of (a) HA-UBE3B(619-end)(C1036A), and (b) HA-UBE3B(757-end)(C1036A), respectively, for 
pENTR/D-TOPO cloning into pENTR vector. (B) PCR amplification screen using Taq DNA Polymerase of mini-
prep (a) pENTR-HA-UBE3B(619-end)(C1036A) and (b) pENTR-HA-UBE3B(757-end)(C1036A) plasmids from 
transformed One Shot Top 10 E.coli cells. 
33 
To determine if UBE3BΔHECT was inserted into pCT-CMV-MCS-copGFP-EF1-Puro, 
clones were digested with XbaI or BamHI. If the construct was present, there will be a 2500bp 
band and an 8000bp band in the digested product (Figure 13D). Sequence-verified plasmids 
were transiently transfected and lentivirus production was as described below.  The pLPC-MYC-
BirA plasmid was a kind gift from Dr. Roderick O’Sullivan at the University of Pittsburgh. To 
create the BirA-UBE3B and UBE3B-BirA fusion plasmids, we had pENTR-BirA-UBE3B and 
pENTR-UBE3B-BirA plasmids synthesized by GenScript. Once sequence verified, we 




Figure 11. Generation of HA-UBE3A and HA-UBE3A(418-end) constructs. 
(A) Optimization of the primers (a) HA-UBE3A-F and UBE3A-R, and (b) HA-UBE3A(418-end)-F and UBE3A-R 
using Platinum® Pfx DNA Polymerase and p4054 HA-E6AP plasmid in gradient PCR for amplification of (a) HA-
UBE3A and (b) HA-UBE3A(418-end), respectively, for pENTR/D-TOPO cloning into pENTR vector. (B) PCR 
amplification screen using Taq DNA Polymerase of mini-prep (a) pENTR-HA-UBE3A and (b) pENTR-HA-
UBE3A(418-end) plasmids from transformed One Shot Top 10 E.coli cells. 
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All the vectors used and developed in this study are listed in Table 2, and all the pENTR 
and pCT-CMV-copGFP-MCS-EF1-Puro/pCT-CMV-MCS-copGFP-EF1-Puro plasmid maps are 
listed in Appendix F. 
 
 
Figure 12. Generation of copGFP-tagged UBE3B wild type and point mutant constructs. 
(A)(a) Optimization of the primers GFP-UBE3B-F and GFP-UBE3B-R using Platinum® Pfx DNA Polymerase and 
pENTR-UBE3B in gradient PCR for amplification of UBE3B with XbaI restriction digest sites for ligation into 
pCT-CMV-copGFP-MCS-Puro vector. (b) Optimization of the primers UBE3B-GFP-F and UBE3B-GFP-R using 
Platinum® Pfx DNA Polymerase and pENTR-UBE3B in gradient PCR for amplification of UBE3B with XbaI 
restriction digest sites for ligation into pCT-CMV-MCS-copGFP-Puro vector. Gradient temperatures: 1: 52°C, 2: 
52.5°C, 3: 53.6°C, 4: 54.9°C, 5: 57°C, 6: 59.6°C, 7: 62.6°C, 8: 65.2°C, 9: 67.2°C, 10: 68.6°C, 11: 69.6°C, and 12: 
70°C. Best temperature chosen for (a) primer set was 62.6°C, and for (b) primer set was 70°C. (B) Restriction 
digested and gel-purified PCR amplified constructs and vectors for ligation using T4 DNA Ligase. 1: UBE3B with 
XbaI restriction digested sites for ligation into pCT-CMV-copGFP-MCS-Puro vector, 2: Restriction digested and gel 
purified constructs and vectors that are ready for ligation. 1: UBE3B with XbaI restriction digested sites for ligation 
into pCT-CMV-MCS-copGFP-Puro vector, 3: UBE3B(R215C/I1059F) with XbaI restriction digested sites for 
ligation into pCT-CMV-copGFP-MCS-Puro vector, 4: UBE3B(R215C/I1059F) with XbaI restriction digested sites 
for ligation into pCT-CMV-MCS-copGFP-Puro vector, 5: UBE3B(R346Q) with XbaI restriction digested sites for 
ligation into pCT-CMV-copGFP-MCS-Puro vector, 6: pCT-CMV-copGFP-MCS-Puro vector with XbaI restriction 
digested sites, and 7: pCT-CMV-MCS-copGFP-Puro vector with XbaI restriction digested sites. 
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Figure 13. Generation of UBE3BΔHECT-copGFP constructs. 
(A) Optimization of the primers UBE3B-GFP-F and UBE3BΔHECT-GFP-R using Platinum® Pfx DNA Polymerase 
and pENTR-UBE3BΔHECT in gradient PCR for amplification of UBE3BΔHECT with XbaI and BamHI restriction 
digest sites on the N- and C-terminals respectively, for ligation into pCT-CMV-MCS-copGFP-Puro vector. Gradient 
temperatures: 1: 52°C, 2: 52.5°C, 3: 53.6°C, 4: 54.9°C, 5: 57°C, 6: 59.6°C, 7: 62.6°C, 8: 65.2°C, 9: 67.2°C, 10: 
68.6°C, 11: 69.6°C, and 12: 70°C. Best temperature chosen was 70°C. (B) XbaI and BamHI restriction digested and 
gel-purified PCR amplified UBE3BΔHECT insert and pCT-CMV-MCS-copGFP-Puro vector for ligation using T4 
DNA Ligase. (C) PCR amplification screen using Taq DNA Polymerase of mini-prep pCT-CMV-UBE3BΔHECT-
copGFP-Puro plasmids from transformed One Shot Top 10 E.coli cells. (D) Lanes 1-4: Undigested mini-prep pCT-
CMV-UBE3BΔHECT-copGFP-Puro plasmids, and Lanes 5-9: Mini-prep pCT-CMV-UBE3BΔHECT-copGFP-Puro 
plasmids digested with XbaI and BamHI. If insert is present, expected band sizes are ~2500bp and ~8000bp. 
 
Table 2. Vectors developed for and used in this study. 
Plasmid name Insert description Parental vector 
pENTR-UBE3B UBE3B pENTR/D-TOPO 
pENTR-UBE3BΔHECT UBE3BΔHECT pENTR/D-TOPO 
pENTR-UBE3B(C1036A) UBE3B(C1036A) pENTR/D-TOPO 
pENTR-UBE3B(R215C/I1059F) UBE3B(R215C/I1059F) pENTR/D-TOPO 
pENTR-UBE3B(R346Q) UBE3B(R346Q) pENTR/D-TOPO 
pENTR-UBE3B(R922C) UBE3B(R922C) pENTR/D-TOPO 
pENTR-HA-UBE3B HA-UBE3B pENTR/D-TOPO 
pENTR-UBE3B-HA UBE3B-HA pENTR/D-TOPO 
pENTR-HA-UBE3BΔHECT HA- UBE3BΔHECT pENTR/D-TOPO 
pENTR-HA-UBE3B(C1036A) HA-UBE3B(C1036A) pENTR/D-TOPO 
pENTR-HA-UBE3B(R922C) HA-UBE3B(R922C) pENTR/D-TOPO 
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pENTR-HA-UBE3B(619-end) HA-UBE3B(619-end) pENTR/D-TOPO 
pENTR-HA-UBE3B(619-
end)(C1036A) HA-UBE3B(619-end)(C1036A) pENTR/D-TOPO 
pENTR-HA-UBE3B(757-end) HA-UBE3B(757-end) pENTR/D-TOPO 
pENTR-HA-UBE3B(757-
end)(C1036A) HA-UBE3B(757-end)(C1036A) pENTR/D-TOPO 
pENTR-HA-UBE3A HA-UBE3A pENTR/D-TOPO 
pENTR-HA-UBE3A(418-end) HA-UBE3A(418-end) pENTR/D-TOPO 
pENTR-UBE3B(ΔIQ)-HA UBE3B(ΔIQ)-HA pENTR/D-TOPO 
pCT-CMV-UBE3B-copGFP-Puro UBE3B-copGFP pCYTO-CMV-MCS-copGFP-EF1-Puro 

































pLVX-HA-UBE3B-IRES-Puro HA-UBE3B pLVX-GW-IRES-Puro 
pLVX-UBE3B-HA-IRES-Puro UBE3B-HA pLVX-GW-IRES-Puro 
pLVX-HA-UBE3BΔHECT-IRES-Puro HA- UBE3BΔHECT pLVX-GW-IRES-Puro 
pLVX-HA-UBE3B(C1036A)-IRES-
Puro HA-UBE3B(C1036A) pLVX-GW-IRES-Puro 
pLVX-HA-UBE3B(R992C)-IRES-Puro HA-UBE3B(R922C) pLVX-GW-IRES-Puro 
pLVX-HA-UBE3B(619-end)-IRES-
Puro HA-UBE3B(619-end) pLVX-GW-IRES-Puro 
pLVX-HA-UBE3B(619-
end)(C1036A)-IRES-Puro HA-UBE3B(619-end)(C1036A) pLVX-GW-IRES-Puro 
pLVX-HA-UBE3B(757-end)-IRES-
Puro HA-UBE3B(757-end) pLVX-GW-IRES-Puro 
pLVX-HA-UBE3B(757-
end)(C1036A)-IRES-Puro HA-UBE3B(757-end)(C1036A) pLVX-GW-IRES-Puro 
pLVX-HA-UBE3A-IRES-Puro HA-UBE3A pLVX-GW-IRES-Puro 
pLVX-HA-UBE3A(418-end)-IRES-
Puro HA-UBE3A(418-end) pLVX-GW-IRES-Puro 
pLVX-UBE3B(ΔIQ)-HA-IRES-Puro UBE3B(ΔIQ)-HA pLVX-GW-IRES-Puro 
pLVX-BirA-UBE3B-Puro BirA-UBE3B pLVX-GW-IRES-Puro 
pLVX-UBE3B-BirA-Puro UBE3B-BirA pLVX-GW-IRES-Puro 
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Lentiviruses were prepared in collaboration with the UPCI Lentiviral facility. Lentiviral 
particles were generated by co-transfection of 4 plasmids [Control plasmid (pLVX-IRES-Puro) 
or one of the plasmids expressing UBE3B or UBE3B mutants, together with pMD2.g (VSVG), 
pVSV-REV and pMDLg/pRRE] into 293-FT cells using TransIT®-2020 Transfection reagent. 
The collection and isolation of lentiviral particles and transduction of LN428 cells were 
performed as described previously (198,199).  Stable cell lines were developed by selection in 
puromycin (2 µg/mL) for 2 weeks. Overexpression of UBE3B (or the indicated mutants or 
fusions) was confirmed by immunoblot (Figure 16). All the stable cell lines developed and used 
in this study are listed in Table 3. 
 
 
Figure 14. Generation of UBE3B(R922C)-copGFP constructs. 
(A) Site-directed mutagenesis and DpnI digestion on plasmid pENTR-UBE3B with primers UBE3B(R922C)-F and 
UBE3B(R922C)-R to create pENTR-UBE3B(R922C) plasmid. (B) Optimization of the primers UBE3B-GFP-F and 
UBE3B-GFP-R using Platinum® Pfx DNA Polymerase and pENTR-UBE3B(R922C) in gradient PCR for 
amplification of UBE3B(R922C) with XbaI restriction digest sites for ligation into pCT-CMV-MCS-copGFP-Puro 
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vector. Gradient temperatures: 1: 52°C, 2: 52.5°C, 3: 53.6°C, 4: 54.9°C, 5: 57°C, 6: 59.6°C, 7: 62.6°C, 8: 65.2°C, 9: 
67.2°C, 10: 68.6°C, 11: 69.6°C, and 12: 70°C. Best temperature chosen was 70°C. (C) XbaI restriction digested 
pCT-CMV-MCS-copGFP-Puro vector, and digested and gel-purified PCR amplified UBE3B(R922C) insert for 
ligation using T4 DNA Ligase. (D) PCR amplification screen using Taq DNA Polymerase of mini-prep pCT-CMV-
UBE3B(R922C)-copGFP-Puro plasmids from transformed One Shot Top 10 E.coli cells. (E) Digestion of mini-prep 
pCT-CMV-UBE3B(R922C)-copGFP-Puro plasmids with either XbaI. If insert (UBE3B(R922C)) is present, 
expected band sizes with XbaI digestion are ~3000bp and ~8000bp. 
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Figure 15. PCR screen and digestion of UBE3B wild type and point mutant plasmids with XbaI and BamHI 
to determine insert orientation. 
(A) PCR amplification using Taq DNA Polymerase of mini-prep plasmids from One Shot Top 10 E.coli cells after 
transformation with ligated plasmids (a) pCT-CMV-copGFP-UBE3B-Puro, (b) pCT-CMV-UBE3B-copGFP-Puro, 
(c) Lanes 1-6 pCT-CMV-copGFP-UBE3B(R215C/I1059F)-Puro, and lanes 7-13 pCT-CMV-
UBE3B(R215C/I1059F)-copGFP-Puro, and (d) pCT-CMV-copGFP-UBE3B(R346Q)-Puro. (B) Digestion of mini-
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prep pCT-CMV-copGFP-UBE3B-Puro plasmids with either (a) XbaI or (b) BamHI. (C) Digestion of mini-prep 
pCT-CMV-UBE3B-copGFP-Puro plasmids with either (a) XbaI or (b) BamHI. (D) Digestion of mini-prep pCT-
CMV-copGFP-UBE3B(R215C/I1059F)-Puro plasmids with either (a) XbaI or (b) BamHI. (E) Digestion of mini-
prep pCT-CMV-UBE3B(R215C/I1059F)-copGFP-Puro plasmids with either (a) XbaI or (b) BamHI. If insert is 
present, expected band sizes with XbaI digestion are ~3000bp and ~8000bp, and with BamHI digestion, expected 
band sizes are ~500bp and ~10,000bp. 
 
 
Figure 16. Immunoblot of whole cell extracts (WCE) from LN428 cells stably expressing cop-GFP tagged 
UBE3B proteins. 
(A) Whole cell extracts (WCE) of cells transduced with different clones of wild type UBE3B with either N- or C-
terminus copGFP tags. (B) WCE of cells transduced with copGFP-UBE3B, UBE3B-copGFP, copGFP-
UBE3B(R922C), UBE3B(R922C)-copGFP, copGFP-UBE3BΔHECT or UBE3BΔHECT-copGFP. (C) WCE of 
cells transduced with UBE3B-copGFP, UBE3BΔHECT-copGFP, UBE3B(C1036A)-copGFP or copGFP-
UBE3B(R922C). Primary antibodies: Turbo-GFP and UBE3B. Loading control: XRCC1. Expected size of full 
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length and point mutant fusions: ~150kDa, ΔHECT mutants: ~98kDa. Positive controls: copGFP-MCS and MCS-
copGFP, where MCS is the Multiple Cloning Site. Negative control: No vector cells.  
 
Table 3. LN428 cell lines developed and used in this study. 
Cell line name Cell line description Growth media* 
LN428 Human glioblastoma tumor cell line Media #1 
LN428/UBE3B-copGFP 




































LN428 cells expressing 
UBE3B(R922C)-copGFP 
Media #2 
LN428/HA-UBE3B LN428 cells expressing HA-UBE3B Media #2 
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LN428/UBE3B-HA LN428 cells expressing UBE3B-HA Media #2 
LN428/HA-UBE3BΔHECT 








LN428 cells expressing HA-
UBE3B(R922C) 
Media #2 
LN428/HA-UBE3A LN428 cells expressing HA-UBE3A Media #2 
LN428/UBE3B(ΔIQ)-HA 
LN428 cells expressing 
UBE3B(ΔIQ)-HA 
Media #2 
LN428/BirA-UBE3B LN428 cells expressing BirA-UBE3B Media #2 
LN428/UBE3B-BirA LN428 cells expressing UBE3B-BirA Media #2 
4.3 TRANSIENT TRANSFECTIONS OF SIRNA 
UBE3B was depleted in LN428 cells by transient siRNA transfection, as previously described 
(200). Briefly, 4 x 105 LN428 cells were wet-reverse transfected with either 90nmol/L siRNA 
UBE3B-s40200 (Ambion) or 90nmol/L Silencer® Negative Control siRNA #2 (Applied 
Biosystems). The siRNA were prepared with siPORT™ NeoFX™ and OptiMEM and the 
transfections were incubated for 24 hours at 37°C before replacement with fresh media.  
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4.4 TRANSIENT TRANSFECTION OF PLASMIDS 
Proteins were overexpressed in LN428 cells by transient plasmid transfection. 1 x 106 cells were 
transfected with 7µg DNA. The plasmids were prepared with OPTI-MEM media and FuGENE® 
Transfection Reagent (Promega) for 30 minutes at room temperature before being added to the 
adherent cells dropwise. The transfections were incubated for 24 hours at 37°C before 
replacement with fresh media. 
4.5 MTS ASSAY 
Twenty-four hours after siRNA-mediated UBE3B KD, cells were seeded into 96-well plates at a 
density of 2,000 cells per well and allowed to grow for 48 hours at 37°C before determining the 
relative amount of metabolically active cells by an MTS assay. Results are the average of three 
separate experiments and normalized to the Silencer® Negative Control siRNA #2 cells, with 
error bars representing the standard error of the mean. 
4.6 QUANTITATIVE RT-PCR ANALYSIS 
Expression of UBE3B mRNA after siRNA-mediated KD was measured by quantitative RT-PCR 
(qRT-PCR) using an Applied Biosystems StepOnePlus system as described previously (201). We 
used the Applied Biosystems TaqMan Gene Expression Assay human UBE3B: 
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Hs00296200_m1, and normalized gene expression to the expression of human β-actin (Cat# 
4333762T).  
4.7 CELL EXTRACION, MITOCHONDRIA ISOLATION AND IMMUNOBLOT 
ANALYSIS 
Mitochondria were isolated using the Mitochondria Isolation Kit for Cultured Cells (Life 
Technologies). Mitochondrial extracts and whole cell extracts (WCE) were prepared using 2X 
clear Laemmli buffer (2%SDS, 20% glycerol and 63mM Tris-HCl pH 6.8). Protein 
concentrations were determined by the Bio-Rad Protein Assay Kit II (Cat# 500-0002) according 
to the manufacturer’s instruction. Ten micrograms of protein was loaded on precast 4%-12% 
Tris-Bis Novex® NuPAGE® SDS-PAGE gels (Life Technologies), run at 200V for an hour at 
room temperature and the proteins were transferred onto PVDF membrane (Bio-Rad). These 
membranes were blocked with 5% Milk in TBST for 1 hour shaking at room temperature and 
probed with respective antibodies overnight shaking at 4°C. Membranes were washed with 1X 
TBST, three times for 5 minutes each wash and then probed with secondary antibody for 1 hour 
shaking at room temperature before being washed as before. The membranes were developed 
using Immun-Star HRP Substrate onto X-Ray film (Thermo Fisher Scientific).  
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4.8 EXPRESSION AND PURIFICATION OF HIS-UBIQUITIN 
Flag-tagged human wild type ubiquitin (pcDNA3.1-Flag-humanUb) and phosphomimetic mutant 
S65D ubiquitin (pcDNA3.1-Flag-humanUb-S65D) plasmids were a generous gift from Dr. 
Noriyuki Matsuda at the Tokyo Metropolitan Institute of Medical Science. Complementary DNA 
was PCR amplified (using primers purchased from Eurofins MWG Operon) with an N-terminus 
polyhistindine tag (His) and cloned into pENTR/D-TOPO plasmid to create pENTR-Ub-WT and 
pENTR-Ub-S65D) vectors via a standard Topo-cloning methodology (197) (Figure 17). Once 
sequence verified, the open reading frames from the plasmids pENTR-Ub-WT and pENTR-Ub-
S65D were transferred into a pDEST-17 vector (Invitrogen) by an LR reaction using the 
Gateway LR Clonase II Enzyme Mix (Life Technologies) as per the manufacturer’s instruction. 
Positive clones were selected and plasmids were extracted with the QIAprep Spin Miniprep Kit 
(Qiagen). The pDEST-17-Ub-WT and pDEST-17-Ub-S65D plasmids were transformed into 
One-Shot BL21(DE3)pLysS Chemically Competent Cells (Life Technologies). To induce the 
expression of the His-Ub-WT and His-Ub-S65D proteins, bacterial cultures were allowed to 
grow at 37°C and 250 rpm to an OD600 = 0.5-0.7, before the addition of Isopropyl β-D-1-
thiogalactopyranoside (IPTG), for a final concentration of 1µM IPTG. The cultures were allowed 
to grow for another 3.5 hrs. The bacteria were pelleted at 6000 x g for 15 minutes at 4°C, 
followed by resuspension of the pellet in Buffer A (50 mM Tris-HCl pH 7.6, 100 mM NaCl, 0.1 
mM PMSF and 1 tablet protease inhibitor/20 mL Buffer A). The bacterial suspensions were 
pelleted at 6000 x g at 4°C for 15 minutes, supernatants discarded and the pellets frozen 
overnight at -80°C. The recombinant His-Ub-WT and His-Ub-S65D proteins were purified using 
the TALON® Metal Affinity Resin and HisTALON™ Buffer Set (Clontech) according to the 
manufacturer’s protocol. The purified proteins were dialyzed with Dialysis Buffer (50 mM Tris-
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HCl, pH 7.6; 100 mM NaCl, 0.5 mM EDTA and 5 mM DTT), changing the buffer four times, 
every 6-8 hours. The dialyzed proteins were concentrated using Amicon Ultra Centrifugal Filter 
Devices (EMD Millipore) and the protein concentrations were measured using the DC™ Protein 
Assay (Bio-Rad) (Figure 18).  
 
 
Figure 17. Generation of Ubiquitin(WT) and Ubiquitin(S65D) constructs. 
(A) Optimization of the primers Ubiquitin-F and Ubiquitin-R using Platinum® Pfx DNA Polymerase and (a) 
pcDNA3.1-Flag-Ubiquitin(WT), or (b) pcDNA3.1-Flag-Ubiquitin(S65D), in gradient PCR for amplification of (a) 
His-Ubiquitin(WT) or (b) His-Ubiquitin(S65D) respectively, for pENTR/D-TOPO cloning into pENTR vector. (B) 
PCR amplification screen using Taq DNA Polymerase of mini-prep (a) pENTR-His-Ubiquitin(WT), or (b) pENTR-
His-Ubiquitin(S65D) plasmids from transformed One Shot Top 10 E.coli cells. 
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Figure 18. Purification process for His-tagged Ubiquitin constructs. 
Schematic of the workflow used to create purified His-tagged ubiquitin wild type and S65D mutant and the 
coomassie stain of the purified His-ubiquitin proteins. Ubiquitin(WT) and Ubiquitin(S65D) was cloned into 
pENTR/D-TOPO vector and then transferred into the His-tag containing pDEST17 vector. BL21 cells were 
transformed with the pDEST17 vectors, cultured and induced to produce the proteins. The proteins were lysed, 
pelleted and purified following the ClonTech Talon His-column purification process. The eluate were dialyzed and 
concentrated to remove the purification salts and impurities, run on a SDS-PAGE gel, and coomassie stained. 
4.9 IMMUNOPRECIPITATION AND UBIQUITYLATION ACTIVITY ASSAY 
LN428 cells expressing HA-tagged UBE3B WT or mutant proteins (and HA-UBE3A as a 
positive control) were grown to 90% confluence in 100mm dishes and harvested using IP Lysis 
Buffer supplemented with Protease Inhibitor (both from Thermo Fisher Scientific). The lysates 
were rotated for 1 hour at 4°C before pelleting the cell debris. The supernatant was incubated by 
rotating overnight at 4°C with Anti-HA Affinity Matrix (Roche). The beads were washed with 
Binding Buffer (10mM Na2H2PO2, 10mM Na2HPO4 and 150µM NaCl; pH 7.0), followed by 
washes with Ubiquitylation Assay Buffer (10 mM Tris-HCl, pH 7.5, 100 mM NaCl, and 0.5 mM 
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DTT). The ubiquitylation assay was performed on the beads for 2 hours at 30°C in a volume of 
30µL containing 0.1µM E1 (Boston Biochem), 0.25µM of each of the E2s 
(UBE2A/UBE2D1/UBE2D3/UBE2G2/UBE2L3/UBE2N/UBE2S/UBE2Z) (Life Sensors), 1µM 
ubiquitin aldehyde (Boston Biochem), 0.75µg/µL purified His-ubiquitin (see below) and 1X 
Magnesium/ATP cocktail (EMD Millipore). The ubiquitylation assays were stopped by adding 
2X blue Laemmli (plus β-Mercaptoethanol) and heating the samples at 70°C for 15 minutes. 
Ubiquitylation activity was measured by immunoblot.  
4.10 AFFINITY CAPTURE OF BIOTINYLATED PROTEINS 
LN428 cells that stably express BirA-UBE3B or UBE3B-BirA proteins were grown to 80% 
confluence in 150mm dishes and incubated in complete media supplemented with 50µM biotin 
to allow for biotin labeling of proteins as previous described (195). Briefly, 24 hours after biotin 
addition, the cells were washed three times with PBS and lysed at 25°C in 1 mL Lysis Buffer (50 
mM Tris, pH 7.4, 500 mM NaCl, 0.4% SDS, 5 mM EDTA, 1 mM DTT, and protease inhibitor; 
Thermo Fisher Scientific) and sonicated. Triton X-100 was added to 2% final concentration. 
After further sonication, an equal volume of 4°C 50 mM Tris (pH 7.4) was added before 
additional sonication (subsequent steps at 4°C) and centrifugation at 16,000 relative centrifugal 
force. Supernatants were incubated with 100μl Dynabeads MyOne Steptavadin C1 (Life 
Technologies) overnight. Beads were collected and washed twice for 8 min at 25°C (all 
subsequent steps at 25°C) in 1 ml Wash Buffer 1 (2% SDS in dH2O). This was repeated once 
with Wash Buffer 2 (0.1% deoxycholate, 1% Triton X-100, 500 mM NaCl, 1 mM EDTA, and 50 
mM Hepes, pH 7.5), once with Wash Buffer 3 (250 mM LiCl, 0.5% NP-40, 0.5% deoxycholate, 
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1 mM EDTA, and 10 mM Tris, pH 8.1) and twice with Wash Buffer 4 (50 mM Tris, pH 7.4, and 
50 mM NaCl). Bound proteins were removed from the magnetic beads with 50μl of Laemmli 
SDS-sample buffer at 95°C. 
4.11 IMMUNOFLUORESCENCE AND CONFOCAL IMAGING 
Cells were cultured on glass coverslips for 24 hours before being fixed with 2% 
paraformaldehyde for 20 minutes, permeabilized with 0.1% Triton X-100 for 15 minutes, and 
blocked with 2% bovine serum albumin for 45 minutes, all at room temperature. Anti-ATP 
Synthase β antibody (Thermo Fisher Scientific) at 1:250 dilution was incubated for 1 hour, 
followed by goat anti-mouse Alexa Fluor 647 (Abcam) at 1:1000 for 1 hour and DAPI stain for 
30 seconds, all at room temperature. Slides were mounted and imaged on the Nikon A1 confocal 
microscope in the University of Pittsburgh Center for Biologic Imaging (CBI) and on the Nikon 
N-SIM super-resolution microscope at the USA Mitchell Cancer Institute Cellular and 
Biomolecular Imaging Facility. 
4.12 PMITO-TIMER TRANSFECTION AND ANALYSIS 
Cells were simultaneously transfected with siRNA specific to UBE3B and the plasmid encoding 
for the Mito-Timer reporter (Addgene). Transfection was performed as described above with the 
addition of pMito-Timer DNA to the transfection mixture. Cells were then plated on Fluorodish 
glass-bottomed dishes (World Precision Instruments), and imaged (live) 72 hours after 
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transfection with the Nikon A1rsi confocal microscope at the USA Mitchell Cancer Institute 
Cellular and Biomolecular Imaging Facility. 
4.13 LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY (LC-
MS/MS) ANALYSIS 
Immunoprecipitated samples were separated on SDS-PAGE gels (Bolt® 4-12% Bis-Tris Plus 
Gel, Life Technologies, Grand Island, NY) to about 1cm (150v for 10min) and stained with 
Simply Blue™ SafeStain (Life Technologies, Grand Island, NY). After washing with Milli-Q 
water, the whole stained regions were excised, washed with HPLC water and destained with 50% 
acetonitrile/25mM ammonium bicarbonate until no visible blue staining. Gel pieces were 
dehydrated with 100% acetonitrile, reduced with 10mM dithiothreitol (DTT) at 56°C for 1 hour, 
followed by alkylation with 55mM iodoacetamide (IAA) at room temperature for 45min in the 
dark. Gel pieces were then again dehydrated with 100% acetonitrile to remove excess DTT and 
IAA, and rehydrated with 20ng/µl trypsin in 25mM ammonium bicarbonate and digested 
overnight at 37°C. The resultant tryptic peptides were extracted with 70% acetonitrile/5% formic 
acid, speed-vac dried and re-constituted in 18µl 0.1% formic acid. 
Tryptic digests were analyzed using a high-resolution liquid chromatography tandem 
mass spectrometer as previously described (199,202). In brief, samples were loaded with a 
nanoAcquity autosampler (Waters, Waltham MA) onto a capillary sample trap column, separated 
using a reverse phase gradient on a commercial PicoChip™C18 column and electrospray 
ionization source (New Objective, Inc. Woburn MA).  Mass analysis was performed on a hybrid 
LTQ/Orbitrap Velos mass spectrometer (Thermo Fisher, Waltham MA). Data dependent 
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acquisition was used to acquire one high resolution full scan mass spectrum followed by 13 low 
resolution tandem mass spectra in the linear ion trap, with dynamic exclusion setting enabled to 
minimize redundant selection of precursor ions.    
MS/MS spectra were searched by COMET against an indexed human database build 
from a non-redundant NCBI human database with the following modifications: static 
modification of cysteine (carboxyamidomethylation, +57.02Da) and variable modification of 
methionine (oxidation, +15.99Da). The mass tolerance was set to 20ppm for precursor ions and 
0.8Da for fragment ions. Custom differential mass spectrometry software (dMS 1.0, InfoClinika, 
Seattle WA) was used to align, integrate, and link the high resolution peak areas data to the 
protein identification results from a COMET sequence database search (203). Relative 
quantitation is achieved by comparing the sum of all isotopes of particular defined peptides. 
Each resulting feature is defined by its particular m/z, elution time, charge state, and intensity. 
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5.0  RESULTS 
5.1 UBE3B’S PREDICTED STRUCTURE IS HOMOLOGOUS TO THE FAMILY OF 
HECT E3 LIGASES 
Previous reports have proposed that UBE3B belongs to the HECT subfamily of E3 ubiquitin 
ligases (204). However, there are no reports on the predicted structure or function of UBE3B. 
Therefore we used the software packages Protein Homology/analogY Recognition Engine 
(Phyre2) and CLUSTALW2 to identify and align homologous proteins to UBE3B, and predict 
the three-dimensional structure of the different domains of UBE3B (205-207). As shown in 
Figure 19A, the N-terminus of UBE3B is predicted to contain the calmodulin-binding (IQ) motif 
and the substrate binding domain. The C-terminus of UBE3B is the HECT domain, which is 
comprised of two lobes, the N-lobe that is predicted to bind to the E2(s), and the C-lobe that is 
predicted to contain the catalytic cysteine, which forms a covalent thioester bond with ubiquitin. 
The N- and C- lobes are connected via a flexible linker. To evaluate the conserved IQ motif and 
HECT domain of UBE3B, we aligned each with other homology motifs/domains (Figures 19B 
and C). Details of the alignment of either the IQ motif or the HECT domain with the top seven 
sequences as ranked by Phyre2 are given in Tables 4 and 5. 
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Figure 19. Alignment of HECT E3 ligases with UBE3B. 
(A) Schematic of UBE3B showing the IQ domain (amino acids 29-58) and the HECT domain (amino acids 757-
1068). The proposed 3-D structures of the IQ and HECT domains using Phyre2 are shown above the schematic. The 
N-terminus of HECT domains are known to bind to substrate. The HECT domain is composed of two lobes; the N-
lobe binds the E2(s), while the C-lobe contains the catalytic cysteine that binds ubiquitin. (B) Alignment of UBE3B 
with calmodulin binding domains as predicted by Phyre2 and using CLUSTALW2. (C) Alignment of UBE3B with 
HECT E3 ligase domains as predicted by Phyre2 and using CLUSTALW2. The conserved catalytic cysteine is 
highlighted in red. “*’ denotes a single fully conserved residue, “:” denotes conservation between groups of strongly 
similar properties, and “.” denotes conservation between groups of weakly similar properties. 
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Table 4. Details of the top seven sequence alignments with the IQ motif of UBE3B using Phyre2. 
Rank Template Alignment 
Coverage % 
Confidence %ID 
1 Myosin-5a 90 86.7 32 
2 Myosin Va 83 79.0 31 
3 Unconventional 
Myosin-1C 
73 77.4 39 
4 Myosin 66 77.0 24 
5 Smooth muscle 
myosin heavy chain 
86 74.9 19 
6 Myosin heavy chain, 
muscle 
66 74.3 30 
7 Myosin heavy chain 86 74.3 30 
The Alignment Coverage, Confidence and % ID for the IQ motif are shown. The Alignment Coverage gives the 
percentage of alignment between the query sequence and the template, the Confidence represents the probability 
(from 0-100) that the match between the query sequence and the template is a true homology, and the % ID is the 
likelihood the model is accurate. For extremely high accuracy models the % ID should be above 30-40% however, if 
the confidence is high even very low % ID (<15%) can be very useful. 
 
Table 5. Details of the top seven sequence alignments with the HECT domain of UBE3B using Phyre2. 
Rank Template Alignment 
Coverage % 
Confidence %ID 
1 Rsp5 97 100.0 34 
2 Huwe1 97 100.0 37 
3 HECT, E3 ligase 97 100.0 34 
4 Nedd4-like 96 100.0 36 
5 Smad 96 100.0 33 
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6 HECT, E3 ligase 97 100.0 30 
7 Ubr5 38 100.0 30 
The Alignment Coverage, Confidence and % ID for the HECT domain are shown. The Alignment Coverage gives 
the percentage of alignment between the query sequence and the template, the Confidence represents the probability 
(from 0-100) that the match between the query sequence and the template is a true homology, and the % ID is the 
likelihood the model is accurate. For extremely high accuracy models the % ID should be above 30-40% however, if 
the confidence is high even very low % ID (<15%) can be very useful. 
5.2 KNOWN MUTATIONS IN UBE3B 
From GWAS studies in humans, fourteen patients from 11 different families were found with 
homozygous mutations in UBE3B that resulted in KOS (157,159,191,192). One pair of 
monozygotic twins was found to carry a homozygous missense mutation in UBE3B that resulted 
in the amino acid R922 to C mutation and gave rise to autism and not KOS (193). All the known 
human UBE3B mutations so far are summarized in Figure 20. It is important to note that 
patients with homozygous missense mutations before the catalytic HECT domain presented with 
milder craniofacial dysmorphisms and no blepharophismosis, suggesting the importance of the 
HECT domain for the proper functioning of UBE3B (157,159,191,192).  
56 
 
Figure 20. Schematic of UBE3B with known mutations. 
UBE3B is 1068 amino acids long and consists of an IQ motif (denoted in blue) and a HECT domain (denoted in 
peach). Above the protein schematic (in black) are truncating mutations, while below the schematic (in green) are 
missense mutations. The N-terminus of HECT E3 ligases contain the substrate binding sites. The C-terminus 
consists of two lobes, the N-lobe contains the E2 binding sites, and the C-lobe contains the ubiquitin binding site and 
the catalytic cysteine. Amino acid 1036 is proposed to be the catalytic cysteine of UBE3B.  
5.3 UBE3B ASSOCIATES WITH THE MITOCHONDRIA 
To determine the subcellular localization of UBE3B and if the HECT domain affected 
localization, we created glioblastoma (LN428) cell lines that stably overexpress the different 
UBE3B constructs with copGFP tags (Schematic of constructs are shown in Figure 21 and 22). 
Using confocal microscopy on fixed cells, we determined that a majority of wild type UBE3B, 
UBE3B(C1036A), UBE3B(R922C), UBE3B(R215C/I1059F) and UBE3B(R346Q) co-localized 
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with the mitochondrial marker ATP Synthase β, while UBE3BΔHECT is significantly more 
cytosolic (Figures 23 and 24).  
                          
Figure 21. Schematic of copGFP-UBE3B constructs. 
Schematic depicting the UBE3B wild type and mutant constructs with N-terminus copGFP tag that were stably 
overexpressed in LN428 cells. The copGFP tag is in green, UBE3B is in yellow, the IQ motif is in blue, the HECT 
domain is a pink, and the position of the point mutants are in purple.  
                             
Figure 22. Schematic of UBE3B-copGFP constructs. 
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Schematic depicting the UBE3B wild type and mutant constructs with C-terminus copGFP tag, that were stably 
overexpressed in LN428 cells. The copGFP tag is in green, UBE3B is in yellow, the IQ motif is in blue, the HECT 
domain is a pink, and the position of the point mutants are in purple.          
 
Figure 23. Immunofluorescence showing the association of copGFP-UBE3B wild type and mutants with the 
mitochondria. 
(A) LN428 cells were transduced with lentiviral particles to create stable cell lines that expressed copGFP-UBE3B, 
copGFP-UBE3BΔHECT, copGFP-UBE3B(R215C/I1059F) or copGFP-UBE3B(R346Q) protein. The mitochondria 
were stained with ATP Synthase β as a marker, fixed and imaged using the Confocal A1 Nikon Microscope. (B) 
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Quantification of the co-localization of UBE3B with the mitochondrial marker ATP Synthase β, using NIS 
Element software and PRISM.              
 
 
Figure 24. Immunofluorescence showing the co-localization of UBE3B-copGFP wild type and mutants with 
the mitochondria. 
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(A) LN428 cells were transduced with lentiviral particles to create stable cell lines that expressed copGFP, UBE3B-
copGFP, UBE3BΔHECT-copGFP, UBE3B(C1036A)-copGFP or UBE3B(R922C)-copGFP protein. copGFP was 
used as a positive GFP control. The mitochondria were stained with ATP Synthase β and the nucleus with DAPI, 
fixed and imaged using the Confocal A1 Nikon Microscope. (B) Quantification of the co-localization of UBE3B 
with the mitochondrial marker ATP Synthase β, using NIS Element software and PRISM.              
 
At this point we decided to continue the project only with the C-terminus copGFP 
constructs, namely, UBE3B-copGFP, UBE3BΔHECT-copGFP and UBE3B(C1036A)-copGFP 
because the location of the copGFP tag does not seem to affect the subcellular localization of 
UBE3B.  
We confirmed the immunofluorescence results by subcellular fractionation, where we 
isolated the mitochondria from the stable expressing cell lines, followed by immunoblot analysis 
(Figure 25A). To confirm that UBE3B’s subcellular recruitment to the mitochondria was not an 
artifact of the overexpression of the tagged proteins, we isolated mitochondria from the control 
LN428 cells and showed the presence of endogenous UBE3B in the mitochondrial fraction 
(Figure 25B).  
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Figure 25. Subcellular fractionation of UBE3B-copGFP wild type and mutants confirm the 
immunofluorescence co-localization of UBE3B with the mitochondria. 
(A) To confirm the immunofluorescence results, subcellular fractionation of the stable cell lines was performed, and 
the mitochondria were isolated. Immunoblots to compare the whole cell lysates (input) and mitochondrial preps 
(mitopreps) were performed. Ab specific to TurboGFP was used to detect UBE3B-copGFP proteins, α-Tubulin was 
used as a cytosolic marker, and Tom20 was used as a mitochondrial marker. (B) To show that endogenous UBE3B 
is on the mitochondria and the immunofluorescence and subcellular fractionation results in A and B are not an 
artifact of overexpression, we performed subcellular fractionation and immunoblot for endogenous UBE3B in 
LN428 cells. 
5.4 KNOCKDOWN OF UBE3B DECREASES MITOCHONDRIAL FUNCTION AND 
CHANGES THE MORPHOLOGY OF THE MITOCHONDRIA 
Since we found that UBE3B associates with the mitochondria, we wanted to identify if changes 
in UBE3B protein expression levels affected mitochondrial morphology. To do this UBE3B was 
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depleted (knocked down; KD) in LN428 cells using siRNA from Ambion (Figure 26A). Via 
MTS Assay, it was determined that loss of UBE3B resulted in decreased NAD(P)H-dependent 
cellular oxidoreductase enzyme activity, an indicator of decreased cellular survival and 
mitochondrial function (Figure 26B). Using fixed cell confocal microscopy we saw that the 
mitochondria of UBE3B-KD cells were more punctate-like, instead of the more linear and 
reticular network observed in the scrambled siRNA (negative control) cells (Figure 26C). To 
confirm that the fragmented phenotype of the mitochondria in the UBE3B-KD was due to the 
loss of mitochondria, we measured the total number of mitochondrial voxels, and found that it 
was significantly decreased in the UBE3B-KD cells as compared to the healthy control cells 
(Figure 26D).  
A novel methodology to study mitochondrial function and biogenesis in cells uses the 
fluorescent probe, pMitoTimer (208-211). The pMitoTimer vector expresses a mitochondrially-
targeted green fluorescent protein whose emission spectrum shifts irreversibly towards the red 
when oxidized (209). Seventy-two (72) hours after co-transfection of pMitoTimer and either 
UBE3B siRNA or scrambled siRNA, the cells were imaged using live cell confocal microscopy. 
We saw  a significantly higher red to green ratio in the UBE3B-KD cells, thus supporting our 
results that mitochondrial function and turnover are affected when UBE3B is depleted from the 
cells (Figure 26E). It is important to note that since pMitoTimer is a dual-emission probe and a 
number of factors can affect its readout, follow-up experiments need to be performed to confirm 




Figure 26. Knockdown of UBE3B results in changes in mitochondrial morphology and a decrease in 
mitochondrial function. 
LN428 cells were transfected with 90nM (final concentration) siRNA UBE3B or scrambled siRNA for 72 hours 
before being used for subsequent experiments. (A) qRT-PCR was performed to measure the knockdown of UBE3B 
mRNA expression levels. β-Actin was used as the endogenous control and mRNA expression was normalized to 
siRNA untreated cells. (B) To determine cellular survival, 2000 cells/well were plated 24 hours after siRNA 
transfection. After 48 hours incubation, an MTS Assay was performed. (C) To determine if there are changes to the 
mitochondrial morphology after depletion of UBE3B protein, confocal imaging was performed on fixed cells, 72 
hours after knockdown (transfection of siRNA). ATP Synthase beta is the mitochondrial marker (excitation 
wavelength: 647 nm, emission wavelength: 666 nm). (D) Z-stacking using the confocal microscope on the fixed 
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cells from (C) was performed to determine the changes in mitochondrial voxels in UBE3B-KD cells as compared to 
scrambled treated cells. (E)  To determine if UBE3B knockdown affected mitochondrial biogenesis, cells were co-
transfected with UBE3B siRNA and the ratiometric reporter vector pMito-Timer. Confocal imaging was performed 
72 hours after transfection. (F) Quantitation of collected images from (E) show a decrease in mitochondrial 
biogenesis in knockdown cells. 
5.5 UBE3B CAN SELF-UBIQUITYLATE USING ITS HECT-DOMAIN CATALYTIC 
CYSTEINE 
HECT E3 ligases have been shown to form poly-ubiquitylation chains on their catalytic 
HECT domains before the transfer of the ubiquitin chain to their substrates (152,212). Therefore, 
the ubiquitylation activity of these ligase proteins can be determined in in vitro ubiquitylation 
assays even without a known substrate. Recent publications have shown a novel activation 
mechanism for Parkin wherein phospho-mimic ubiquitin (Ub-S65D) can activate Parkin and 
increase the poly-ubiquitin chain formation on Parkin as opposed to wild type ubiquitin (Ub-
WT) (101,105,106). We expressed and purified recombinant His-tagged wild type ubiquitin 
(His-Ub-WT) or His-tagged phospho-mimic ubiquitin (His-Ub-S65D) (Figures 17 and 18) and 
used these to determine if UBE3B’s E3 ligase function is activated in the same way as Parkin in 
cells. We performed an in vitro ubiquitylation activity assay using either His-Ub-WT or His-Ub-
S65D and immunoprecipitated N-terminus HA-tagged UBE3B (HA-UBE3B) (Figure 27A). We 
did not see a difference in the formation of poly-ubiquitin chains on UBE3B between the two 
forms of ubiquitin. Next, we wanted to determine if poly-ubiquitylation on UBE3B was time 
dependent. For this we measured the in vitro ubiquitylation activity on UBE3B at 30 minute 
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intervals from 0 hours up to 3 hours (Figure 27B). An increase in the poly-ubiquitin chain 
formation is seen with the increase in time, with a plateau at 2 hours.  
 
Figure 27. UBE3B is a HECT E3 ligase that can self-ubiquitylate its catalytic cysteine C1036 in vitro. 
Cell lysates from LN428 cells that stably express UBE3A, UBE3B, UBE3BΔHECT or UBE3B(C1036A), all with 
N-terminal HA tags were immunoprecipitated (IPed) using Anti-HA Affinity Matrix and subjected to ubiquitylation 
activity assays. The ubiquitylation assays were carried out in 30µL reactions with 0.1µM E1, 0.25µM of each of the 
E2s (UBE2A/UBE2D1/UBE2D3/UBE2G2/UBE2L3/UBE2N/UBE2S/UBE2Z), 1µM ubiquitin aldehyde, 0.75µg/µL 
His-ubiquitin and 1X Magnesium/ATP cocktail, unless otherwise stated. The HECT E3 ligase, UBE3A was used as 
a positive control. (A) Ubiquitylation activity assay was performed in vitro using His-tagged wild type ubiquitin 
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(His-Ub-WT) or phosphomimetic ubiquitin (His-Ub-S65D). (B) Time dependent increase in poly-ubiquitin chain 
formation was seen in the ubiquitylation assay. (C) Polyubiquitin chain formation was lost when ubiquitin, or E1, 
E2s and ATP were removed from the reaction mix, or after 20 µg of the catalytic core of the deubiquitinating 
enzyme USP2 was added to a completed reaction for 30 minutes at 37°C. (D) Polyubiquitin chains were not formed 
in the reactions containing the catalytic inactive (HA-UBE3B(C1036A)) and HECT delete (HA-UBE3BΔHECT) 
mutants of UBE3B. Completed reactions were applied to immunoblot for analysis of ubiquitylation with 
hemagglutinin (HA), UBE3B or Ubiquitin (Ub) antibodies. Bottom panel shows comparable loading of the 
immunoprecipitated proteins. Representative immunoblots from three independent experiments are shown. 
Antibodies used for each of the immunoblots are listed on the side of the panels. 
 
To show that this ubiquitylation activity was specific to UBE3B and not a reaction 
between the cocktail of E1, E2s, ubiquitin and Mg2+/ATP, a drop-out ubiquitylation assay was 
performed. Here, one enzyme/set of enzymes was missing from each reaction. As a control to 
show that the smear seen was indeed ubiquitylation, the catalytic core of the deubiquitylating 
(DUB) enzyme USP2 was added to the in vitro ubiquitylation assay that contained all the 
enzymes after 2 hours (Figure 27C) (210). Lastly, to show that the HECT domain of UBE3B, 
specifically the proposed catalytic cysteine in the HECT domain, catalyzes the formation of the 
poly-ubiquitylation chains observed, the ubiquitylation activity was performed using UBE3B 
with an inactive catalytic cysteine (HA-UBE3B(C1036A)) or UBE3BΔHECT (HA-
UBE3BΔHECT) (Figure 27D). As shown, the mutation of C1036 or the deletion of the HECT 
domain eliminated the ubiquitylation activity. 
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5.6 UBE3B INTERACTS WITH CALMODULIN VIA ITS IQ MOTIF 
As seen from Figure 19B, UBE3B contains a proposed IQ motif near its N-terminus, suggesting 
an interaction between UBE3B and calmodulin (213-215). Thus far, there are no known E3 
ligases that interact with calmodulin. Therefore, determining if calmodulin binds to and/or 
regulates UBE3B will be a novel finding. Since HA-tagged UBE3B (HA-UBE3B) is readily 
immunoprecipitated from stable LN428/HA-UBE3B cells, we analyzed the immunoprecipitated 
proteins by mass spectrometry. Quantification results for two proteotypic CaM peptides showed 
a significant increase in signal for both peptides bound to either HA-UBE3B or HA-
UBE3B(C1036A), with only a background-level signal in the control cells (Figure 28A). The 
interaction between UBE3B and calmodulin was also confirmed by immunoprecipitation of HA-
UBE3B followed by immunoblot for calmodulin (Figure 28B). These results were also 
confirmed when calmodulin (eGFP-HA-His-CALM1) was overexpressed in UBE3B-copGFP 
cells, immunoprecipitated and the isolated proteins were probed for UBE3B by immunoblot 
(Figure 28C).  
To more elegantly determine if the UBE3B and calmodulin interaction is observed in 
cells and not limited to a protein-protein interaction in cell lysates, we developed the Bio-ID 
system to validate UBE3B interacting proteins by fusing the promiscuous E. coli biotin ligase 
BirA-R118G to either the N- or C-terminus of UBE3B and developed stable cell lines expressing 
each (Figure 29). These cells were then pulsed with biotin (50 µM; 24 hrs) and the resulting 
biotinylated proteins represent those ‘in proximity’ of UBE3B, within 10 nm (195,216). In 
support of the mass spectrometry and IP/IB results above, we find that calmodulin is strongly 
biotinylated in cells expressing either BirA-UBE3B or UBE3B-BirA but not in control cells and 
only when biotin is added to the cells 24 hrs prior to lysate preparation (Figure 28D). This 
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supports our contention that UBE3B and calmodulin interact and is in-line with earlier reports 
that the resulting biotinylated proteins are within 10 nm of the BirA-fusion protein in cells (216).  
 
Figure 28. UBE3B associates with Calmodulin through its IQ motif and the interaction is calcium-dependent. 
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 (A) Quantification results for two proteotypic calmodulin peptides, VFDKDGNGYISAAELR and 
DTDSEEEIREAFR. Bar graphs of mean and SEM following affinity purification and high resolution LC-MS 
analysis of LN428 cells expressing an empty vector, wild type HA-tag UBE3B (HA-UBE3B), and the catalytic 
inactive UBE3B with an HA-tag (HA-UBE3B(C1036A)). (B) Immunoblot to confirm the interaction of CaM to 
UBE3B as seen by LC-MS. (C) To confirm that the interaction between CaM and UBE3B is specific, we performed 
reverse IPs, where eGFP-HA-His-CALM1 was overexpressed in UBE3B-copGFP cells and lysates were HA-IPed. 
Immunoblots were probed against CaM and UBE3B antibodies. We used HA-UBE3B as a positive control for the 
IPs, and the expected size of UBE3B-copGFP is 150kDa. (D) BioID expression of BirA-UBE3B and UBE3B-BirA 
with Streptavidin IP to confirm the HA-UBE3B and CaM interaction. Lanes 1-6 are Input and Lanes 7-12 are 
Streptavidin IP samples. Lanes 1-3 and 7-9 were not treated with Biotin; and Lanes 4-6 and 10-12 were treated with 
5 µM Biotin for 24 hours before harvest. Lanes 1, 4, 7 and 10 are cells with no vector; Lanes 2, 5, 8 and 11 are cells 
that stably express BirA-UBE3B protein; and Lanes 3, 6, 9 and 12 are cells that stably express UBE3B-BirA protein. 
(E) LN428 cells were transiently transfected with UBE3BΔIQ-HA plasmid followed by immunoprecipitation with 
HA-Affinity Matrix beads after 24 hours. Ubiquitylation assay as described in Figure 26 was performed on the 
beads and immunoblots were performed on the reaction using Ubiquitin, HA and CaM antibodies. (F) CaM 
interaction with UBE3B is lost when IP beads are washed with CaCl2. Ubiquitylation is increased when CaM is not 
bound to UBE3B. 
 
To show that the interaction between calmodulin and UBE3B is indeed through the IQ 
motif, we created UBE3B(ΔIQ)-HA, where the IQ motif of UBE3B was deleted (amino acids 1-
63) (Figure 28E). Immunoblot confirmed the loss of this CaM-UBE3B interaction after 
immunoprecipitation. Interestingly, we also saw an increase in poly-ubiquitin chains with 
UBE3B(ΔIQ) compared with wild type UBE3B in the in vitro ubiquitylation assays (Figure 
28E).  
Lastly, we wanted to determine if the CaM-UBE3B binding was calcium dependent or 
independent. To do this, we washed the immunoprecipitation HA-Affinity Matrix beads with 
70 
Binding and Ubiquitylation Buffers supplemented with either 5mM CaCl2 or 1mM EGTA (a 
calcium specific chelator) before the in vitro ubiquitylation assays. CaM binding is lost with the 
CaCl2 washes, while the ubiquitylation activity of UBE3B is increased (Figure 28F).  
 
Figure 29. Schematic of BirA and UBE3B fusions and expression process. 
(A) Schematic of the two Biotin Ligase (BirA) and UBE3B constructs used. One has BirA on the N-terminus of 
UBE3B, and the other has BirA on the C-terminus of UBE3B. (B) Schematic for the creation of stable cell lines 
expressing either BirA-UBE3B or UBE3B-BirA proteins. The fusions were inserted into a lentivirus vector and 
stable cell lines were created. Cells were treated with 50 nM Biotin for 24 hours, harvested, immunoprecipitated 






6.0  DISCUSSION 
Ubiquitylation is a well-controlled, tightly regulated three step post translational process that 
controls the fate of its target protein. The third step involves an E3 ligase that controls the 
substrate specificity and timing of ubiquitylation with every E3 ligase interacting with only 
specific substrate proteins. HECT E3 ligases are the second most abundant family of E3 ligases 
(123,217). It is important to note that HECT E3 ligases retain the decision of ubiquitylation type 
because of their distinctive mode of action while RING E3 ligases are more promiscuous in the 
type of ubiquitylation they perform and depend on their E2 partner to define the type of 
ubiquitylation (218). Here we focus on defining the function and identifying the interactors of 
the novel HECT E3 ligase UBE3B in glioblastoma cells.  
We had previously performed a synthetic lethal siRNA screen in glioblastoma cells and 
determined that knockdown of UBE3B resulted in sensitization of the cells to Temozolomide 
(TMZ) treatment (200). In the same study we also found that within 30 minutes of treatment with 
TMZ, ROS was produced in the cell, specifically in the mitochondria. Besides the GWAS 
studies that identified homozygous mutations in UBE3B as the cause of KOS, no studies have 
been published about the cellular function of UBE3B. From our Phyre2 and CLUSTALW2 
alignments, UBE3B is proposed to be a HECT E3 ligase with an IQ motif at its N-terminus and a 
C-terminus HECT domain, with the region around the catalytic cysteine being highly conserved 
and homologous to other well-studied E3 ligases such as UBE3C, Huwe1, Nedd4, Itch and 
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Hace1. Our first goal was to determine the subcellular localization of UBE3B. From the stable 
cell lines that expressed UBE3B with a copGFP tag, we saw that UBE3B associates with the 
mitochondria. However, when the HECT domain of UBE3B is deleted, we see a more cytosolic 
expression of the protein. Since the copGFP tag did not affect mitochondria localization, we 
decided to only use the C-terminus cop-GFP cell lines for the subcellular fractionation 
experiments. Here we confirmed the results of the immunofluorescence where we see a reduction 
of UBE3BΔHECT protein compared to UBE3B wild type and UBE3B(C1036A) proteins in the 
mitochondria fraction. 
Next we wanted to determine if knocking down UBE3B would impact the cell, especially 
the mitochondria. It has been shown that the C.elegans ortholog of UBE3B, oxi-1, was required 
for proteasomal degradation after oxidative stress (157). We found that knocking down UBE3B 
using siRNA resulted in a more fragmented, punctate-like mitochondrial network compared to 
the tubular mitochondria of the control siRNA cells. Interestingly, mitochondrial biogenesis in  
UBE3B-KD cells was decreased when compared with the control. These results suggest that 
UBE3B might play an important role in regulating morphology and oxidative stress levels in 
mitochondria. We were unable to generate stable cell lines depleted of UBE3B suggesting a 
critical role of UBE3B in cellular survival. 
From our results using the in vitro ubiquitylation assays, we have demonstrated that 
UBE3B is indeed a HECT E3 ligase that uses its catalytic cysteine to bind to ubiquitin and form 
poly-ubiquitin chains. Deletion of the HECT domain and inactivation of the catalytic cysteine 
results in loss of UBE3B’s ability to form poly-ubiquitin chains. Unlike the RING-in-between-
RING (RBR) E3 ligase Parkin, UBE3B’s ubiquitylation activity is not enhanced by the binding 
of phosphomimetic ubiquitin (Ub-S65D) (105,106,219,220). HECT E3 ligases are involved in a 
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large number of cellular processes, from UBE3C promoting growth and metastasis of renal cell 
carcinoma, to Nedd4 enhancing cell proliferation and autophagy, to Itch inhibiting skin 
inflammation (221-223). Amongst the reported disease-associated mutations in UBE3B that 
cause Kaufman oculocerebrofacial syndrome (KOS), the seven different nonsense, frame-shift 
and splice site mutations that are predicted to cause protein truncation before or at the beginning 
of the HECT domain, and therefore abolish UBE3B’s ligase activity, have the most severe 
phenotypic effects (157,159,191,192). Therefore, our results defining that the HECT domain of 
UBE3B is the active E3 ubiquitin ligase domain are consistent with these clinical findings. 
Identifying E3 ligase substrates is extremely difficult as the interaction between the E3 
ligase and substrates are generally weak and transient. One novel approach is proximity-
dependent biotin labeling (BioID), a novel, semi-quantitative mass spectrometry method that is 
used to identify interacting proteins in cells. A recent study combined 26S proteasome inhibitor 
(MG132) treatment with BioID labeling to identify the interacting partners of the beta transducin 
repeat-containing polypeptides β-TrCP1 (FBXW1) and β-TrCP2 (FBXW11), which are part of 
the E3 ligase SCF complex (224). In combination with mass spectrometry, we used two different 
labeling methods to identify the interacting partners of UBE3B, HA-UBE3B and BirA/UBE3B 
fusions. CaM was one of the proteins that were identified in both the mass spectrometry 
experiments (Figure 28). From the literature, the IQ motif of proteins has been known to interact 
with calmodulin, the universal calcium sensor in eukaryotes (214,225-227). Calcium binding to 
calmodulin has been shown to induce major conformational changes in the IQ motifs and to 
increase the flexibility of the myosin-1c tail (228). Therefore, we believe that calmodulin might 
be a regulatory factor, rather than a substrate for UBE3B’s function. From studies on auto-
inhibition of HECT E3 ligases, one study performed by Wang et al showed that calcium binds to, 
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and activates the E3 ligase Nedd4 by releasing the C2 domain auto-inhibition (229). From our 
studies, we found that deletion of UBE3B’s IQ motif abolishes the interaction with CaM and 
results in a significant increase of UBE3B’s ability to form poly-ubiquitin chains in vitro. We 
also found that increasing the calcium concentration in the reaction releases the CaM binding 
with wild type UBE3B followed by an increase in UBE3B’s ubiquitylation activity. Therefore 
we propose that an increase in calcium signaling within the cell results in the disassociation of 
the calmodulin interaction with UBE3B, which activates UBE3B and enhances its ubiquitylation 
activity. 
       
Figure 30. Schematic of UBE3B’s activation in response to calcium signaling/mitochondrial stress. 
We propose that the E3 ligase UBE3B associates with the mitochondria. Under normal cellular conditions, UBE3B 
is bound to calmodulin through its N-terminus IQ motif in a calcium-dependent manner. However, in response to 
mitochondrial stress the intracellular calcium levels increase thereby activating CaM and releasing it from UBE3B. 
CaM-free UBE3B can now bind to its substrates (potentially damaged mitochondrial proteins) and ubiquitylate 
substrates for degradation by the UPS.  
 
 We propose a dynamic model for the regulation of mitochondrial structure and 
ubiquitylation that comprises the secondary messenger calmodulin, the HECT E3 ligase UBE3B 
and damaged mitochondrial proteins (Figure 30). We hypothesize that CaM inhibits UBE3B’s 
75 
E3 ligase activity. When there is an increase in calcium signaling after mitochondrial stress, CaM 
is activated. Activated calmodulin in turn is released from UBE3B thus allowing for its 
ubiquitylation activity to ubiquitylate damaged mitochondrial proteins for proteasomal 
degradation. Thus, identifying the substrates of UBE3B will be important to determine the 
clinical significance of UBE3B mutations and determine a therapeutic strategy for patients who 
suffer from KOS. 
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7.0  FUTURE DIRECTIONS 
The findings during this dissertation are novel and exciting for the field of ubiquitylation. This is 
the first study, which we know of, that shows CaM directly interacting with and modulating the 
function of an E3 ligase.  However this is only the beginning in the long road of discoveries for 
the function of, and role played by UBE3B. I would like to outline a few of these potential future 
directions for this project.  
7.1 STUDYING THE ROLE OF CALMODULIN BINDING TO UBE3B  
The interaction between UBE3B and CaM is turning out to be an exciting discovery. We saw 
two important results, (i) CaM binding is lost when there is an excess of Ca+2, and reduced when 
the Ca+2 levels are chelated by EGTA, and (ii) UBE3B’s ubiquitylation activity is increased in 
both these cases compared to when CaM is strongly bound. This leads us to believe that any 
perturbations to the intracellular Ca+2 levels in the cell (which could be because of an increase in 
ROS in the cell, or an influx of Ca+2 from extracellular sources) activates UBE3B’s E3 ligase 
activity to ubiquitylate damaged proteins, thus reducing the harmful effects they can have on the 
overall survival of the cell. It is important to note that we were unable to create stable cell lines 
that expressed UBE3BΔIQ-HA protein, and transient transfection of the construct lead to the 
death of a high number of cells compared with the control. Therefore the next step would be to 
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develop an inducible system to control the expression of UBE3BΔIQ-HA protein in our cells. 
This way we can try and determine the death pathways that are activated when UBE3BΔIQ is 
overexpressed, evaluate the impact on mitochondrial morphology and function and determine the 
sub-cellular localization of UBE3B when not bound to CaM, among many other possible 
endpoints.  
As seen from our mass spectrometry results in Appendix B, PP2A is one potential 
protein that is associated with UBE3B. Therefore, we can determine how the phosphorylation 
occurs (explained in greater detail in Appendix B), and if PP2A phosphorylation and CaM 
binding working agonistically or antagonistically to effect the function of UBE3B.  
We can use the wide array of newly synthesized fluorescent protein (FP) chimeras that 
modulate their fluorescence in response to intracellular Ca+2 changes (230). Thus we can use live 
cell imaging to see if there are changes in the sub cellular localization of UBE3B (more 
recruitment to the mitochondria, perhaps?), see if there are differences between varied expression 
levels of UBE3B (overexpressed, normal and KD) after calcium signaling over time, or 
determine a good time to harvest the cells for the in vitro ubiquitylation assay.  
We now know that the IQ motif of UBE3B is required for binding to CaM. To determine 
the amino acids critical for this association we can start by mutating each of the key IQ residues 
IQAHVRSFLCR individually to alanine. We can start combining two-three mutations at a time 
to determine if multiple residues are required for this interaction. 
Therefore, there are a large number of experiments that can be conducted to study how 
the UBE3B-CaM interaction occurs and how it affects the cell.  
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7.2 VALIDATION OF THE INTERACTION BETWEEN UBE3B AND THE MASS 
SPECTROMETRY IDENTIFIED PROTEINS  
The proteins identified during our mass spectrometry experiments (detailed in Appendix B) 
provide a large number of directions we can follow for this project. We are currently in the 
process of using the new BirA/UBE3B fusion constructs followed by mass spectrometry to 
confirm the HA-UBE3B results and/or identify other potential UBE3B interacting proteins. Once 
we have narrowed our list to highly probable hits, we can start to validate those one-by-one using 
methods similar to the ones we will use to study the UBE3B-CaM interaction stated above 
(Section 7.1).   
7.3 EFFECTS OF DISEASE ALLELES ON UBE3B’S ACTIVITY 
To date, fourteen patients with homozygous mutations in UBE3B are known to suffer from the 
disease KOS. These mutations are listed in Figure 20. It will be very interesting to study how 
each of these clinically relevant mutations affect the subcellular localization and activity of 
UBE3B in cells. Methods such as (i) ubiquitylation activity assay to determine if UBE3B’s 
activity is affected, (ii) MTS assay to determine changes in mitochondrial function and cell 
survival, (iii) Cell proliferation assays such as CellTiter GLO and crystal violet, (iv) JC-1 as a 
marker for changes in mitochondrial membrane potential, and (v) live and fixed-cell imaging 
assays to determine the changes in the expression of mitofusion and mitofission markers (MFNs 
and Drp1), can be employed. It will also be of interest to see how/if the interaction between 
UBE3B and calmodulin is affected by these mutations.  
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7.4 E2(S) THAT BIND TO UBE3B 
 Recent studies have found that specific E2(s) bind different E3s and control their activity in the 
ubiquitylation reaction (231,232). In this dissertation we used eight E2s in the in vitro 
ubiquitylation activity assays for UBE3B. To determine which E2(s) are specific for UBE3B 
from this array, we will have to repeat the ubiquitylation activity assays with each E2 
individually, or a combination of E2s. From the Phyre2 results, it is predicted that the E2 binding 
sites are at positions F826, N829, L830, S832, I833, Y836, L843, L845, Y849, D850, D852, 
L857, L862, Y879 and M883. Therefore, once we identify the E2(s) that bind to UBE3B, we can 
mutates these amino acids and determine which residue is important for the interaction. In the 
case of Parkin, it was seen that UBE2D, UBE2L3 and UBE2N all resulted positively regulated 
its activation, translocation and enzymatic function (233). Interestingly, UBE2R1 functions 
antagonistically to these three E2s, wherein it inhibits the translocation of Parkin to the 
mitochondria and prevents Parkin from ubiquitylating its target proteins (233). Therefore, it will 
be interesting to see if there are E2(s) that perform a similar antagonist effect on the function of 
UBE3B.   
7.5 IS THE FUNCTION OF UBE3B DIFFERENT IN OTHER CELL LINES  
The studies on UBE3B we have performed so far are all using the glioblastoma cell line, LN428. 
It will be interesting to know if UBE3B functions in the same way in other high energy cell lines 
such as the heart and muscle, where its mRNA expression levels are high, as well as cells that 
have a lower mRNA expression level, such as the breast and pituitary cells (for more information 
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please visit http://www.genecards.org/cgi-bin/carddisp.pl?gene=UBE3B and 
http://www.gtexportal.org) (234-238). We will need to perform similar experiments as we did 
using the different LN428 cell lines we developed and compare the results to determine if the 
enzymatic function and associated proteins of UBE3B are similar between the different cell 
lines.  
7.6 CRYSTAL STRUCTURE OF UBE3B 
There are a vast number of programs available today that predict the three dimensional structure 
of proteins. However, having the crystal structure of a protein is invaluable. Not only will you be 
able to know the unique tertiary structure of the protein, but you can also determine regions of 
high flexibility, and how proteins change their spatial arrangement to modulate their function 
during protein-protein interactions, to name a few. Therefore, we will be able to learn a lot more 
about UBE3B once we are able to solve its crystal structure. We will also be able to then 
determine how the clinical mutations affect this structure and its interactions, thus helping us 






STUDY OF THE FUNCTION OF ANKZF1 IN THE MITOCHONDRIA 
A.1 INTRODUCTION 
Fuzzy onion (Fzo) is an outer mitochondrial membrane (OMM) protein that mediates 
mitochondrial fusion and is the best characterized mitochondrial target of ubiquitin-proteasome 
system (UPS) dependent degradation in yeast (184,239). The human homologs are known as 
mitofusin 1 and mitofusin 2 (MFN1, MFN2). After mitochondrial stress, the E3 ubiquitin ligase 
Parkin is recruited and ubiquitylates damaged mitochondrial proteins such as MFNs1/2 and 
hexokinase I (HKI) (240,241). Until the characterization of the ubiquitin-dependent molecular 
chaperone, p97, it was not known how the UPS removed damaged proteins from the OMM 
(242). p97, also known as valosin-containing protein (VCP) or Cdc48 in yeast and 
Caenorhabditis elegans (C.elegans), is an ATPase Associated with diverse cellular Activities 
(AAA). In addition to the mitochondrial UPS, p97 also participates in endoplasmic reticulum 
(ER) proteostasis, autophagy and membrane remodeling (242-246), with mutations in p97 being 
associated with a wide spectrum of degenerative diseases from inclusion body myopathy with 
Paget’s disease of bone and frontotemporal dementia (IBMPFD) to Parkinson’s disease (PD) 
(247-249). Thus p97 plays a key role in the two main degradation systems in a cell: the 
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proteasome and the autophagy pathways (250). The p97 protein is composed of a N-terminal 
domain, an unstructured C-terminal domain and two ATPase cassettes (D1 and D2). The ATPase 
cassettes are required to extract polyubiquitylated proteins from the mitochondria and present 
them for proteasomal degradation (251-253). Therefore, ubiquitin serves as a major determinant 
of p97 function (254).  
Since p97 is involved in diverse, unrelated cellular functions and pathways, it relies on 
different adaptor proteins (also known as p97 cofactors) to determine its specificity (255-257). 
Cofactors of p97 cofactors are defined as proteins that contain p97-interacting domains or motifs 
such as the ubiquitin binding and ubiquitin interacting motifs. Recently, studies performed in 
yeast identified a new Cdc48/p97-binding cofactor, Vms1 (258-260). Under normal growth 
conditions the Vms1 complex resides in the cytosol. However, on treatment with mitochondrial 
toxicants Vms1 recruits Cdc48/p97 and Npl4 (another Cdc48 cofactor), to the mitochondria to 
extract ubiquitylated proteins for proteasomal degradation (258). Deletion of VMS1 caused an 
increase in polyubiquitylated mitochondrial proteins, a decrease in the rate of Fzo1 degradation 
(a known substrate of the mitochondrial E3 ligase Mdm30), biochemical defects and respiratory 
failure. Knockdown of Vms1 in C.elegans resulted in hypersensitivity to H2O2 (259,261). High 
levels of the loss-of-function variant of ubiquitin B (UBB) UBB+1 impairs the UPS to overcome 
the mechanisms that would eliminate the proteins, which in turn affects mitochondrial dynamics 
and triggers cell death (262-267). A recent study has found that the cell cytotoxicity of UBB+1 is 
antagonized by Cdc48/Vms1 complexes (268). Thus, in yeast and C. elegans Vms1 is critical at 
the mitochondria for cellular and organismal viability under conditions of mitochondrial stress. 
However, the cellular function of the human analog of Vms1, Ankyrin repeat and zinc finger 
domain containing 1 (ANKZF1) (also referred to as VMS1) is currently unknown and 
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identification of its function will be critical to developing therapeutic agents for mammalian 
diseases. 
A.2 METHODS AND MATERIALS 
A.2.1 Chemicals and Reagents 
OptiMEM, alpha EMEM and phosphate buffered saline (PBS) were from Invitrogen. FuGENE® 
Transfection Reagent (Cat# E2311) was from Promega. Puromycin was from Clontech 
Laboratories, and gentamycin was from Irvine Scientific. All the plastic tissue culture supplies 
were from Corning and Thermo Fisher Scientific. All PCR primers were from Eurofins MWG 
Operon. DreamTaq DNA Polymerase (Cat# FEREP0703) was from Thermo Fisher Scientific 
and dNTPs (Cat# 4303442) were from Life Technologies. The Pfu Turbo DNA Polymerase 
(Cat# 600250) and QuickChange II XL site-Directed Mutagenesis kit (Cat# 200521) were from 
Agilent Technologies. The TOPO® TA Cloning® Kit for Sequencing, with One Shot® TOP10 
Chemically Competent E.coli (Cat# K4575-40), Gateway® LR Clonase® II Enzyme Mix (Cat# 
11791-100) and T4 DNA Ligase (Cat# EL0011) were from Life Technologies. Restriction 
enzymes XbaI, EcoRI and Bsu36I were from New England Biolabs. The QIAquick PCR 
Purification Kit (Cat# 28106) and QIAquick Gel Extraction Kit (Cat# 29706) were from 
QIAGEN. Oligomycin (Cat# O4876), Rotenone (Cat# R8875), H2O2 (Cat# H1009) and MG132 
(Cat# C2211) were from Sigma. Primary antibodies: β-actin antibody (Cat# A1978) from Sigma, 
Turbo-green fluorescent protein (TurboGFP) antibody (Cat# AB513) from Evrogen, adenosine 
triphosphate synthase beta (ATP synthase β) antibody (Cat# MA1-930) from Thermo Fisher 
84 
Scientific. Secondary antibodies: goat anti-mouse horseradish peroxidase (GAM-HRP) 
conjugates and goat anti-rabbit horseradish peroxidase (GAR-HRP) conjugates were from Bio-
Rad, goat anti-mouse Cy5 (Cat# ab150115) from Abcam and goat anti-rabbit Cy3 (Cat# A-
11011) was from Life Technologies. The Novex® NuPAGE® SDS-PAGE gel systems were 
from Life Technologies. Signal generation substrates were from Bio-Rad and Thermo Fisher 
Scientific.   
A.2.2 Stable Cell line generation and culture conditions 
LN428 glioblastoma cells and culture conditions were as previously described (196). Cells were 
maintained at 37°C in 5% CO2 and grown in alpha EMEM media containing 10% heat-
inactivated fetal bovine serum (FBS), antibiotic/antimycotic, ʟ-glutamine and gentamycin. 
Human pRS425-ANKZF1 complementary DNA was a kind gift from Jeffrey Brodsky 
(University of Pittsburgh). With this plasmid as the template, ANKZF1-copGFP protein was 
made, either via standard PCR. The sequence of each primer is listed in Table 1. Briefly, we used 
pRS425-ANKZF1 and pCT-CMV-MCS-copGFP-EF1-Puro vector (System Biosciences), and 
primer pair ANKZF1-XbaI-F and ANKZF1-EcoRI-R (Figure 31A). The open reading frame was 
PCR amplified to engineer the restriction enzyme sites XbaI and EcoRI for cloning in-frame with 
copGFP using standard protocols. After PCR, products were digested with the enzymes; purified 
fragments were ligated into the pCT-CMV-MCS-copGFP-EF1-puro lentiviral vector also 
hydrolysed by XbaI and EcoRI (Figure 31B). Positive clones were selected; plasmids were 
extracted with the QIAprep Spin Miniprep Kit (Qiagen), and sequenced (Figure 31C). To 
determine if ANKZF1 was correctly inserted into the pCT-CMV-copGFP-MCS-EF1-Puro 
vector, the clones were digested with Bsu36I. If the constructs were present in the correct 
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orientation, there was a 2000bp and an 8000bp band (Figure 31D). Sequence-verified plasmids 
were transiently transfected and lentivirus production was as described below.   
 
Figure 31. Generation of ANKZF1-copGFP stable cell lines. 
(A) Optimization of the primers ANKZF1-XbaI-F and ANKZF1-EcoRI-R using Platinum® Pfx DNA Polymerase 
and plasmid pRS426-ANKZF1 in gradient PCR for amplification of ANKZF1 with XbaI and EcoRI restriction 
digest sites for ligation into pCT-CMV-MCS-copGFP-Puro vector. Gradient temperatures: 1: 52°C, 2: 52.5°C, 3: 
53.6°C, 4: 54.9°C, 5: 57°C, 6: 59.6°C, 7: 62.6°C, 8: 65.2°C, 9: 67.2°C, 10: 68.6°C, 11: 69.6°C, and 12: 70°C. Best 
temperature chosen was 70°C. (B) XbaI and EcoRI restriction digested and gel-purified PCR amplified ANKZF1 
insert and pCT-CMV-MCS-copGFP-Puro vector for ligation using T4 DNA Ligase. (C) PCR amplification screen 
using Taq DNA Polymerase of mini-prep pCT-CMV-ANKZF1-copGFP-Puro plasmids from transformed One Shot 
Top 10 E.coli cells. (D) Digestion of mini-prep pCT-CMV-ANKZF1-copGFP-Puro plasmids with Bsu36I enzyme. 
LN428 cells were transduced with lentiviral particles to create stable cell lines expressing ANKZF1-copGFP protein 
(E) lysed to make whole cell extracts (WCE) and immunoblotted, or (F) fixed and imaged using the Confocal A1 
Nikon Microscope. The mitochondria were stained with ATP Synthase β as a marker. 
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Lentiviruses were prepared in collaboration with the UPCI Lentiviral facility. Lentiviral 
particles were generated by co-transfection of 4 plasmids [Control plasmid (pLVX-IRES-Puro) 
or one of the plasmids expressing UBE3B or UBE3B mutants, together with pMD2.g (VSVG), 
pVSV-REV and pMDLg/pRRE] into 293-FT cells using TransIT®-2020 Transfection reagent. 
The collection and isolation of lentiviral particles and transduction of LN428 cells were 
performed as described previously (198,199).  Stable cell lines were developed by selection in 
puromycin (2 µg/mL) for 2 weeks. Overexpression of ANKZF1-copGFP was confirmed by 
immunoblot (Figure 31E).  
A.2.3 Transient Transfections of Plasmids 
Proteins were overexpressed in LN428 cells by transient plasmid transfection. 1 x 106 cells were 
transfected with 7µg DNA. The plasmids were prepared with OPTI-MEM media and FuGENE® 
Transfection Reagent (Promega) for 30 minutes at room temperature before being added to the 
adherent cells dropwise. The transfections were incubated for 24 hours at 37°C before 
replacement with fresh media. 
A.2.4 Cell Extract 
Whole cell extracts (WCE) were prepared using 2X clear Laemmli buffer (2%SDS, 20% 
glycerol and 63mM Tris-HCl pH 6.8), and the protein concentrations were determined by the 
Bio-Rad Protein Assay Kit II (Cat# 500-0002), according to the manufacturer’s instruction. Ten 
micrograms of protein was loaded on precast 4%-12% Tris-Bis Novex® NuPAGE® SDS-PAGE 
gels (Life Technologies), run at 200V for an hour at room temperature and the proteins were 
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transferred onto PVDF membrane (Bio-Rad). These membranes were blocked with 5% Milk in 
TBST for 1 hour shaking at room temperature and probed with respective antibodies overnight 
shaking at 4°C. Membranes were washed with 1X TBST, three times for 5 minutes each wash 
and then probed with secondary antibody for 1 hour shaking at room temperature before being 
washed as before. The membranes were developed using Immun-Star HRP Substrate onto X-Ray 
film (Thermo Fisher Scientific).   
A.2.5 Treatment with Oligomycin, Rotenone and MG132 
5 x 104 cells were plated on coverslips and allowed to attach overnight at 37°C, 5% CO2. The 
next day the media was removed and fresh media containing either no drug, 2µM Oligomycin 
(Sigma), 2µM Rotenone (Sigma), or 25µM or 50µM MG132 (Sigma) was added and any 
changes in the cells was observed for up to 2 hours. The cells were fixed and imaged following 
the Immunofluorescence and Confocal Imaging Protocol.  
A.2.6 Treatment with H2O2 
5 x 104 cells that stably overexpressed either ANKZF1-copGFP or Mito-copGFP were plated on 
coverslips and allowed to attach overnight at 37°C, 5% CO2. The next day the media was 
removed and fresh media containing either no drug or 0.25mM or 0.5mM H2O2 (Sigma) was 
added to the cell for 3 hours. The cells were fixed and imaged following the 
Immunofluorescence and Confocal Imaging Protocol.  
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A.2.7 Immunofluorescence and Confocal Imaging 
Cells were cultured on glass coverslips for 24 hours before treatment. The treated cells were 
fixed with 2% paraformaldehyde for 20 minutes, permeabilized with 0.1% Triton X-100 for 15 
minutes, and blocked with 2% bovine serum albumin for 45 minutes, all at room temperature. 
Anti-ATP Synthase β antibody (Thermo Fisher Scientific) at 1:250 dilution was incubated for 1 
hour, followed by goat anti-mouse Alexa Fluor 647 (Abcam) at 1:1000 for 1 hour and DAPI 
stain for 30 seconds, all at room temperature. Slides were mounted and imaged on the Nikon A1 
confocal microscope in the University of Pittsburgh Center for Biologic Imaging (CBI). 
A.3 ANKZF1 RESULTS AND DISCUSSION 
The current model for mitochondrial protein degradation suggests that (i) damaged 
mitochondrial proteins are presented on the surface of the outer mitochondrial membrane 
(OMM), (ii) Parkin is recruited from the cytosol to the mitochondria in response to the change in 
mitochondrial membrane potential, (iii) the damaged proteins are ubiquitylated by Parkin and 
additional E3 ligases, and (iv) the ubiquitylation recruits the Vms1/Cdc48 complex to degrade 
the proteins via the proteasomal degradation pathway (269-271). In studies performed by Heo et 
al. they found that under normal log phase growth, the levels of Fzo1 are identical in wild-type 
and the Vms1 deletion mutant (vms1Δ), however, the vms1Δ mutant exhibited elevated levels of 
Fzo1 protein at day 2.5 of culture (261). Therefore, they concluded that Vms1 is required for 
mitochondrial protein degradation. 
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In this project we wanted to study the function of the human homology of Vms1, 
ANKZF1. Using the data available from the Vms1 studies, we predict the domain structure of 
ANKZF1 as detailed in Figure 32.  
 
Figure 32. Schematic representation of the domain structure of full-length ANKZF1 with C-terminus GFP 
Tag. 
Full-length ANKZF1 contains a zinc-finger domain (ZnF), a mitochondrial targeting domain 
(MTD), an ankyrin repeat (Ank R), a predicted coiled-coil region (CC), and a VCP (Valosin-
containing protein) interacting motif (VIM). Adapted from (258). 
 
To study ANKZF1, we generated stable cells that overexpressed ANKZF1 with a C-
terminus copGFP. Using confocal microscopy we were able to show that ANKZF1, just like its 
yeast homolog Vms1, is cytosolic under normal growing conditions (Figure 33). It was found 
that Vms1 was recruited to the mitochondria after treatment with H2O2 and depletion of Vms1 in 
C.elegans resulted in hypersensitivity to H2O2 (259,261). We wanted to determine the effects of 
H2O2 on ANKZF1. We treated our stable overexpressing cell lines with 0.25mM and 0.5mM 
H2O2 and observed the changes in the subcellular localization of ANKZF1 over 3 hours. As seen 
in Figure 33, ANZKF1 is recruited from the cytosol to the perinuclear region. However, this 
recruitment does not coincide with the mitochondria, therefore suggesting that ANKZF1 is 
recruited to another organelle besides the mitochondria. From the study performed by Tran et al., 
they found that the Saccharomyces cerevisiae homolog of ANKZF1, Vms1p, is involved in the 
90 
ERAD pathway (259). Therefore, ANKZF1 might also play a similar function in the post-
ubiquitylation step in ERAD and the recruitment of ANKZF1 we see after H2O2 treatment could 
be to the ER.  
 
   
Figure 33. Treatment with H2O2 recruits ANKZF1 to the perinuclear region, but not the mitochondria. 
LN428 cells were transduced with lentiviral particles to create stable cell lines that express either ANKZF1-copGFP 
or Mito-copGFP proteins. The cells were treated with no drug, 0.25mM H2O2, or 0.5mM H2O2 for 3 hours, washed 
fixed and imaged using the Confocal A1 Nikon Microscope. The mitochondria were stained with ATP Synthase β 
and the nucleus with DAPI. 
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Lastly we treated the cells with 2µM Oligomycin, 2µM Rotenone, or two concentrations 
of MG132 (25µM or 50µM) to determine if the subcellular localization of ANKZF1 changes in 
the cell. We noticed that after 2 hours of treatment with MG132, ANKZF1 is recruited to the 
mitochondria (Figure 34). However, this mitochondrial recruitment is not observed with the 
treatment of Oligomycin. It is important to note that treatment with Rotenone completely killed 
the cells, even after only a 10 minute treatment with the drug (data not shown).  
   
Figure 34. ANKZF1 is recruited to the mitochondria after treatment with MG132 but not Oligomycin. 
LN428 cells were transduced with lentiviral particles to create stable cell lines that express ANKZF1-copGFP 
proteins. The cells were treated with no drug, 50µM MG132 or 2µM Oligomycin for 2 hours, washed fixed and 
imaged using the Confocal A1 Nikon Microscope. The mitochondria were stained with ATP Synthase β and the 
nucleus with DAPI.  
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Identification of the function of ANKZF1 in mammalian cells will be important because 
of the crucial role its homologs play in the yeast and C.elegans UPS system. Even though we 
could not study this pathway in the detail we had proposed, continued efforts will be made to 
finish the proposed aims by the lab.  
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APPENDIX B 
MASS SPECTROMETRY ANALYSIS OF UBE3B BINDING PROTEINS 
B.1 INTRODUCTION 
Mass spectrometry (MS) is a very useful technique that is now widely used to identify the 
amount and type of chemicals present in a compound by measuring the mass-to-charge ratio and 
the abundance of gas-phase ions (272). Briefly, the atoms or molecules are first charged 
(ionized) by removing electrons to yield a positive ion. Next, the ions are accelerated and 
deflected by a magnetic field based on their masses, such that, the lighter the ion, the more they 
deflect. Lastly, these ions are passed through a machine that detects them electronically (272).  
In our research we wanted to identify the proteins that associate with UBE3B. Therefore, 
we used Affinity Capture – MS (AC-MS) where a bait protein (here it is UBE3B) is affinity 
captured from cell extracts by either polyclonal antibody or, in our case, epitope tag and the 
associated interaction partner(s) are then identified by MS methods.  
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B.2 RESULTS AND DISCUSSION 
There is no prior report in the literature describing the isolation of proteins associated with 
UBE3B. Therefore, to identify proteins that are associated with UBE3B in vivo we used the LC-
MS/MS approach and HA-UBE3B and HA-UBE3B(C1036A) as the bait proteins. Our 
experiments identified 40 proteins that we deem specifically associated with UBE3B (Figure 
35).  
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Figure 35. Peptides identified from LC-MS/MS of proteins associated with UBE3B. 
40 potential peptides that associate with UBE3B were identified. Bar graphs of mean and SEM following affinity 
purification and high resolution LC-MS analysis of LN428 cells expressing an empty vector, wild type HA-tag 
UBE3B (HA-UBE3B), and the catalytic inactive UBE3B with an HA-tag (HA-UBE3B(C1036A)). 
 
Amongst them are the E1 activating enzyme ubiquitin-like modifier-activating enzyme 1 
(UBA1), and a deubiquitylating enzyme ubiquitin carboxyl-terminal hydrolase 5 (USP5), which 
fits with our main results that UBE3B is an E3 ligase that participates in ubiquitylation. 
Interestingly, we also identified the nuclear import and export proteins Importin-4 (IPO4) and 
exportin-1 (XPO1). Given these findings we ran a nuclear export sequence (NES) test on 
UBE3B using LocNES (http://prodata.swmed.edu/LocNES/LocNES.php), an online Support 
Vector Machine (SVM) predictor that locates classical nuclear export signals (NESs) in CRM1 
cargoes. We found five potential NES sequences (Table 6). It is important to note that we did 
not see any nuclear localization in our overexpression cell lines. Therefore, the interactions 
between UBE3B and IPO4 and/or XPO1 will need to be validated further to confirm the mass 
spectrometry data.  
 
Table 6. There are five potential NES of UBE3B as predicted by LocNES. 
Position Sequence Score 
29-43 RERAAVVIQAHVRSF 0.006 
71-85 RSALCIFKIARKLLF 0.032 
72-86 SALCIFKIARKLLFL 0.038 
73-87 ALCIFKIARKLLFLF 0.021 
75-89 CIFKIARKLLFLFRI 0.044 
151-165 EILQDSRLITLYLTM 0.313 
153-167 LQDSRLITLYLTMLV 0.096 
155-169 DSRLITLYLTMLVTF 0.105 
199-213 HLNQHGFYSVLQILL 0.010 
223-237 CLSKGTLTAAFSLAL 0.080 
226-240 KGTLTAAFSLALRPV 0.012 
241-255 IAAQFSDNLIRPFLI 0.005 
246-260 SDNLIRPFLIHIMSV 0.010 
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253-267 FLIHIMSVPALVTHL 0.018 
256-270 HIMSVPALVTHLSTV 0.072 
263-277 LVTHLSTVTPERLTV 0.120 
305-319 EGCHTLCLMGNLLHL 0.189 
323-337 SPRVLEEETDGFVSL 0.108 
366-380 FSQSVDYGLNESMHL 0.011 
373-387 GLNESMHLITKQLQF 0.037 
374-388 LNESMHLITKQLQFL 0.014 
382-396 TKQLQFLWGVPLIRI 0.015 
384-398 QLQFLWGVPLIRIFF 0.031 
387-401 FLWGVPLIRIFFCDI 0.064 
451-465 RVDSAEVQKVCNICV 0.008 
465-479 VLYQTSLTTLTQIRL 0.022 
467-481 YQTSLTTLTQIRLQI 0.087 
481-495 ILTGLTYLDDLLPKL 0.040 
488-502 LDDLLPKLWAFICEL 0.043 
518-532 DTEESKQLLAMLMLF 0.078 
534-548 DCSRHLITILDDIEV 0.188 
549-563 YEEQISFKLEELVTI 0.030 
556-570 KLEELVTISSFLNSF 0.251 
558-572 EELVTISSFLNSFVF 0.038 
613-627 EDHWLRKDLKPSVLF 0.004 
633-647 DRKRAQLILQYIPHV 0.010 
671-685 VETSSASPHVTHITI 0.007 
700-714 QLSQHAMKGVIRVKF 0.015 
706-720 MKGVIRVKFVNDLGV 0.015 
735-749 LEEIIKRVFDPALNL 0.067 
778-792 VGKMLGKAVYEGIVV 0.000 
782-796 LGKAVYEGIVVDVPF 0.003 
787-801 YEGIVVDVPFASFFL 0.019 
790-804 IVVDVPFASFFLSQL 0.012 
874-888 ENKISYIHLMAHFRM 0.023 
892-906 IKNQTAALISGFRSI 0.057 
982-996 PPLLGFAYLKPPFSI 0.009 
987-1001 FAYLKPPFSIRCVEV 0.005 
1007-1021 TGDTLGSVLRGFFTI 0.312 
1028-1042 GRLPTSSTCFNLLKL 0.094 
1047-1061 KKSVLREKLRYAISM 0.045 
1053-1067 EKLRYAISMNTGFEL 0.039 
All predicted NES sequences on UBE3B with the predicted scores. The top five significant NES sequences were 
identified on UBE3B and are in bold. The first column is location of the NES candidate, the second column is the 
sequence of the NES candidate, and the last column is the probability of the candidate being a real NES. Cross-
validation showed that a cutoff of 0.1 gives 68% recall rate with 26% precision. Recall is defined as the fraction of 
real NESs whose probability score is higher than the cutoff value. Precision measures the percentage of real NESs 
among NES candidates with probability score higher than a cutoff. 
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The protein kinase, Ca2+/calmodulin-dependent protein kinase IV (CaMKIV) functions as 
a potent stimulator of Ca+2-dependent gene expression and has also been shown to stably 
associate with protein serine/threonine phosphatase 2A (PP2A) (273-275). However, the timing 
and mechanism of binding of these two complexes to CaMKIV was unknown. Recently, it was 
found that the Ca2+/CaM binding-autoinhibitory domain of CaMKIV is required for association 
of the kinase with PP2A and that binding of PP2A and Ca2+/CaM appears to be mutually 
exclusive (276).  Therefore it is proposed that CaMKIV is activated when intracellular Ca+2 
levels are increased, and dephosphorylation of CaMKIV by PP2A terminates this activation 
(276). In our MS analysis, we found CaM and Protein Phosphatase 2A, Catalytic subunit, Alpha 
isoform (PPP2CA) as potential interactors of UBE3B. PPP2CA is a subunit of PP2A. PPP2CA 
and γ-H2AX co-immunoprecipitated and co-localized at DNA double-strand break foci, with 
PPP2CA dephosphorylating γ-H2AX in vitro. When PPP2CA was inhibited by RNA 
interference γ-H2AX foci persisted, there was an inefficiency of DNA repair, and the cells were 
hypersensitive to DNA damage (277). Therefore, we hypothesize that CaM and PPP2CA 
function antagonistically as the activator and deactivator of UBE3B, respectively, just as 
Ca+2/CaM and PP2A regulate the function of CaMKIV.   
The website The Biological General Repository for Interaction Datasets (BioGRID) 
(http://thebiogrid.org) is an open access database that archives and disseminates genetic and 
protein interaction data from model organisms and humans (278). One of the four proteins 
predicted to interact with UBE3B is IQ motif containing B1 (IQCB1), which was isolated in a 
high-throughput proteomic study using human retinal pigment epithelial (RPE) cells (279). The 
IQCB1 protein is linked to the ciliopathic group of disorders which includes Nephronophthisis 
(NPHP), Joubert syndrome (JBTS), and Meckel-Gruber syndrome (MKS), and manifests 
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clinically as cystic kidney disease, cerebellar/neural tube malformation, retinal degeneration, 
cerebellar vermis aplasia (a significant malformation of the cerebellum that is linked to ataxia), 
and occipital encephalcele (279-282). It is important to note that we did not isolate this peptide in 
our mass spectrometry analysis of UBE3B binding proteins. A possible explanation for this 
discrepancy could be because the interaction between UBE3B and IQCB1 occurs only under 
certain cellular conditions, ones that did not occur in our cells before harvest. Also, it is highly 
possible that UBE3B interacts with different proteins in different cells.  
Cav3.2 is a T-type Ca+2 channels that transmits nociceptive signals in the primary afferent 
pain pathway and is ubiquitylated by the E3 ligase WWP1 (283). The deubiquitylating enzyme 
USP5 was found to interact with Cav3.2 and knockdown of USP5 increased Cav3.2 
ubiquitylation, thereby decreasing Cav3.2 protein levels and reducing the whole cell current. As 
mentioned before, USP5 was found to be associated with UBE3B during our mass spectrometry 
analysis. Therefore, it will be very interesting to validate this interaction, and see if the 
UBE3B/USP5 complex acts as a dynamic pair that ubiquitylate/deubiquityate proteins to 
maintain cellular homeostasis, or if USP5 is a deubiqutylating enzyme that controls the function 
of UBE3B and prevents it from ubiquityating undamaged target proteins.   
The results from this section are novel and exciting for the study of UBE3B. The next 
steps would be to validate the identified peptides, and then uncover the mechanisms that govern 




DEVELOPMENT AND ANALYSIS OF MITOCHONDRIAL-TARGETED, ROS-
INDUCING DNA DAMAGING PROTEINS 
C.1 INTRODUCTION 
Replication of mtDNA is independent of cellular division with only a few enzymes that are 
known to participate in this process, all of which are encoded by the nuclear DNA (nDNA) and 
imported into the mitochondria (284). mtDNA is organized in dynamic structures which consists 
of mitochondrial proteins and the mtDNA, and are known as nucleoids. The proteins that are 
involved in mtDNA transcription and packaging, such as mitochondrial RNA polymerase 
(POLRMT), Twinkle, mitochondrial single-stranded DNA-binding protein (mtSSB), and 
mitochondrial transcription factor B2 and A (TFB2M and TFAM) are localized in the nucleoids 
and are essential for the replication process (284-286). TFAM is the most abundant protein and 
functions in packaging and compaction of mtDNA (287-289). Because mtDNA replication is cell 
cycle independent, its replication rates are higher than that of nDNA, thus increasing the 
possibility of mutations and increased sensitivity to damage (290).  
Complex I and III of the ETC in the mitochondria are important sources of ROS, 
particularly the superoxide anion, and during non-replicative phases, oxidative damage 
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represents one of the main types of DNA damage in aerobic organisms (291,292). A novel 
approach to study oxidative damage in the different organelles of a cell uses a fluorescent 
dependent signal that relies on the interaction between a reporter polypeptide and a small 
chemical label (the fluorogen) that is only fluorescent when bound to the reporter (293). These 
reporter polypeptides are selected from a library of single chain antibodies (scFv’s), improved by 
directed evolution to increase their specificity, and renamed to fluorogen activating proteins 
(FAPs) (293). Therefore, each FAP is now specific to a particular fluorogen.  
Here we endeavored to create FAPs that are targeted to the mitochondria via a TFAM 
sequence. Using different FAPs, we want to generate different constructs that, when bound to a 
fluorogen, will generate different types of ROS in the mitochondria, thus allowing us to study the 
differences in mitochondrial damage based on that particular oxidative stress.  
C.2 METHODS AND MATERIALS 
C.2.1 Chemicals and Reagents 
OptiMEM, alpha EMEM and phosphate buffered saline (PBS) were from Invitrogen. FuGENE® 
Transfection Reagent (Cat# E2311) was from Promega. Puromycin was from Clontech 
Laboratories, and gentamycin was from Irvine Scientific. All the plastic tissue culture supplies 
were from Corning and Thermo Fisher Scientific. All PCR primers were from Eurofins MWG 
Operon. DreamTaq DNA Polymerase (Cat# FEREP0703) was from Thermo Fisher Scientific 
and dNTPs (Cat# 4303442) were from Life Technologies. The Pfu Turbo DNA Polymerase 
(Cat# 600250) and QuickChange II XL site-Directed Mutagenesis kit (Cat# 200521) were from 
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Agilent Technologies. The TOPO® TA Cloning® Kit for Sequencing, with One Shot® TOP10 
Chemically Competent E.coli (Cat# K4575-40), Gateway® LR Clonase® II Enzyme Mix (Cat# 
11791-100) and T4 DNA Ligase (Cat# EL0011) were from Life Technologies. Restriction 
enzymes XbaI, EcoRI and Bsu36I were from New England Biolabs. The QIAquick PCR 
Purification Kit (Cat# 28106) and QIAquick Gel Extraction Kit (Cat# 29706) were from 
QIAGEN. Primary antibody: adenosine triphosphate synthase beta (ATP synthase β) antibody 
(Cat# MA1-930). Secondary antibodies: goat anti-mouse Cy3 (Cat# ab97035) from Abcam and 
DRAQ5 (Cat# 62254) were from Thermo Fisher Scientific. 
C.2.2 Stable Cell line generation and culture conditions 
LN428 glioblastoma cells and culture conditions were as previously described (196). Cells were 
maintained at 37°C in 5% CO2 and grown in alpha EMEM media containing 10% heat-
inactivated fetal bovine serum (FBS), antibiotic/antimycotic, ʟ-glutamine and gentamycin. 
Human pCMV6-TFAM-TurboGFP, pBABE-NLS-HA-mCer3, pBABE-NLS-myc-
Charlie-G4S-mCer3, pBABE-NLS-myc-dH6-2XG4S-mCer3, pBABE-NLS-myc-dL5-2XG4S-
mCer3, pLVX-GFP-LC3-P2A-Luc-T2A-FP635-IRES-Puro, pLVX-TRE3G-TagRFP/TRF1 and 
pLVX-TRE3G-KR/TRF1 complementary DNA was a kind gift from Marcel Bruchez (Carnegie 
Mellon University/University of Pittsburgh). With these plasmids as template, we amplified 
Human TFAM, mCer3, Charlie-mCer3, dH6-mCer3, dL5-mCer3, TagRFP and KillerRed via 
standard PCR. The sequence of each primer is listed in Table 1. Briefly, we made TFAM with 
different C-terminus joining ends using primer pair TFAM-F/TFAM-mCer3-R, TFAM-
F/TFAM-Charlie-R, TFAM-F/TFAM-dH6-R, TFAM-F/TFAM-dL5-R, TFAM-F/TFAM-FP635-
R, TFAM-F/TFAM-TagRFP-R, TFAM-F/TFAM-KR-R, mCer3 using primer pair TFAM-
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mCer3-R/mCer3-R, Charlie-mCer3 using primer pair TFAM-Charlie-F/mCer3-R, dH6-mCer3 
using primer pair TFAM-dH6-F/mCer3-R, dL5-mCer3 using primer pair TFAM-dL5-R/mCer3-
R, FP635 using primer pair TFAM-FP635-F/FP635-R, TagRFP using primer pair TFAM-
TagRFP-F/TagRFP-R, and KillerRed using primer pair TFAM-KR-F/KR-R.  
 
Table 7. Oligodeoxynucleotides used. 




















TFAM was fused on the N-terminus of the different FAPs. The mCer3 and TagRFP tags were used as a subcellular 
fluorescent marker for the proteins and can be used as a negative control when a fluorogen is added. 
 
The open reading frames of mCer3, Charlie-mCer3, dH6-mCer3, dL5-mCer3, TagRFP 
and KillerRed were engineered to include 10 base pairs (bp) of TFAM on their N-terminus for 
PCR joining with respective TFAM, which was also engineered to include between 19-28 bp of 
each of the FAPs on its C-terminus. Joining PCR was carried out with PCR purified products for 
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10 cycles without polymerase to join the respective products, and then used in standard PCR 
with polymerase (Figure 36A). PCR purified complementary DNA was cloned into pENTR/D-
TOPO plasmid to create the pENTR-UBE3B vector as per standard Topo-cloning methodology 
(197). Positive clones were selected and plasmids were extracted with the QIAprep Spin 
Miniprep Kit (Qiagen) (Figures 36B).  
Once sequenced verified, the open reading frames from each of the plasmids, pENTR-
TFAM-mCer3, pENTR-TFAM-mCer3-Charlie, pENTR-TFAM-mCer3-dH6, pENTR-TFAM-
mCer3-dL5, pENTR-TFAM-KillerRed, pENTR-TFAM-FP635 and pENTR-TFAM-TagRFP 
were transferred into a Gateway-modified pLVX-IRES-Neo vector, (Clontech) by the LR 
reaction using the Gateway LR Clonase II Enzyme Mix (Life Technologies) as per the 
manufacturer’s instruction. Positive clones were selected and plasmids were extracted with the 
QIAprep Spin Miniprep Kit (Qiagen). All the vectors developed for this project are listed in 
Table 8.  
Table 8. Vectors developed for and used in this study. 
Plasmid name Insert description Parental vector 
pENTR-TFAM-mCer3 TFAM-mCer3 pENTR/D-TOPO 
pENTR-TFAM-mCer3-Charlie TFAM-mCer3-Charlie pENTR/D-TOPO 
pENTR-TFAM-mCer3-dH6 TFAM-mCer3-dH6 pENTR/D-TOPO 
pENTR-TFAM-mCer3-dL5 TFAM-mCer3-dL5 pENTR/D-TOPO 
pENTR-TFAM-FP635 TFAM-FP635 pENTR/D-TOPO 
pENTR-TFAM-TagRFP TFAM-TagRFP pENTR/D-TOPO 
pENTR-TFAM-KillerRed TFAM-KillerRed pENTR/D-TOPO 
pLVX-TFAM-mCer3-IRES-Neo HA-mCer3 pLVX-GW-IRES-Neo 
pLVX-TFAM-mCer3-Charlie-
IRES-Neo TFAM-mCer3-Charlie pLVX-GW-IRES-Neo 
pLVX-TFAM-mCer3-dH6-IRES-
Neo TFAM-mCer3-dH6 pLVX-GW-IRES-Neo 
pLVX-TFAM-mCer3-dL5-IRES-
Neo TFAM-mCer3-dL5 pLVX-GW-IRES-Neo 
pLVX-TFAM-FP635-IRES-Neo TFAM-FP635 pLVX-GW-IRES-Neo 
pLVX-TFAM-TagRFP-IRES-Neo TFAM-TagRFP pLVX-GW-IRES-Neo 
pLVX-TFAM-KillerRed-IRES-Neo TFAM-KillerRed pLVX-GW-IRES-Neo 
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Lentiviruses were prepared in collaboration with the UPCI Lentiviral facility. Lentiviral 
particles were generated by co-transfection of 4 plasmids [Control plasmid (pLVX-IRES-
Neomycin) or one of the plasmids, together with pMD2.g (VSVG), pVSV-REV and 
pMDLg/pRRE] into 293-FT cells using TransIT®-2020 Transfection reagent. The collection and 
isolation of lentiviral particles and transduction of LN428 cells were performed as described 
previously (198,199).  Stable cell lines were developed by selection in neomycin (2 µg/mL) for 2 
weeks. 
Table 9. LN428 cell lines developed and used in this study. 
Cell line name Cell line description Growth media* 
LN428 Human glioblastoma tumor cell line Media #1 
LN428/TFAM-mCer3 LN428 cells expressing TFAM-mCer3 Media #2 
LN428/TFAM-mCer3-Charlie LN428 cells expressing TFAM-mCer3-Charlie Media #2 
LN428/TFAM-mCer3-dH6 LN428 cells expressing TFAM-mCer3-dH6 Media #2 
LN428/TFAM-mCer3-dL5 LN428 cells expressing TFAM-mCer3-dL5 Media #2 
LN428/TFAM-FP635 LN428 cells expressing TFAM-FP635 Media #2 
LN428/TFAM-TagRFP LN428 cells expressing TFAM-TagRFP Media #2 
LN428/TFAM-KillerRed LN428 cells expressing TFAM-KillerRed Media #2 
*Media #1: α-MEM with 10% heat inactivated FBS, 5μg/ml Gentamycin, 80μg Penicillin/80μg 
Streptomycin/0.32μg Amphotericin per ml, 2mM L-Glutamine. 





Figure 36. Generation of TFAM-fusion constructs. 
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After primer pairs were optimized using Platinum® Pfx DNA Polymerase and respective plasmids (refer to Tables 1 
and 2 respectively) and PCR purified, the PCR products were used in (A) Joining PCR using 72°C as the best 
annealing temperature for primers (B) PCR amplification screen using Taq DNA Polymerase of mini-prep (a) Lanes 
1-6: pENTR-TFAM-Charlie and Lanes 7-12: pENTR-TFAM-dH6, (b) Lanes 1-6: pENTR-TFAM-dL5 and Lanes 7-
12 : for controls for TFAM-Charlie, TFAM-dH6 and TFAM-dL5 (c) Lanes 1-4: pENTR-TFAM-FP635 and Lanes 5 
and 6: Controls for FP635, (d) Lanes 1-6: pENTR-TFAM-KillerRed and Lanes 7-12: pENTR-TFAM-mCer3 (e) 
pENTR-TFAM-FP635, (f) pENTR-TFAM-TagRFP, (g) pENTR-TFAM-FP635, (h) pENTR-TFAM-FP635, (i) 
pENTR-TFAM-TagRFP, (j) pENTR-TFAM-Charlie, (k) pENTR-TFAM-KillerRed, and (l) pENTR-TFAM-mCer3, 
plasmids from transformed One Shot Top 10 E.coli cells. Only plasmids with correct size inserts were sequenced 
verified and used in LR reactions to transfer the open reading frame inserts into pLVX-GW-IRES-Neo vector. 
C.3 RESULTS AND DISCUSSION 
In this project we utilized a novel system of organelle specific (in this case, the mitochondria) 
oxidative damage that utilizes genetically encoded and small-molecule activated photosensitizer 
proteins. These proteins are directed to the mitochondria via fusion with TFAM. Upon visible 
light-stimulation and/or small-molecule binding (fluorogen activating proteins or HaloTag), ROS 
is produced only in the mitochondria, thus allowing us to study its damaging effects on the 
mitochondria, specifically the damaged mitochondrial proteins.  
We generated seven different constructs fused to the TFAM sequence (Figure 37). Three 
were controls (TFAM-mCer3, TFAM-FP635 and TFAM-TagRFP), to determine transfection 
efficiently or select for cells stably expressing the fusions, and to show that the tag itself was 




                               
Figure 37. Schematic for the TFAM-fusions. 
TFAM was fused on the N-terminus of the different FAPs. The mCer3 and TagRFP tags were used as a subcellular 
fluorescent marker for the proteins and can be used as a negative control when a fluorogen is added.  
         
Figure 38. : Immunofluorescence for LN428 cells stably expressing the TFAM-fusion proteins. 
LN428 cells were transduced with lentiviral particles to create stable cell lines that expressed TFAM-mCer3, 
TFAM-mCer3-Charlie, TFAM-mCer3-dH6, TFAM-mCer3-dL5, TFAM-KillerRed, TFAM-FP635 and TFAM-
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TagRFP protein. The mitochondria were stained with ATP Synthase β as a marker, fixed and imaged using the 
Confocal A1 Nikon Microscope. 
 
This novel system has the advantage of selectively directing the ROS generating complex 
to the mitochondrial genome and will provide insight into the source of ROS needed to activate 
the UBE3B response, this identifying the degradation pathway(s) that lead to disruption of 
mitochondrial homeostasis and disease.  
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APPENDIX D 
CACL2 TREATMENT IN CELLS 
We performed these experiments to determine if we would see similar changes in the 
UBE3B/CaM interaction after CaCl2 treatment of cells.  
LN428 cells expressing HA-tagged UBE3B WT or were grown to 90% confluence in 100mm 
dishes. Serum-free media was added to the cells for 12 hours. The cells were treated with growth 
media, 1.25 mM CaCl2, 1.25 mM CaCl2 + 1µM Ionomycin, 1.25 mM CaCl2 + 10µM MG-132,  
1.25 mM CaCl2 + 1µM Ionomycin + 10µM MG-132, or 0.25mM EGTA for 6 hours in normal 
growth media. The treated cells were harvested using IP Lysis Buffer supplemented with 
Protease Inhibitor (both from Thermo Fisher Scientific). The lysates were rotated for 1 hour at 
4°C before pelleting the cell debris. The supernatant was incubated by rotating overnight at 4°C 
with Anti-HA Affinity Matrix (Roche). The beads were washed with Binding Buffer (10mM 
Na2H2PO2, 10mM Na2HPO4 and 150µM NaCl; pH 7.0), followed by washes with Ubiquitylation 
Assay Buffer (10 mM Tris-HCl, pH 7.5, 100 mM NaCl, and 0.5 mM DTT). The ubiquitylation 
assay was performed on the beads for 2 hours at 30°C in a volume of 30µL containing 0.1µM E1 
(Boston Biochem), 0.25µM of each of the E2s 
(UBE2A/UBE2D1/UBE2D3/UBE2G2/UBE2L3/UBE2N/UBE2S/UBE2Z) (Life Sensors), 1µM 
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ubiquitin aldehyde (Boston Biochem), 0.75µg/µL purified His-ubiquitin (see below) and 1X 
Magnesium/ATP cocktail (EMD Millipore). The ubiquitylation assays were stopped by adding 
2X blue Laemmli (plus β-Mercaptoethanol) and heating the samples at 70°C for 15 minutes. 
Ubiquitylation activity and the presence of CaM were measured by immunoblot (Figure 39).  
                                               
Figure 39. In vivo treatment of HA-UBE3B with CaCl2. 
HA-UBE3B overexpressing cells were serum starved for 12 hours. They were treated with No Treatment, 1.25 mM 
CaCl2, 0.25 mM EGTA, 1.25 mM CaCl2 + 10µM MG132, 1.25 mM CaCl2 + 1µM Ionomycin  + 10µM MG132, or  
1.25 mM CaCl2 + 1µM Ionomycin for 6 hours. The cells were lyzed, immunoprecipitated (IPed) using Anti-HA 
Affinity Matrix and subjected to ubiquitylation activity assays. The ubiquitylation assays were carried out in 30µL 
reactions with 0.1µM E1, 0.25µM of each of the E2s 
(UBE2A/UBE2D1/UBE2D3/UBE2G2/UBE2L3/UBE2N/UBE2S/UBE2Z), 1µM ubiquitin aldehyde, 0.75µg/µL 
His-ubiquitin and 1X Magnesium/ATP cocktail. Completed reactions were applied to immunoblot for analysis of 
ubiquitylation with Ubiquitin (Ub), and CaM binding with Calmodulin (CALM1) antibodies. Representative 
immunoblots from three independent experiments are shown. Antibodies used for each of the immunoblots are listed 






The book chapter was published in Genotoxicity and DNA Repair: A Practical Approach, 
Methods in Pharmacology and Toxicology, and compiled below.  
 
USE OF RNA INTERFERENCE TO STUDY DNA REPAIR 
Elise Fouquerel, Jianfeng Li, Andrea Braganza, Zhongxun Yu, Ashley R. Brown, Xiao-
Hong Wang, Sandy Schamus, David Svilar, Qingming Fang, and Robert W. Sobol 
E.1 ABSTRACT 
 
DNA repair pathways maintain the integrity of the genome and thereby help prevent the onset of 
cancer, disease, and aging phenotypes (294). As such, the critical requirement for DNA repair 
proteins and pathways in response to radiation and genotoxic chemotherapeutics implicates DNA 
repair proteins as prime targets for improving response to currently available anticancer 
regimens. Although defects in critical DNA repair pathways or proteins can predispose to cancer 
onset (295), such cancer-specific DNA repair defects offer novel approaches for tumor-selective 
therapy. 
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To effectively evaluate the functional role of a specific DNA repair protein with regard to 
cell survival, response to genotoxins, and genome stability, it has become standard practice to 
employ select genetic tools to alter expression of the gene of interest and/or reexpress a mutant 
transgene (196,201,296). A useful approach to reduce or suppress a specific gene of interest in 
cells is RNA interference. Briefly, RNA interference is a posttranscriptional gene-silencing 
biological mechanism whereby RNA molecules inhibit gene expression either by translational 
suppression or by the targeted degradation of specific mRNA molecules. Once the gene of 
interest is suppressed in this manner and validated for gene expression loss, the resulting 
knockdown (KD) cells can be used for functional analysis to define the cellular impact of gene 
loss and provide a resource for evaluating mutants of the gene, such as somatic or germ-line 
mutations, for impact on function (297). Herein, we describe methods to modify human cells via 
RNA interference as well as methods to validate gene KD and some measures of cellular 
response to genotoxins to uncover functional DNA repair defects in the absence of the gene. 
 
Key words RNA interference, siRNA, shRNA, Lentivirus, Knockdown, qRT-PCR, PARP, DNA 
damage response, Cell survival 
E.2 INTRODUCTION 
 
In this chapter, we describe several methods we have employed for regulating gene expression in 
human cells via RNA interference. We present approaches for both transient (siRNA) and stable 
(shRNA) gene knockdown (KD) as well as the details for several procedures routinely used for 
validation of gene expression loss (Figure 40). Finally, we describe numerous functional 
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endpoints useful in characterizing the impact of the targeted gene depletion with regard to DNA 


































Figure 40. Simplified diagram of siRNA and shRNA processing to facilitate gene knockdown. 
The transduced shRNA is exported from the nucleus to the cytoplasm and processed by Dicer to yield a siRNA-like 
molecule similar to the transfected siRNA. These are bound with the RISC complex and the Ago proteins to trigger 
translational suppression or target mRNA degradation.  
E.2.1 RNA Interference in Human Cells Using siRNA 
RNA interference (RNAi) is a highly specific posttranscriptional gene-silencing mechanism that 
is mediated by the introduction of double-stranded (ds) RNA molecules 21 bp in length, referred 
to as short interfering RNA or siRNA (Figure 40). One strand of the siRNA is then incorporated 
into an RNA-silencing complex (RISC) to target the complementary RNA for destruction by a 
118 
second nuclease, Ago2 (298-300). Note that there are multiple Ago family proteins (Ago1–
Ago4) involved in siRNA and microRNA (miRNA) processing (301). Molecules of siRNA are 
now routinely used to transiently silence gene expression in a gene- and sequence-specific 
manner (302-304). Molecules such as siRNAs are important tools to investigate DNA repair 
pathways because the expression of select DNA repair factors can be transiently suppressed 
(knocked down; KD) with high specificity and selectivity using these complementary 
oligoribonucleotide molecules. This method of gene regulation has become invaluable to identify 
gene function, validate anticancer gene targets, and is currently being evaluated for clinical 
potential (305). The utility of RNAi as a genetic tool for the study of biological pathways and 
stress responses in mammalian cells has made significant strides since the first demonstration of 
RNAi in mammalian cells in 2001 (303). 
The siRNA can be delivered directly to cells using multiple approaches, including 
microinjection, electroporation, and transfection (306). Currently there are two variations of 
siRNA transfection procedures being used: forward transfection and reverse transfection. They 
differ in the order and timing of the addition of the three necessary components for transfection: 
(1) the siRNA molecules, (2) the lipid-based transfection reagent, and (3) the cells to be targeted. 
In the forward (standard) transfection proto-col, the siRNA and lipid are complexed together and 
then added to pre-plated cells (e.g., normally the cells are seeded to the wells of a plate 24 h 
before addition of the siRNA/lipid complex). In the reverse transfection protocol, the 
siRNA/lipid mixture is added to the wells of the plate first and then the cells are added 
subsequently. Reverse transfection offers the flexibility of testing siRNA reagents at various 
concentrations or utilizing existing siRNA library resources to perform large-scale screens (200). 
To demonstrate the utility of siRNA, we will focus on the reverse transfection procedure 
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optimized in our lab and will provide detailed information on the procedures and expected 
outcomes using siRNA to knock down the DNA repair gene UNG (200). 
 
E.2.2 RNA Interference in Human Cells Using shRNA 
RNAi-mediated knockdown can also be achieved via the expression of double-stranded RNA 
(dsRNA) hairpins of 21–23 bp in length (Figure 40), referred to as small hairpin RNA or short 
hairpin RNA (shRNA). The expressed shRNA is transported from the nuclease to the cytoplasm 
and cleaved by a nuclease (Dicer) into dsRNAs of 21–23 bp in length to yield the desired siRNA 
and is processed as indicated above. Stable expression of shRNAs can mediate effective gene 
knockdown (307-309). Most recently, expression of shRNA in cells is typically accomplished 
using retroviral or lentiviral vectors although lentiviral vectors have become the most routinely 
used and are the most commonly available resource. To prepare HIV-based lentivirus particles, 
the shuttle vector (encoded to express the shRNA and a selection cassette such as puromycin, 
G418, or EGFP) is co-transfected with the required lentiviral packaging vectors into a packaging 
cell line such as 293FT (310), a clonal derivative of the human kidney 293T cell line 
(Invitrogen). Complete libraries of shRNA shuttle vectors specific to any human or mouse gene 
are available from a number of commercial sources, including Sigma, Thermo Scientific, System 
Biosciences, among many others. Numerous packaging systems have been reported and most are 
commercially available or available from Addgene (http://www.addgene.org). We routinely use 
the so-called “third-generation” packaging system in which the gene-specific shRNA plasmids 
are co-transfected into 293FT cells together with the packaging plasmids pMD2.g(VSVG), 
pRSV-REV, and pMDLg/ pRRE to generate replication-defective viral particles capable of 
120 
transducing numerous cell types (201,311). Virus particles are isolated from the cell culture 
supernatant and may be stored at −80 °C or used immediately for transduction of the target cell. 
With the proper selection, a stable gene silenced or KD mammalian or human cell line can be 
readily established (196,200,201,312). 
E.2.3 Validating Gene Knockdown by qRT-PCR 
A critical and essential aspect of any RNAi experiment is validation of gene knockdown. This is 
most readily accomplished by a quantitative reverse transcription polymerase chain reaction 
(qRT-PCR) analysis using a real-time qRT-PCR protocol (313). Although the specificity of 
siRNA is normally very precise (314), it is essential to also test the expression of other relevant 
genes to most effectively conduct your study. For example, when studying the role of DNA 
polymerase β (Polβ) in response to chemotherapeutic agents (197), we routinely test the 
expression of several of the relevant base excision repair (BER) genes such as MPG, APE1, and 
PARP1 (296). An advantage of analysis by qRT-PCR is the ready availability of specific 
reagents. Material for RNA isolation or qRT-PCR-ready cell lysates are readily available, and 
validated primers and probes for real-time qRT-PCR are available for any gene. In general, we 
routinely analyze a transfected (siRNA) or transduced (shRNA) cell line for gene knockdown 
using RNA from three separate samples, comparing expression to a control such as the same cell 
line transfected with a control siRNA or transduced with a GFP-expressing or scrambled 
shRNA-expressing lentivirus. Analysis across samples is normalized to the expression of β-actin, 
measured for each sample. As expected, the goal is to achieve complete gene expression knock-
down. In practice, knockdown greater than 75 % is likely to yield a significant loss of steady-
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state protein levels and result in a functional impact from the loss of the expressed mRNA 
(196,201,296). 
 
E.2.4 Validating Gene Knockdown by Immunoblot 
The ultimate and most stringent validation to demonstrate that you have succeeded in “knocking 
down” your gene is to show a loss or suppression of protein expression (315). We routinely use 
immunoblotting to validate the loss of gene expression and in some cases, complement this 
analysis with a functional test (296). However, the loss of protein, as determined by 
immunoblotting, is a highly reliable method for validating gene expression loss. This standard 
laboratory analytical procedure is only limited by the availability of the antibody. 
 
E.2.5 PARP Activation in Response to DNA-Damaging Agents 
 
Genomic DNA damage from genotoxins must be repaired to prevent gene mutations, aneuploidy, 
senescence, or cell death that can contribute to cancer, early-onset aging, and/or degenerative 
diseases (294). There are multiple overlapping mechanisms and processes in human cells that 
govern and orchestrate the response to genotoxins, collectively referred to as the DNA damage 
response (DDR) (316). The initial DDR of a cell involves the recognition of the DNA damage 
followed by the propagation of a series of signals ranging from alterations in RNA or protein 
expression and modification of protein function or stability through posttranslational 
modification, among other signals. The cell’s defense to genotoxic lesions is triggered and 
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accomplished by a series of events that mediate and regulate proliferation, cell death, or DNA 
repair crucial to its survival (317,318). 
PARP1 is a major response protein in the DDR pathway and binds to and is activated by 
damaged DNA (strand breaks) to initiate a signal cascade by utilization of NAD+ to modify 
numerous proteins with poly-ADP-ribose (PAR), including histones, polymerases, 
topoisomerases, and PARP1 itself (319). PARP1 (as well as PARP2 and PARP3) (320,321)  acts 
as sensors of DNA damage such as DNA single-strand or double-strand breaks and becomes 
activated, consuming NAD+ to synthesize PAR (201). It is clear that activated PARP1 (together 
with PARP2 and PARG) facilitates DNA repair via roles in BER (322) and nonhomologous end 
joining (NHEJ) (320,323-330), the latter also involving PARP3 (320). In this context, being able 
to detect PAR levels in cells is an effective method to define the sensitivity of a cell to a DNA-
damaging agent and its capacity to repair such damage. In this chapter, we describe two standard 
approaches to detect and quantify PAR, either by immunoblot or immunofluorescence. 
E.2.6 Complementing Gene KD Cells and Evaluating Cell Survival in Response to DNA-
Damaging Agents 
One of the advantages of developing a stable KD cell line, deficient in the expression of the 
endogenous gene, is the capacity to then complement the cell line by reexpression of the cDNA, 
for example, with the wild-type (WT) cDNA or encoding a mutation (Figure 41). By analysis of 
normal and cancer tissues, it has been found that most of the 150–200 genes among the DNA 
repair pathways harbor germ-line or somatic mutations. For example, there are numerous 
mutations for the BER gene Polβ found to have either protein-altering germ-line single-
nucleotide polymorphisms (SNPs) or functionally altering somatic mutations when isolated from 
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tumor tissue (297). In fact, it was recently described that “… we can expect all cancer cells to be 
defective in some aspect of DNA repair … There are at least 150 different proteins that catalyze 
DNA repair … To seed new therapies, geneticists and molecular biologists are needed to explore 
the detailed consequences of an alteration in each of these repair pathways…” (331). 
To facilitate effective complementation and expression of the transgene while reducing 
endogenous expression by RNAi, one must either mutate the cDNA to eliminate the RNAi target 
sequence or use an shRNA specific for the 3′untranslated region of the target gene (Figure 41). 
Once accomplished, the utilization of an RNAi-resistant expression system is a robust method to 
reexpress or complement a KD cell line. Following gene knockdown, we routinely develop 
lentiviral-based cDNA expression vectors to complement the KD cells. With such a system, the 
investigator is open to effectively study KD phenotype rescue, the functional role of specific 
amino acid residues such as those in the enzyme active site, those implicated in protein-protein 
interactions, or those that may be a target for posttranslational modification. Once in hand, these 
modified cell lines are then valuable resources to evaluate the role of these proteins (and 


















Figure 41. Scheme for transgene complementation after gene knockdown. 
The target for RNA interference can be within the open reading frame (ORF) of the target mRNA or specific to the 
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3′untranslated region (3′UTR). As indicated, effective transgene design for shRNA-resistant expression of your 
target gene requires either deletion of the shRNA target site within the ORF, mutation of the shRNA target site 
within the ORF, or expression of the transgene in cells targeted with a 3′UTR-specific shRNA 
 
Cells treated with cytotoxic compounds will respond differently depending on the DNA 
repair capacity of the cell. For example, cells expressing the protein MGMT are highly resistant 
to the cytotoxic effects of the alkylating agent-induced DNA lesion O 6-methyl-dG, but in the 
absence of MGMT expression, the lesion is highly toxic (296). There are many methods to 
measure cytotoxicity. Here, we will focus on the MTS assay and the CyQUANT assay that are 
used to monitor the cytotoxicity of a genotoxin after short-term or long-term exposure to the 
agent, respectively. 
The MTS assay measures the reducing potential of the cell using a colorimetric reaction. 
Viable cells can reduce the agent 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium (MTS) to produce a formazan product that has an absorbance 
maximum at 490–500 nm in phosphate-buffered saline (PBS), in the presence of phenazine 
methosulfate (332). The MTS assay is more convenient than the MTT assay, since the reagent 
can be added to the cells directly without the intermittent steps required in the MTT assay. 
However, this convenience makes the MTS assay susceptible to colorimetric interference (333). 
In general, one needs to take caution when using this assay, depending on the cell type, the 
DNA-damaging agent, and the experiment as a whole. Since the assay measures cellular 
reducing potential (mitochondrial function), a resting cell may have a lower overall level of 
reducing potential, whereas a highly proliferative cell is likely to have a high reducing potential. 
In that regard, treatments that induce senescence but not cell death may appear in this assay to 
reduce cell number. To avoid such potential problems, we routinely test cells using the MTS 
assay as well as a second assay, as described below. 
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The CyQUANT assay is based on a cell-permeable DNA-binding dye in combination 
with a background suppression reagent to estimate cell number (334). We routinely use this 
assay to evaluate genotoxic response 8–12 days after exposure to the agent. As DNA content is 
highly regulated, cell number estimates are very accurate. The masking dye blocks staining of 
dead cells and cells with compromised cell membranes, causing only healthy cells to be stained. 
Recent studies using diverse sets of cytotoxic compounds and assay types have shown that cell 
number (proliferation) is among the most sensitive indicators of cytotoxicity (335). In our hands, 
this assay yields cell survival or proliferation outcomes similar to that of a clonogenic assay if 
control cells are allowed to undergo seven or more doublings before analysis. Therefore, the 
CyQUANT assay provides a highly accurate measure of cell number, allowing for the evaluation 
of proliferation as well as cytotoxicity in response to genotoxin exposure. 
E.3 MATERIALS 
E.3.1 RNA Interference in Human Cells Using siRNA 
• siRNA specific for human UNG (Ambion; cat# 4390824; siRNA ID: s14679) 
 
• Silencer® Negative Control #2 siRNA (50 μM) (Ambion; AM4613) 
 
• siPORT™ NeoFX™ Transfection Agent (Applied Biosystems; AM4511) 
 
• Opti-MEM® 1 Reduced-Serum Medium (1×), liquid (Invitrogen; 31985-070) 
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• Trypsin, 0.25 % (1×) with EDTA, liquid (Invitrogen; 25200-114) 
• PBS (Invitrogen; 14190-250) 
All the listed reagents are stored according to the manufactures’ instructions.  
E.3.2 RNA Interference in Human Cells Using shRNA 
• The three lentiviral packaging plasmids (pMD2.g(VSVG), pRSV-REV, and pMDLg/pRRE), 
available from Addgene (cat# 12259, #12253, and cat #12251, respectively) 
• The 293FT cell line (cat# R700-07), available from Life Technologies 
• TransIT-293 (cat# MIR-2704, 2700, 2705, or 2706), avail-able from Mirus 
• Millipore Steriflip vacuum filters (cat# SE1M003M00), avail-able from Fisher Scientific 
(Fisher Scientific cat# SC50 FL0 25) 
• Lenti-X Concentrators (cat# 631231), available from Clontech 
• Ultracentrifuge tubes (Beckman Ultra-Clear tubes, cat# 344058), available from Fisher 
Scientific (Fisher Scientific cat# NC9146666) 
E.3.3 Validating Gene Knockdown by qRT-PCR 
• TaqMan® Gene Expression Cells-to-CT™ Kit (cat# AM1728), available from Life 
Technologies. 
• PBS (cat# 14190-250), available from Invitrogen. 
• DNase and RNase-free H2O. 
• Two heat blocks set to 37 and 95 °C or a PCR thermocycler. 
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• Applied Biosystems StepOnePlus™ Real-Time PCR System. 
• Applied Biosystems StepOne™ Software. 
• TaqMan® Gene Expression Assays (the specific assay will depend on the gene you are 
targeting) are available from Life Technologies. 
• TaqMan® Gene Expression Master Mix is available from Life Technologies. 
E.3.4 Validating Gene Knockdown by Immunoblot 
Cell extracts diluted twice in the sample buffer (2×). For cell extracts prepared for detection 
of PAR, see Sect. 2.5. 
Note: Alternatively and depending on the molecular weight of the protein of interest, a 
higher or lower concentration of Acryl/ Bis 30 % can be used. 
• Sample buffer (2×) (LaemmLi blue 2×: 2 % SDS, 20 % glyc-erol, 62.5 mM Tris-HCl, pH 
6.8, 0.01 % Bromophenol blue). 
• Stacking gel buffer (Tris-HCl 0.5 M, pH 6.8, SDS 0.4 %) - also sold as a ready-to-use 
solution by Bio-Rad (cat# 161-0799) (stable at room temperature). 
• Separating gel buffer (Tris-HCl 1.5 M, pH 8.8, SDS 0.4 %) - also sold as a ready-to-use 
solution by Bio-Rad (cat# 161-0798) (stable at room temperature). 
• Isopropanol (100 %). 
• Acryl/Bis 30 %; ratio 37.5/1 (Bio-Rad cat#) (keep at 4 °C). 
• Ammonium persulfate (APS). 
• N,N,N′,N′-Tetramethylethylenediamine (TEMED) (Bio-Rad cat# 161-0800) kept at 4 °C. 
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• Running buffer, 5× (30 g/L Tris-base, 144 g/L glycine, 0.5 % SDS) stored at room 
temperature. A 1× solution is prepared by mixing 200 mL of a 5× stock solution and 800 mL 
of dH2O. This solution can be used up to five times and is kept at room temperature. 
• Vertical electrophoresis system, 1.0 mm gel thickness (e.g., Mini-PROTEAN® Tetra Cell, 
Bio-Rad). 
• Prestained protein molecular weight markers—for example, Precision Plus Protein 
Kaleidoscope™ from Bio-Rad (cat# 161-0375). 
• Blotting transfer buffer, 10× (30 g/L Tris-base, 144 g/L glycine, 1 % SDS). The stock 
solution can be stored at room temperature. Before the transfer, prepare a 1× solution by 
diluting 100 mL of the 10× stock solution in 615 mL of dH2O and adding 285 mL of 70 % 
ethanol. This solution can be reused up to five times if stored at 4 °C. 
• Blotting transfer system (Mini Trans-Blot Electrophoretic Transfer Cell, Bio-Rad). 
• Nitrocellulose transfer membrane (Bio-Rad Nitrocellulose Membranes 0.45 μm; cat# 162-
0115). 
• TBS-Tween 0.3 % buffer (TBT): prepared by diluting Tris-buffered saline, pH 7.4 (10×; 
Boston BioProducts; cat# BM-300), in 900 mL dH 2O and adding 3 mL of 100 % Tween 20. 
The TBS is also available in powder format (Sigma-Aldrich; cat# D5773). 
• Blocking powder (Blotting-Grade Blocker; cat# 170-6404) or low-fat dry milk. 
Note: BSA can be used for special antibodies if speciÞed by the company. 
• Primary antibody against the protein of interest. 
• Secondary antibody (we use goat anti-mouse or goat anti-rabbit horseradish peroxidase 
(HRP) conjugate from Bio-Rad; an alternate secondary antibody can be used depending on 
the primary antibody species). 
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• Detection reagents: For expected normal-to-strong signals, we use Immun-Star™ HRP from 
Bio-Rad (cat# 170-5040). If the signal is expected to be weak or low, a more sensitive 
product can be used such as SuperSignal ® West Femto Maximum Sensitivity Substrate from 
Thermo Fischer (cat# 34095). 
• Detection system: The HRP signal can be detected using X-ray film. We use Premium X-ray 
Film from Phenix (#EBA45) or a Bio-Rad Molecular Imager® Chemidoc™ XRS+ system. 
E.3.5 PARP Activation in Response to DNA-Damaging Agents 
Poly-ADP-ribose Detection by Immunoblot 
• DNA-damaging agents specific to your experiment (MNNG, methyl methanesulfonate 
(MMS), H 2O2, ionizing radiation, etc). In the example shown here, we use MNNG, N′-
methyl-N′-nitro-N-nitrosoguanidine (prepared as a 10 mM stock solution in DMSO), 
available from TCI America (# N0527; Portland, OR). 
• Plated cells. 
• Ice-cold PBS (cat# 14190-250), available from Invitrogen. 
• Sample buffer 2× (see Sect. 2.4). 
• Materials for SDS-PAGE and immunoblot as described in Sect. 2.4. 
• Mouse monoclonal PAR antibody 10H (196,201). 
• Secondary antibody; goat anti-mouse Ab conjugated with HRP. 
Poly-ADP-ribose Detection by Immunofluorescence 
• Coverslips washed in 5 mL 70 % ethanol 
• Microscope slides 
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• DNA-damaging agents specific to your experiment (MNNG, MMS, H2O2, ionizing radiation, 
etc) 
• Methanol and acetone (100 %), stored at −20 °C 
• PBS-Triton X-100, 0.1 % (alternatively, PBS-Tween 0.3 % can be used) 
• PBS-BSA, 0.5 % 
• PBS-BSA, 2 % 
• Primary antibody mouse; monoclonal anti-PAR, clone 10H (196,201) 
• Secondary antibody; goat anti-mouse Ab conjugated with Alexa Fluor 488 
• Mounting solution containing DAPI (ProLong® Gold Antifade Reagent with DAPI; Life 
technologies cat# P-36931).  
E.3.6 Complementing Gene KD Cells and Evaluating Cell Survival in Response to DNA-
Damaging Agents 
Complementation or reexpression of the protein of interest after gene KD can be accomplished 
using any plasmid- or viral-based transgene expression system. We have found success with 
lentiviral vectors (e.g., from Clontech), allowing expression of DNA polymerase β (Polβ) with 
numerous selection agents such as hygromycin, G418, or EGFP. Most of the shRNA lentiviral 
vectors we have used employ a puromycin cassette for selection. Therefore, using separate 
selection agents for complementation is critical. We find no difficulty with transducing a cell 
multiple times, for example, to express shRNA for gene KD followed by transduction with a 
cDNA expression vector to reexpress the gene of interest or to express mutants of the cDNA 
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(332). Once stable cell lines are developed, they yield a valuable resource for analysis of cell 





• Cell culture medium (depends on which cell used). 
• PBS (cat# 14190-250), available from Invitrogen. 
• MNNG, N′-methyl-N′-nitro-N-nitrosoguanidine (prepared as a 10 mM stock solution in 
DMSO), available from TCI America (# N0527; Portland, OR). 
• Promega CellTiter 96 AQueous One, available from Promega (Catalogue No. G356B), 
aliquot and store at −30 °C. 
• Hemocytometer, CASY counter, or similar cell counting device. 
• Multi-well aspirator. 
• Multichannel pipettor. 
• Cell culture medium (depends on which cell used). 
• PBS (cat# 14190-250), available from Invitrogen. 
• MNNG, N′-methyl-N′-nitro-N-nitrosoguanidine (prepared as a 10 mM stock solution in 
DMSO), available from TCI America (# N0527; Portland, OR). 
• CyQUANT GR reagent (Catalogue No. C7026, Life technol-ogies), store at −30 °C. 
• Lysis buffer, store at 4 °C. 
• Parafilm. 
• Hemocytometer, CASY counter, or similar cell counting device. 
• Multi-well aspirator. 
• Multichannel pipettor. 
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E.4 METHODS 
E.4.1 RNA Interference in Human Cells Using siRNA 
Validated siRNAs are available from a number of sources and are generally available as 
individual siRNAs or a gene-specific pool. Further, libraries can be obtained for the entire 
genome or those that are limited to specific functional biological pathways or other subgroups 
such as the druggable genome (200). 
 
The siRNA provided by Ambion is supplied as a lyophilized powder. The user is advised 
to centrifuge briefly at the highest speed and resuspend the powder with nuclease-free water to a 
final concentration of 2 μM. All the pipette tips should also be nuclease-free. The siRNA stock 
solutions can be stored at −20 °C for up to 3 months. For each transfection condition, include 
three replicate transfections. Remember to include a Negative Control (scrambled) siRNA and a 
non-transfected control (cells that are mock-transfected with Opti-MEM 1 Medium but no 
transfection reagent and no siRNA). When possible, prepare master mixes to minimize 
variability. 
For this procedure, cells are seeded in each well of a 6-well plate at 3 × 105 cells for each 
well. 
Note: The amount of cells for transfection could range from 2 × 105 to 3 × 105, depending on the 
cell type. 
For this specific gene (UNG), we used 135 nM siRNA (final concentration after 
transfection) for transfection. 
 
Note: The final concentration should be modified according to the specific siRNA. The 
recommended concentration ranges from 10 to 150 nM. 
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These conditions generally result in effective gene knockdown, with loss of UNG mRNA 
as much as 65 % in this example (Figure 42), sufficient to reduce UNG protein levels below 
detection and to suppress UNG enzymatic activity to background levels (200). 
 
1. On the day of transfection, aspirate the growth media from the cells. 
2. Wash cells twice with 1× PBS. 
3. Aspirate the PBS. 
4. Add enough trypsin to cover the cells (0.5 mL) and place the plate in the incubator for 5 min 
to allow the cells to detach. 
5. After 5 min, gently tap the plate/dish to detach any unbound cells from the surface and 
suspend the cells in Opti-MEM 1 Media (2.5 mL). 
Note: In practice, if you cannot prepare the cell solution as quickly as possible, we recommend 
using normal growth media (with serum) to neutralize the trypsin. Then prepare the cell solution 
with Opti-MEM 1 Medium. This helps to prevent cell death caused by trypsin. 
 
6. Count cells using either a hemocytometer or an automated cell counter. 
Make the required dilution of cells to yield a final suspension of 3 × 105 cells per well in a 
volume of 2 mL per well.  
7. Store the cell suspension on ice while you quickly prepare the transfection reagent and 
siRNAs. 
Note: Here, the cell solution volume is 1.4 mL and the siRNA transfection reagent complex is 0.6 
mL. The total volume for each well is 2 mL. 
8. For each well, dilute the 5 μL of siPORT NeoFX in 295 μL Opti-MEM 1 Medium and 
incubate the diluted siPORT NeoFX for 10 min at room temperature. 
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Note: The 10 min incubation time should be controlled precisely and you can dilute your siRNA 
with Opti-MEM 1 Medium dur-ing this period of time. In addition, you can prepare the master 
mixes in a 15 mL falcon tube. 
 
9. For each well, dilute 135 μL of 2 μM siRNA in 165 μL Opti-MEM 1 Medium. 
10. After the 10 min incubation, mix the diluted siRNA with the diluted siPORT NeoFX in a 1:1 
ratio. 
11. Incubate at room temperature for 10 min. 
12. Dispense 600 μL of the siRNA/siPORT NeoFX complex into the wells of a 6-well culture 
plate and set up the non-transfected controls (i.e., add only OPTI-MEM 1 Medium to the 
negative control wells). 
13. Overlay 1.4mL of the cells (3 x 105 cells) per well into each well and mix gently by tilting 
back and forth to distribute evenly. DO NOT swirl the plate.  
  
14. Incubate plate at 37 °C for 24 h. 
Note: If you observe cytotoxicity caused by transfection, we recommend changing the media 
back to normal growth media 8-10 h after transfection instead of 24 h as indicated. 
15. After 24 h, wash cells with fresh growth media. 
16. Gene expression can be measured by qRT-PCR 24 h after transfection or by immunoblot 48 
























Figure 42. Relative mRNA expression as measured by qRT-PCR after siRNA to knock-down UNG. 
Quantification of siRNA-mediated UNG knockdown as determined by qRT-PCR. TaqMan probes were used to 
quantify mRNA levels on an Applied Biosystems StepOnePlus machine. The qRT-PCR data was analyzed using the 
Ct method and was normalized to a mock-transfected control. Expression of UNG was normalized to the expression 
of human ß-actin. The mean of three independent experiments is plotted ± SEM 
E.4.2 RNA Interference in Human Cells Using shRNA 
Lentivirus production and cell transduction are essentially as we have described previously 
(196,200,201,296). The method is a classical procedure for virus production. The shuttle or 
transfer vector (the shRNA-expressing plasmid) is co-transfected into 293FT cells together with 
the packaging plasmids pMD2.g(VSVG), pRSV-REV, and pMDLg/pRRE to generate 
replication-defective viral particles capable of transducing numerous cell types (201,311). 
Importantly, the cells should be sub-confluent when transfected (Figure 43A). Virus particles 
can be isolated after 48 h. If the transfection efficiency is low or if not transfected, the cells will 
reach confluence by 48 h (Figure 43B). However, if transfection is successful, virus production 
leads to a suppression of cell growth (Figure 43C). Effective virus preparation should allow for a 
high level of transduction, approaching 100 %, as shown here for cells transduced with an 



































Figure 43. Demonstration of lentivirus production and transduction. 
Panels a–c are white light images of 293FT cells before transfection (Panel a) or 48 h after transfection in the 
absence of plasmid (Panel b) or in the pres-ence of the viral vectors (Panel c). Panel d is a fluorescent image of cells 





We utilize this procedure for the preparation of five different lentiviral preparations: 
1. Small-scale, low titer: Seed 1.7 × 106 293FT cells (less than 2 weeks old) in a 60 mm dish 
with 5.5 mL complete growth media and culture the cells at 37 °C, 5 % CO 2 overnight. 
Transfect as indicated below (Table 10). The final yield of the lentiviral particle suspension is 4 
mL and the virus titer is approximately 1 × 106 transforming units per mL (TU/mL). 
2. Medium-scale, low titer: Seed 1.2 × 107 293FT cells (less than 2 weeks old) in a 150 mm dish 
with 27 mL complete growth media and culture the cells at 37 °C, 5 % CO 2 overnight. 
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Transfect as indicated below (Table 11). The final yield of the lentiviral particle suspension is 25 
mL and the virus titer is approximately 1 × 106 transforming units per mL (TU/mL). 
3. Large-scale, low titer: Seed 1.2 × 107 293FT cells (less than 2 weeks old) in each of three 
(295) 150 mm dishes with 27 mL complete growth media each and culture the cells at 37 °C, 
5 % CO2  overnight. Transfect as indicated below (Table 11). The final volume of the 
lentiviral particle suspension is 75 mL and the virus titer is approximately 1 × 10 6 
transforming units per mL (TU/mL). 
4. Medium-scale, medium titer: Seed 1.2 × 107 293FT cells (less than 2 weeks old) in a 150 mm 
dish with 27 mL complete growth media and culture the cells at 37 °C, 5 % CO2 overnight. 
Transfect and concentrate as indicated below (Table 11). The virus titer is approximately 1 × 
10 8 transforming units per milliliter (TU/mL). An aliquot of 10 μL would normally yield 
~100 % transduction efficiency when infecting a 100 mm dish of cells. 
5. Large-scale, high titer: Seed 1.2 × 107 293FT cells (less than 2 weeks old) in three (295) 150 
mm dishes with 27 mL complete growth media and culture the cells at 37 °C, 5 % CO2 
overnight. Transfect and concentrate as indicated below (Table 11). The final volume of the 
lentiviral particle suspension is 30 μL and the virus titer is approximately 1 × 10 9 TU/mL. 
Protocol 
1. Seed 293FT cells as indicated above. 
2. On the second day, prepare the transfection mix according to the materials listed in Table 10 
for transfection of cells in a 60 mm dish or as in Table 11 for transfection of cells in a 150 
mm dish. 
3. Add the plasmids, media, and transfection reagent to a tube in this order: (1) media, (2) 
TransIT-293, and (3) plasmids. 
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4. Tap gently to mix (do not vortex) and incubate at room temperature for 15–30 min. 
5. Add the transfection mix to each dish (do not remove the old media), dropwise. 
6. After incubation at 37 °C for 48 h, collect culture media containing viral particles from 
transfected cells and filter the collection through a 0.45 µm Steriflip vacuum filter. 
 
 
Table 10. Transfection mix recipe for a 60 mm dish. 












8 µL 0.375 mL 10µL 
  pMD2-g(VSVG) 4 µL   
  pRSV-REV 4 µL   
  pMDLg/pRRE 4 µL   
 
Table 11. Transfection mix recipe for a 150 mm dish. 












56 µL 2.7 mL 70µL 
  pMD2-g(VSVG) 28 µL   
  pRSV-REV 28 µL   
  pMDLg/pRRE 28 µL   
 
7. For the low titer preps, aliquot (1.0 mL per tube) into sterile vials and store at −80 °C.  
   
8. For the medium titer and high titer concentration procedures, see below.    
  
Medium Titer Lentivirus Concentration 
1. After  filtering  the  viral  particles,  mix  1  vol of  Lenti-X Concentrator with 3 volumes of 
the filtered viral particles (simply measure the amount of viral supernatant to be 
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concentrated, divide  by  3,  and  add  the  resulting  amount  of  Lenti-X Concentrator to 
your viral supernatant).    
2. Mix by gentle inversion. Larger volumes may be accommodated through the use of larger 
(i.e., 250 or 500 mL) centrifuge tubes. 
3. Incubate mixture at 4 °C for 30 min (can be up to overnight and larger volumes (>100 mL) 
may require longer incubation times). 
4. Centrifuge sample at 1,500 × g for 45 min at 4 °C. After centrifugation, an off-white pellet 
will be visible. 
5. Carefully remove the supernatant, taking care not to disturb the pellet. Residual supernatant 
can be removed with either a pipette tip or by brief centrifugation at 1500 × g. 
6. Gently resuspend the pellet in 25 μL 1× PBS at 4 °C and keep it at 4 °C overnight. The pellet 
can be somewhat sticky at first, but will go into suspension quickly. The final volume after 
the overnight incubation will be just over 100 μL.  
7. Aliquot (10 μL per tube) into sterile vials. Determine titer of sample immediately or store at −80 °C in 
single-use aliquots (ten aliquots).  
8. An aliquot of 10 μL would normally yield ~100 % transduction efficiency when infecting a 
100 mm dish of cells (50 % confluent). 
 
High Titer Lentivirus Concentration 
1. After filtering the viral particles, add 36 mL of filtered supernatant to each of two 
ultracentrifuge tubes and balance the two tubes with additional media or supernatant. It may be 
useful to titer some of the leftover supernatant to determine if there is a loss of virus during 
concentration.  
140 
2. Cover tubes with a small piece of Parafilm and spin tubes using an SW-28 rotor at 25,000 rpm 
for 90 min at 4 °C. 
3. Decant liquid and leave tube upside down on KimWipe for 10 min in the tissue culture hood. 
Aspirate remaining media being careful not to touch the bottom of the tube. 
4. Add 12.5 μL cold, sterile tissue culture grade PBS to each tube and cover the tubes with 
Parafilm and then keep those tubes at 4 °C overnight without shaking. 
5. To resuspend the pelleted virus, hold the tube at an angle and pipette fluid (the PBS that was 
added last night) over the pellet 20 times, being careful not to touch the pellet with the pipette 
tip. It is expected that the pellet will not be resuspended after this is completed. This pellet does 
not contain virus and can be discarded. 
6. Combine the two virus suspensions and aliquot at 5 μL per tube (six tubes), flash-freeze in 
liquid nitrogen, and store at −80 °C. There should be no change in titer with freezing 
concentrated virus. Avoid multiple freeze-thaws. 
 
E.4.3 Viral Titer Analysis 
1. For a rapid titer determination, the Lenti-X qRT-PCR Titration  Kit (Clontech Cat. No. 
632165) directly quantifies the viral genomes in your virus stock, which is much faster and often 
more useful than antibiotic selection since it exploits conserved regions contained in most 
lentiviral preps. 
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2. Lenti-X GoStix (Clontech Cat. No. 631244) can also be used for a quick viral titer 
determination if the viral titer measurement does not need to be highly accurate. It only takes 
about 30 min. 
E.4.4 Lentiviral Transduction Protocol  
This protocol is based on a procedure optimized for transduction of the human glioma cell line 
LN428 (196,201,296) but should be applicable to most other cell lines with minimal alteration. 
Table 12. Virus dilution recipe for lentiviral transduction. 





1 Negative control (no virus) 2.0 0 2 




or GFP control 
1.0 1.0 2 
 
Cell Seeding 
1. Thaw a vial of cells and culture the cells until they are 80 % confluent. 
2. Passage the cells and culture the cells until they are 50 % confluent. 
3. Trypsinize, count, and then seed 1 × 105 cells per well in a 6-well plate with 2 mL growth 
medium. 
4. Incubate at 37 °C, 5 % CO2 overnight. 
Transduction  
1. On the second day, prepare the virus dilutions on ice in sterile tubes, according to Table 12. 
2. Remove the growth media from each well. 
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3. Add the lentivirus preparation to each well. 
4. Incubate at 32 °C, 5 % CO2 overnight (16–18 h). 
Second Transduction (Optional) 
1. In the morning, replace the lentivirus preparation with 2 mL fresh growth media and incubate 
at 37 °C, 5 % CO2 for 6–7 h. 
2. In the late afternoon, remove the growth media from each well and add the lentivirus 
preparation (new prep but identical to the first transduction) to each well, according to Table 12. 
3. Incubate at 32 °C, 5 % CO2 overnight (16–18 h). 
4. The next morning, replace the lentivirus preparation with 2 mL fresh growth media and 
incubate at 37 °C, 5 % CO2 for 24 h. 
 
Selection of Transduced Cells 
1. Prepare selection medium by adding the proper concentration of selection antibiotic to the 
growth medium. The concentration of the antibiotic (puromycin, G418, hygromycin) is 
usually determined empirically. It is recommended that a selection antibiotic titration be 
performed to determine the lowest concentration of the selection antibiotic needed to 
efficiently select transduced cells and kill all non-transduced cells. 
2. For LN428 cells, the final puromycin concentration is 1 μg/mL. 
3. In the morning, remove the growth media and wash the cells in each well with 1 mL pre-
warmed PBS. 
4. Add 300 μL trypsin and keep the plate in a 37 °C incubator for 5 min. 
5. Add 1 mL selection media with the proper concentration of selection antibiotic to each well 
and pipette up and down to prepare a single cell suspension. 
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6. Transfer the cell suspension of each well to a freshly prepared 100 mm cell culture dish 
containing 9 mL of selection medium. 
7. Incubate at 37 °C, 5 % CO2 until the cells reach 90 % confluence. Change medium with the 
selection medium every 3–4 days. 
8. When the cells reach approximately 90 % confluent, remove the growth media and wash the 
cells in each dish with 3 mL pre-warmed PBS. 
9. Add 1 mL trypsin and keep the plate in 37 °C incubator for 5 min and then add 4 mL 
selection medium and pipette up and down to make a single cell suspension. 
10. Transfer 1 mL single cell suspension from each dish to a freshly prepared 100 mm dish with 
9 mL selection medium. 
11. Keep culturing the cells until the cells in the negative dish (mock transduction) without virus 
are 100 % dead. 
12. Check the knockdown level via qRT-PCR (see below). 
13. Freeze three vials of cells and passage the remaining cells for the designed experiment. 
E.4.5 Validating Gene Knockdown by qRT-PCR 
Cell Lysis and Reverse Transcription 
TaqMan® Gene Expression Cells-to-CT™ Kit (cat #AM1728). 
 
Note: There are many different kits available to prepare cDNA. We prefer the Cells-to-Ct Kit due 
to convenience. It is the fastest method as it only takes about 1.5-2 h to go from cells to cDNA. 
However, you can choose any RNA extraction and RT kit. 
 
1. This protocol is designed for use with the Applied Biosystems 
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2. Prepare cells for lysis (two options). 
3. Option #1: Prepare a cell pellet of 800,000 cells (pellet can be frozen at −80 °C or used 
immediately); resuspend cell pellet in 50 μL of PBS making a cell suspension of 16,000 cells/μL; 
distribute 5 μL of the cell suspension to a 1.5 mL tube and place on ice until continuing with the 
lysis. 
Note: You can use less than 800,000 cells if you do not have a lot of cells to work with. This 
number was chosen so you can see the cell pellet in the tube. If you use less, adjust the amount of 
PBS to resuspend the cells. 
4. Option #2: At least 24 h prior to lysis, seed enough cells into a well of a 96-well plate to yield 
around 80,000 cells/well at harvest (this will depend on the growth rate of your cell line); the 
following day, aspirate the media from each well, add 100 μL of PBS to wash, aspirate PBS and 
repeat to wash a second time, remove as much PBS as possible, and place on ice for immediate 
use or freeze at −80 °C to use at a later date. 
Note: The 96-well plate method is going to be easier if you are working with a lot of different 
cell lines. You will lyse directly in the plate so you do nÕt have to worry about opening and 
closing a lot of tubes. If you use this method, DO NOT seed too many cell lines in the 96-well 
plate at one time. They will all have to be lysed at the same time and there are time points you 
have to hit. I usually do not seed more than 18Ð20 wells on each plate. Also, we  usually 
prepare two or three replicates for each sample. 
Cell Lysis 
1. Prepare a master mix for the lysis consisting of 49.5 μL of lysis solution and 0.5 μL of DNase 
I (both supplied in the kit) for each sample. Add 0.5× excess to make sure you will not run out of 
the mix. 
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Note: For example, if you have ten samples (10.5×), prepare a master mix of 519.75 μL of lysis 
solution and 5.5 μL of DNase I. 
2. Add 50 μL of the lysis master mix (prepared above) to each sample. 
3. Mix the lysis reaction by pipetting up and down five times (avoid bubble formation). 
4. Incubate the lysis reaction for 5 min at room temperature. 
Note: IMPORTANT! Do not allow reaction to exceed 5 min. 
5. Add 5 μL of stop solution (supplied in the kit) to each sample. 
6. Mix the reaction by pipetting up and down five times (avoid bubble formation). 
7. Incubate at least 2 min at room temperature. 
Note:  IMPORTANT! DO NOT allow reaction to remain at room temperature longer than 20 
min; lysates can be stored on ice for up to 2 h or at −20 ¡C for up to 5 months. 
 
Reverse Transcription 
1. Prepare a master mix for the RT reaction consisting of 25 μL of 2× RT buffer, 2.5 μL of 20× 
RT enzyme mix, and 12.5 μL of nuclease-free water (RT buffer and enzyme mix supplied in the 
kit) for each sample. Add 0.5× excess to make sure you will not run out of the mix. Mix the 
components gently, but thoroughly. 
 
Note: For example, if you have ten samples, prepare a 10.5× mas-ter mix of 262.5 μL of 2× RT 
buffer, 26.25 μL of 20× RT enzyme mix, and 131.25 μL of H2O. 
2. Distribute 40 μL of the master mix prepared above to a nuclease-free tube for each reaction. 
3. Add 10 μL of the sample lysate (or nuclease-free water as a control) to each tube for a final 
volume of 50 μL. 
4. Mix reactions gently, and then centrifuge briefly (assembled reactions can be stored at 4 °C for 
up to 4 h).  
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5. Run RT reaction (two options).  
6. Option #1: Distribute reactions into a PCR tube or multi-well plate and run on a 
thermocycler—step 1, 37 °C for 60 min; step 2, 95 °C for 5 min; and step 3, 4 °C for forever.  
7. Option #2: Distribute reactions into a 1.5 mL tube and run reaction in a 37 °C heat block for 
60 min, immediately transferring to a 95 °C heat block for 5 min and then placing tubes on ice 
for at least 5 min.  
8. Store reactions at −20 °C or immediately proceed with qRT-PCR analysis.  
 
Quantitative RT-PCR 
1. This protocol is designed for use with the Applied Biosystems StepOnePlus™ Real-Time PCR 
System, StepOne™ Software, and TaqMan® Gene Expression Reagents. It is important to 
thoroughly plan out your experiment before beginning. 
Note: The advantage to using the TaqMan® Assays and Reagents vs. SYBR Green is time. There 
are hundreds of predesigned TaqMan® Assays and each assay is designed for the same PCR 
con-ditions. This means there is no need for optimization on your part. 
 
2. For each sample, you will run your gene(s) of interest plus one or more endogenous controls. 
You do not need to measure the concentrations of the cDNA before running the PCR. The 
endogenous controls will help account for differences in concentration between samples. When 
choosing your endogenous control, be sure to choose one that is not modified by your 
experiments. 
3. For each plate you run, you will need a “wild-type” control sample to compare to the rest of 
your samples. This is important. Your final value is relative, based on your “wild-type” control. 
Your control will automatically be set to 1 (or 100 % expression), and all other samples will have 
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an RQ (relative quantity) value compared to the control (e.g., sample 2 has an RQ value of 0.5; 
this means sample 2 has 50 %, or half, the expression of your control sample). 
4. For each sample, it is recommended to run three reactions/ assay. The software will average 
these replicates together in your final calculations. This will help eliminate pipetting errors 
across the wells. 
5. The StepOnePlus™ system is designed to read up to 4 dyes/ well. This gives you the ability to 
add more than one TaqMan® assay/well. However, there is some optimization required with 
multiplexing. It is a great option if you have limited sample available and will save on reagents, 
but you have to optimize to ensure you are not getting false results. 
6. It is recommended to have an NTC (no template control) for each assay. We usually use water 
or you can use the water control from the Cells-to-CT reaction. This will allow the software to 
account for any background signal in the calculations. 
7. Plan your plate layout and figure out how many wells you will be using for each assay. Then, 
prepare your master mixes as follows: 
(a) A “1×” master mix for each assay. 
(b) 10 μL of 2× TaqMan Universal PCR Mix. 
Note: Here, you can use either the Fast or Standard Mix. It is important to pay attention to 
which one you are using. The Fast Mix will allow you to run your entire reaction in about 40 
min. The Standard takes about 2 h. They both will provide the same results; the Fast Mix is just 
more convenient. 
(c) 1 μL of 20× TaqMan Gene Expression Assay (some assays will come as a 40× stock; you 
must dilute these to 20× before use). 
(d) 5 μL of nuclease-free water. 
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8. When preparing your mix, add 0.5× excess so you will not run out of your master mix. 
9. Keep master mixes on ice until ready for use. 
10. Distribute 4 μL of cDNA from the Cells-to-CT™ reaction to each well. 
11. Add 16 μL of your master mix to each well. 
Note: Between each of the two steps above, inspect the wells by eye to make sure each well has 
approximately the same amount of either cDNA or master mix added. It works best to add the 
cDNA followed by the master mix. This way you can tell the difference in amounts of liquid in 
each well. It is difficult to see by eye the difference between 16 μL and 20 μL, but a lot easier to 
see the difference between 4 μL and 20 μL. 
 
12. Cover the plate or tubes, mix gently, and centrifuge briefly (mixed reactions can be stored at 
4 °C for 1 h). 
13. Place plate or tubes in the StepOne™ PCR machine, follow the prompts on the StepOne 
software to set up your experiment, and run the PCR. 
Analysis 
1. When analyzing data, ensure the three replicate wells have a similar CT (cycle time) values. 
2. The AB software will calculate the RQ (relative quantity) value for you, taking into 
consideration the endogenous controls and sample replicates and comparing all your samples to 
the “wild-type” control. 
3. Make sure the correct sample is selected as the “wild-type” control and the correct assay is 
selected as the endogenous control in the experimental setup stage (these can be changed as 
many times as needed after the PCR has run). 
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4. Multiply the RQ values by 100 to find the percentage of mRNA expression in relation to your 
“wild-type” control (e.g., wild type has an RQ value of 1.0 = 100 % expression; sample 1 has an 



























Figure 44. Relative mRNA expression as measured by qRT-PCR after shRNA to knock down several 
different genes involved in apoptosis signaling. 
Quantification of shRNA-mediated knockdown of the apoptosis genes CASP3, CASP9, BBC3, CASP8, BID, and 
DR4 as determined by qRT-PCR following lentiviral transduction and stable cell line development. TaqMan probes 
were used to quantify mRNA levels on an Applied Biosystems StepOnePlus machine. The qRT-PCR data was 
analyzed using the Ct method and was normalized to GFP-transduced control cells. Expression for each was 
normalized to the expression of human ß-actin. The mean of three independent experiments is plotted ± SEM. 
E.4.6 Validating Gene Knockdown by Immunoblot 
The goal of any RNAi experiment is to reduce expression of the protein, preferably below 
detection or at least 75–90 % below the level of the control, such as we have described 
(196,197,200,201). In this example, we show an example of loss of expression of the protein 
pRb, suggested to play a role in the cellular response to DNA damage (337). As shown, protein 
lysates were prepared from cells transduced with a control shRNA (lane 1) and an shRNA 
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specific to pRb (lane 2), resulting in greater than 90 % loss of the expression of the protein 
(Figure 45). 
The following describes the procedures required to validate gene knockdown by 
immunoblot although it is expected that most labs will have some general knowledge of the 
immunoblot procedure (338). While precast SDS-PAGE gels are available (e.g., Bio-Rad, Life 
Technologies), SDS-PAGE gels prepared in the lab are inexpensive and easy to prepare. 
However, the reliability of the assay is of course dependent on the specificity and effectiveness 











Figure 45. Demonstration of shRNA-mediated gene (pRb) knockdown by immunoblot. Depletion of pRb 
protein expression following lentiviral transduction and stable cell line development. 
Cell extracts from control and pRb-KD cell lines were resolved on a 4–20 % SDS-PAGE gel and immunoblotted for 
pRb. The blot was stripped and re-probed for tubulin, which was used as a loading control 
   
1. Assemble the spacer plate with a short plate in the casting frame and squeeze the system into 
the casting stand. 
2. Prepare the 10 % separating gel mixing using 4.5 mL H2O, 3 mL Acryl/Bis (30 %), and 2.5 
mL of the separating buffer. Mix by inverting the tube two to three times and then add 68 μL 
APS and 14 μL TEMED. Mix and pour approximately 8 mL, leaving enough space for the 
stacking gel. 
Note: Alternatively and depending on the molecular weight of the protein of interest, a higher or 
lower concentration of Acryl/ Bis 30 % can be used. 
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3. Pour 200 μL of isopropanol carefully onto the gel solution. The polymerization can take 
greater than 10 min. 
4. Remove the isopropanol by inverting the plates and wash with now solidified gel with dH2O. 
5. Prepare the stacking gel by mixing 3.04 mL H2O, 660 μL Acryl/Bis 30 %, 1.25 mL of the 
stacking buffer, 40 μL APS, and 8 μL of TEMED. Mix, pour, and insert the comb. Leave to 
polymerize approximately 10 min. 
6. Gently remove the comb and wash the wells with dH2O before inserting the gel into the 
electrophoresis unit. 
7. Prepare the 1× running buffer and pour into the unit, avoiding bubbles under the plates to 
allow better protein migration. 
8. Mix the cell extract and the 2× sample buffer at a 1:1 ratio and heat 10 min at 95 °C and load 
into the wells. 
Note: A 10-well gel can only contain up to 40 μL of sample per well. 
9. Load 5 μL of the prestained protein molecular weight marker in one well. 
10. Close the unit with the lead containing the power cables and connect to a power supply. 
11. Run the gel at 90 V for 30 min, time enough for the samples to get through the stacking gel 
and then increase the voltage to 130 V for approximately 1.5 h or until the dye front reaches the 
bottom of the gel. 
12. Carefully disassemble the plates using the gel releaser and soak the gel in a tray containing 
the 1× transfer buffer prechilled at 4 °C, two foam pads, two pieces of Whatman™ 3MM paper, 
and the nitrocellulose membrane cut to the size of the gel. 
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13. Set up the transfer sandwich in a gel holder cassette as shown in Figure 46: one foam pad, 
one piece of Whatman paper, the sheet of nitrocellulose membrane, and the gel. Remove any 
bubbles that might be trapped between the gel and the membrane by gently rolling a pipette on 
the gel. Then add the second piece of Whatman paper and the foam pad. Place the sandwich in 
the tray ensuring that the membrane is close to the anode (+) and the gel on the cathode side (−). 
Fill the tray with the cold transfer buffer and connect it to the power supply. The transfer is 
performed at 4 °C (or at RT with a cooling unit inserted in the tank) at 230 mA for 2 h. 
10.  
Note: Here, you can use either the Fast or Standard Mix. It is important to pay attention to 
which one you are using. The Fast Mix will allow you to run your entire reaction in about 40 
min. The Standard takes about 2 h. They both will provide the same results; the Fast Mix is just 
more convenient. 
14. At the end of the transfer, remove the membrane from the sandwich and verify the presence 
of the prestained molecular weight marker proteins. 
15. Wash the membrane briefly in PBT buffer and incubate (30 min to 1 h) in TBT containing 5 
% (w/v) Blotting-Grade Blocker, at room temperature, on a rocking platform. 
16. Replace the blocking buffer with 10 mL blocking buffer containing the primary antibody 
diluted at the desired concentration. Incubate for 2 h at room temperature or overnight at 4 °C 
on a rocking platform. 
17. Wash the membrane three times with PBT (10 min) at room temperature. 
18. Incubate the membrane for 1 h in 10 mL blocking buffer containing the HRP-conjugated 
secondary antibody corresponding to the species of the primary antibody. 
19. Wash the membrane three times with PBT (10 min each) at room temperature. 
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20. Place the membrane on a glass plate (proteins facing up) and add 1 mL of detection reagent 
freshly prepared by mixing an equal amount of each solution. Incubate in the dark for 2 min 























Figure 46. Cartoon diagram demonstrating the preparation of the gel-membrane sandwich for transfer from 
SDS-PAGE to nitrocellulose in preparation for an immunoblot. 
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E.4.7 PARP Activation in Response to DNA-Damaging Agents 
 
PAR Detection by Immunoblot 
PAR can be detected by immunoblot using one of several poly-clonal or monoclonal antibodies. 
We routinely use the monoclonal Ab 10H (196,201,296). Care must be taken not only for the 
analysis but also in the lysate preparation, as detailed below. No signal should be observed in 
samples isolated from an untreated cell, unless the cell is defective in homologous recombination 
(339) or defective in expression of the PAR-degrading enzyme PARG (296). As shown (Figure 
47), PAR production is followed by loss of signal due to PAR hydrolysis mediated by PARG, as 
we have shown (296). Note also that a more quantitative analysis using these anti-PAR 






















Figure 47. PARP1 activation as measured by immunoblot. 
PAR production in LN428/ MPG cells or when depleted for PARG by shRNA (LN428/MPG/PARG-KD) detected 








1. Seed 105 to 5 × 105 cells in a 60 mm dish and incubate for 24 h. 
2. When cells reach approximately 80 % confluence, treat the cells to trigger PAR production. 
The time of treatment may have to be adjusted depending on the damaging agent, its 
concentration, and the cell sensitivity. 
3. After treatment (note above that the treatment time varies depending on the genotoxin), wash 
cells two times with ice-cold PBS. 
4. Remove excess PBS and add 60–100 μL of sample buffer (2×) directly to the plate. 
5. Scrape the cells, collect the sample, and transfer to a 1.5 mL microcentrifuge tube. 
6. Incubate for 10 min at 95 °C (boiling water bath). 
7. Load 30 μL of the sample on an SDS-PAGE gel and transfer to the nitrocellulose membrane 
as described in Sect. 3.4. We have found that an overnight transfer at 0.08 mA (16 h) gives a 
better signal when probing for PAR. 
8. Discard the blocking buffer and add TBT containing the monoclonal mouse anti-PAR 
antibody (clone 10H) diluted 1–1,000. Incubate 2 h at RT or overnight at 4 °C on a rocking 
platform. 
9. Wash the membrane three times (10 min each) with PBT and incubate 1 h at RT with TBT 
containing the HRP-conjugated goat anti-mouse Ab diluted 1–5,000. 
   
10. Detect signal as described in Sect. 3.4. An example of the expected result is shown in Figure 
47. Here we show the accumu-lation of PAR after MMS treatment of LN428/MPG cells (201) 
that have been depleted of the PAR-degrading enzyme PARG, essentially as we have shown 
(296). 
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Figure 48. PARP1 activation as measured by immunofluorescence. 
PAR production in cells after 0 or 15 min of MNNG treatment (5 μM). PAR is shown in cells exposed to MNNG (5 
μM) using the anti-PAR 10H antibody (left ) and the nucleus is visualized using DAPI (right ). 
 
 
PAR Detection by Immunofluorescence  
The monoclonal Ab 10H can also be used to detect PAR in cells by immunofluorescence (340). 
To perform this assay, cells must be cultured and grown on glass coverslips. This is readily 
accomplished by introducing a coverslip into the wells of a 6- or 12-well plate, depending on the 
number of cells needed. The diameter of the coverslip is chosen to fit the wells of the plate 
selected. An example is shown in Figure 48, in which LN428/MPG cells (201) were treated with 
media or with media supplemented with MNNG (5 μM, 15 min). As indicated, no PAR is 
detectable in the untreated cells, but after treatment with the alkylating agent MNNG, the PAR 
signal is evident and coincides with nuclear staining by DAPI. 
1. Sterilize coverslips in 70 % ethanol and let them dry on the edge of the wells. 
2. Seed cells (around 5 × 104 cells/well for a 6-well plate) and incubate for 24 h at 37 °C. 
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3. Wash cells once with pre-warmed PBS and replace with fresh media containing the DNA-
damaging agent. 
4. Place the plate on ice and wash cells twice with ice-cold PBS. 
5. Fix the cells by adding 3 mL of methanol-acetone (1:1) freshly prepared and stored at −20 °C. 
Incubate for 20 min on ice. 
6. Wash three times with PBS. 
7. Permeabilize the cells by treating with PBS-Triton X-100 (0.1 %) for 15 min. 
8. Wash three times with PBS followed by five washes with PBS-BSA (0.5 %). 
9. Block with PBS-BSA (2 %) for 30–45 min. 
10. Wash three times with PBS-BSA (0.5 %). 
11. Dilute the monoclonal mouse anti-PAR antibody (clone 10H) to 1/500 in PBS-BSA (0.5 %) 
and gently drop 50–100 μL on each coverslip. Incubate for 1.5 h at room temperature or 
overnight at 4 °C in a box containing a wet tissue to keep the slides humid and to avoid 
dehydration. 
12. Wash three times in PBS-BSA (0.5 %) and incubate for 1 h with 50–100 μL of secondary 
antibody (goat anti-mouse Alexa Fluor 488) at room temperature in the dark. 
13. Wash two times in PBS-BSA (0.5 %) and three times in PBS. 
14. Drop 25 μL of ProLong® Gold Antifade Reagent with DAPI on a microscope slide. Carefully 
pick up each coverslip with tweezers and dip in water to remove excess of salts from the PBS. 
Place the coverslip on the SuperGold with the face con-taining the cells down. 
Note: We use a ready-to-use mounting reagent containing DAPI to stain the nucleus. But it is 
also possible, prior to mounting, to incubate the cells for 20 min with 0.05 ng/μL DAPI (Sigma-
Aldrich) in PBS or for 30 s with Hoechst (Sigma-Aldrich cat# B-2883) diluted in dH2O at 1 
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mg/100 mL. The cells are then washed with PBS, rinsed in dH2O, and mounted with a drop of 
anti-fading reagent (Mowiol/Dabco or Gelvatol). 
15. Let dry overnight at room temperature in the dark (Figure 48). 
E.4.8 Complementing Gene KD Cells and Evaluating Cell Survival in Response to DNA-
Damaging Agents 
As described earlier, we routinely complement cells after gene KD with either the WT transgene 
or a mutant transgene, depending on the focus of the investigation (196,197,201,296,341). We 
use standard molecular biology procedures for the development of these expression vectors and 
so we will not detail these here. Importantly, as pointed out in Figure 41, care must be taken to 
ensure that the transgene is not a target of the transfected siRNA or the transduced shRNA. 
 
Evaluating cell survival in response to DNA-damaging agents after gene KD and/or after 
transgene complementation can be performed using transiently transfected cells, but unless the 
transfection efficiency is high or the measureable effect is strong, a stable gene KD is preferred 
for such assays. Examples of the results from either an MTS assay (Panel a) or a CyQUANT 
assay (Panel b) are shown in Figure 49. Here, we show the cellular response to the DNA 
alkylating agent MNNG. In the MTS assay, the cells are exposed to MNNG for 48 h and 
analyzed as detailed below. The LN428 cell line used here has reduced Polβ levels, and as 
expected, complementation with the WT Flag-Polβ transgene confers MNNG resistance (Figure 
49, Panel a). Note that complementation with the mutant (K72A) Flag-Polβ transgene has 
reduced MNNG resistance, owing to its defect in the dRP lyase activity of Polβ (201). Similarly, 
the T98G cell line is sensitive to MNNG in a long-term assay as shown in Panel b (Figure 49) 
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in a Polβ-dependent manner, as complementation with the WT transgene also confers resistance. 
























Figure 49. Cell survival analysis in response to MNNG. 
 (a) Cell viability of LN428 cells expressing Flag-Polß(WT), Flag-Polß(K72A), or EGFP (as indicated) after MNNG 
treatment (3 μM), as measured by the MTS assay 48 h after exposure. Plots show the relative surviving fraction as 
compared to untreated (control) cells. Means are calculated from triplicate values in each experiment. Results 
indicate the mean ± S.D. of three independent experiments. (b) Cell viability of T98G cells expressing Flag-
Polß(WT) or EGFP (as indicated) after MNNG treat-ment (2 μM), as measured by the CyQUANT assay 10 days 
after exposure. T98G cells or those modified to express Flag-Polß(WT) or EGFP (control) were treated with MNNG 
and evaluated for cell viability. The plot shows the % viable cells as compared to untreated (control) cells. Results 
indicate the mean ± S.D. of three independent experiments.  
 
MTS Assay 
The MTS assay is performed as we have described previously (197). Before starting the MTS 
assay, seed 1,000–10,000 cells/well into a 96-well plate and let the cells grow for 48 h. Then add 
MTS dye to the wells, incubate 3 h at 37 °C, and then measure absorbance at 490 nm. This step 
is to determine how many cells are needed to obtain the best result. In general, the seeded cell 
number depends on the duplication time and the size of the cells. You need to determine the 
number of cells that yield a robust signal but also yield ½ signal strength when ½ of the cells 
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were seeded (to ensure linearity). After you know how many cells are needed, then you can 
begin to prepare cells for the MTS assay. For LN428 cells, we suggest seeding 2,000 cells/well. 
 
1. After your desired cells reach 70–80 % confluence, wash the cells with PBS, then trypsinize 
cells, and resuspend cells with media. 
2. Take 100 μL of the cell suspension of the cells and count using a hemocytometer or an 
automated cell counter. 
3. Dilute the cells and seed 200 μL of the required number of cells/well in 96-well plates from 
column 2 to 11 (eight rows per drug dose) and add media in column 1 and column 12. 
4. Incubate seeded cells for 24 h at 37 °C. 
5. Twenty-four (24) hours after seeding the cells, remove media from each well of the plate with 
a multi-well aspirator but leave medium in column 1. 
Note: This step of the MTS assay should be performed very care-fully. Otherwise, you may 
remove cells and that will lead to unre-liable data. 
6. After mixing the medium with compound thoroughly, add 200 μL mixture with different 
concentrations of compound to each 8-well row using a multichannel pipettor. We prepare 
MNNG as a 10 mM stock solution in DMSO and store at −80°C. Here, we dilute the 10 mM 
MNNG (10 mM) to 10 μM with media. In this example, we treated cells with 0 or 3 μM MNNG. 
7. Incubate the treated cells for 48 h at 37 °C. 
8. Remove the media very carefully and rinse each well with 200 μL fresh media. 
Note: This step of the MTS assay should be performed very care-fully. Otherwise, you may 
remove cells and that will lead to unre-liable data. 
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9. Prepare CellTiter Solution (Promega CellTiter 96 AQueous One, #G356B) as suggested by the 
manufacturer. 
10. Place 120 μL of fresh medium mixed with CellTiter in each well including column 12 
(control well) and incubate for 3 h at 37 °C. 
11. Place microplate in the microplate reader to measure absorbance at 490 nm. 




The CyQUANT assay is performed as we have described previously (200). Similar to the 
MTS assay, the seeding cell number depends on the duplication time and the size of the cells. 
For the CyQUANT assay, the cells need to be cultured for a minimum of six duplication cycles. 
As such, different cells may require different culture times. For example, for HCT116 cells, we 
incubate for 5 days after drug treatment, whereas for LN428 or T98G cells, we incubate for 10–
12 days after drug treatment. Determining the proper cell number for seeding is very important 
for this assay. Usually we seed 50–400 cells/well and let the cells grow for 5–10 days to 
determine how many cells we need to seed per well to obtain the optimal result. For T98G or 
LN428 cells, we suggest to seed 50–70 cells/well; for HCT116 cells, we suggest to seed 150–200 
cells/well. 
1. After your cells reach 70–80 % confluence, wash the cells with PBS, then trypsinize cells, and 
resuspend cells with 5–10 mL media and pass the cell suspension through 0.7 μm filter to obtain 
a single cell suspension. 
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2. Take 100 μL of the cell suspension of the cells and count using a hemocytometer or an 
automated cell counter. 
3. Dilute the cells and seed 100 μL of the proper number of cells/well in a 96-well plate to 
columns 3–11 but seed half the number of cells in column 2. Add media only in column 1 and 
column 12. 
4. Incubate seeded cells for 24 h at 37 °C. 
5. Twenty-four (24) hours after seeding cells, remove media from the plate with a multi-well 
aspirator and leave media in column 1 and column 12. 
6. After mixing the media with compound thoroughly, add 200 μL of the mixture with different 
concentrations of compound to the appropriate column using a multichannel pipettor. Before this 
step we need to calculate the volume of genotoxin, in this case MNNG, needed. We suggest to 
calculate the volume of the stock compound used and the volume of final mixture needed. 
7. Incubate the treated cells for six duplication cycles at 37 °C. 
8. After six duplication cycles, remove the media and rinse each well with 200 μL PBS. Remove 
the PBS completely. 
Note: This step should be performed very carefully. Otherwise, you may remove cells and that 
will lead to unreliable data. 
9. Seal edges of the plate with Parafilm to prevent water leaving or entering plate. 
10. Freeze plates at −80 °C overnight. 
11. Prepare the lysis/dye solution. Remember this dye is light sensitive, so keep it in the dark and 
add to the plate in a dark environment. 
12. Follow dilution shown in Table 13 to prepare lysis solution. 
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13. Remove the plates from the freezer and add 200 μL of cell lysis solution with dye to each 
well being tested. 
14. Seal the edges of the plate with Parafilm and cover the plates with aluminum foil to keep the 
plate protected from the light. 
15. Shake the plates for 1 h at room temperature and then incubate overnight at −30°C. 
16. Remove the plates from the freezer and thaw the plates slowly at room temperature. 
Remember to keep them from the light at all times. This process takes approximately 2 h. 
Note: Remember to wait for the solution to be thawed completely. 
17. Read the plates on a fluorescent plate reader. 
18. Calculate the result and plot result as % control vs. compound concentration (Figure 49, 
Panel b). 
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Note: CyQUANT reagent is light sensitive. Avoid light exposure for CyQUANT reagent. After lysis buffer with 
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PLASMID MAPS FOR PENTR AND PCT-COPGFP-MCS-EF1-PURO/PCT-MCS-
COPGFP-EF1-PURO VECTORS 
 





Figure 51. Plasmid maps for UBE3B-copGFP constructs. 
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Figure 52. Plasmid maps for pENTR-D/TOPO HA-tagged UBE3A and UBE3B constructs. 
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Figure 54. Plasmid maps for pENTR/D-TOPO TFAM fluoro-fusion constructs. 
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